View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2016	Feb. 14, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Chemours Co
Entity Central Index Key	0001627223
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		183,153,218
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 1.5

Consolidated Statements of Operations - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Income Statement [Abstract]

Net sales

$ 5,400

$ 5,717

$ 6,432

Cost of goods sold

4,290

4,762

5,072

Gross profit

1,110

955

1,360

Selling, general and administrative expense

934

632

685

Research and development expense

143

Restructuring and asset related charges, net

170

333

Goodwill impairment

Total expenses

1,184

1,087

849

Equity in earnings of affiliates

Interest expense, net

(213)

(132)

Other income, net

247

(Loss) income before income taxes

(11)

(188)

550

(Benefit from) provision for income taxes

(18)

(98)

149

Net income (loss)

(90)

401

Less: Net income attributable to noncontrolling interests

Net income (loss) attributable to Chemours

$ 7

$ (90)

$ 400

Per share data

Basic earnings (loss) per share of common stock

$ 0.04

$ (0.50)

$ 2.21

^[1]

Diluted earnings (loss) per share of common stock

0.04

(0.50)

2.21

^[1]

Dividends per share of common stock

$ 0.12

$ 0.58

$ 0

[1]

On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours’ common stock to holders of its common stock. Basic and diluted earnings (loss) per common share for the year ended December 31, 2014 was calculated using the shares distributed on July 1, 2015. Refer to Note 10 for information regarding the calculation of basic and diluted earnings per share.

Consolidated Statements of Operations (Parenthetical)	Jul. 02, 2015 shares
Income Statement [Abstract]
Stock issued, common stock	180,966,833

Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Statement Of Income And Comprehensive Income [Abstract]

Net income (loss), pre-tax

$ (11)

$ (188)

$ 550

Net Income (loss), tax

(149)

Net income (loss)

(90)

401

Other comprehensive income (loss):

Unrealized gain on net investment hedge, pre-tax

Unrealized gain on net investment hedge, tax

Unrealized gain on net investment hedge, after-tax

Cumulative translation adjustments, pre-tax

(73)

(304)

Cumulative translation adjustments, tax

Cumulative translation adjustments, after-tax

(73)

(304)

Defined benefit plans, net:

Net loss, pre-tax

(17)

(11)

Net loss, tax

Net loss, after-tax

(12)

(10)

Prior service credit, pre-tax

Prior service credit, tax

(4)

Prior service credit, after-tax

Effect of foreign exchange rates, pre-tax

Effect of foreign exchange rates, tax

(3)

(8)

Effect of foreign exchange rates, after-tax

Amortization of prior service cost, pre-tax

^[1]

(1)

Amortization of prior service cost, tax

^[1]

Amortization of prior service cost, after tax

^[1]

(1)

Amortization of loss, pre-tax

^[1]

Amortization of loss, tax

^[1]

(6)

(3)

Amortization of loss, after tax

^[1]

Settlements, pre-tax

^[1]

Settlements, tax

^[1]

(1)

Settlements, after-tax

^[1]

Curtailment gain, pre-tax

^[1]

(2)

Curtailment gain, tax

^[1]

Curtailment gain, after-tax

^[1]

(2)

Defined benefit plans, net, pre-tax

Defined benefit plans, net, tax

(5)

(14)

Defined benefit plans, net, after-tax

Other comprehensive loss, pre-tax

(36)

(230)

Other comprehensive loss, tax

(5)

(14)

Other comprehensive loss, after-tax

(41)

(244)

Comprehensive (loss) income, pre-tax

(47)

(418)

550

Comprehensive (loss) income, tax

(149)

Comprehensive (loss) income, after-tax

(34)

(334)

401

Less: Comprehensive income attributable to noncontrolling interests, pre-tax

Less: Comprehensive income attributable to noncontrolling interests, tax

Less: Comprehensive income attributable to noncontrolling interests, after-tax

Comprehensive (loss) income attributable to Chemours, pre-tax

(47)

(418)

549

Comprehensive (loss) income attributable to Chemours, tax

(149)

Comprehensive (loss) income attributable to Chemours, after-tax

$ (34)

$ (334)

$ 400

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs. Refer to Note 22 for further information.

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 902	$ 366
Accounts and notes receivable - trade, net	807	859
Inventories	767	972
Prepaid expenses and other	77	104
Total current assets	2,553	2,301
Property, plant and equipment	7,997	9,015
Less: Accumulated depreciation	(5,213)	(5,838)
Net property, plant and equipment	2,784	3,177
Goodwill and other intangible assets, net	170	176
Investments in affiliates	136	136
Other assets	417	508
Total assets	6,060	6,298
Current liabilities:
Accounts payable	884	973
Short-term borrowings and current maturities of long-term debt	15	39
Other accrued liabilities	872	454
Total current liabilities	1,771	1,466
Long-term debt, net	3,529	3,915
Deferred income taxes	132	234
Other liabilities	524	553
Total liabilities	5,956	6,168
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; shares issued and outstanding at December 31, 2016: 182,600,533 and 2015: 181,069,751)	2	2
Additional paid-in capital	789	775
Accumulated deficit	(114)	(115)
Accumulated other comprehensive loss	(577)	(536)
Total Chemours stockholders’ equity	100	126
Noncontrolling interests	4	4
Total equity	104	130
Total liabilities and equity	$ 6,060	$ 6,298

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, shares authorized (in shares)	810,000,000	810,000,000
Common stock , par value (USD per share)	$ 0.01	$ 0.01
Common stock, shares Issued (in shares)	182,600,533	181,069,751
Common stock, shares outstanding (in shares)	182,600,533	181,069,751

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	DuPont Company Net Investment [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]	Accumulated Deficit [Member]
Shares, beginning balance at Dec. 31, 2013		0
Total stockholders' equity, beginning balance at Dec. 31, 2013	$ 3,217	$ 0	$ 3,195	$ 0	$ 19	$ 3	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	401		400			1
Other comprehensive loss	0
Net transfers to from DuPont	55		55
Shares, ending balance at Dec. 31, 2014		0
Total stockholders' equity, ending balance at Dec. 31, 2014	3,673	$ 0	3,650	0	19	4	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(90)		25				(115)
Other comprehensive loss	(244)				(244)
Issuance of common stock at separation (in shares)		180,966,833
Issuance of common stock at separation		$ 2		(2)
Common stock issued - compensation plans (in shares)		102,918
Establishment of pension plans, net and related accumulated other comprehensive income (loss)	(43)		268		(311)
Dividends	(105)		(100)	(5)
Non-cash debt exchange	(507)		(507)
Cash provided at separation by DuPont	247		247
Net transfers to from DuPont	(2,814)		(3,583)	769
Stock-based compensation expense	13			13
Shares, ending balance at Dec. 31, 2015		181,069,751
Total stockholders' equity, ending balance at Dec. 31, 2015	130	$ 2	0	775	(536)	4	(115)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	7						7
Other comprehensive loss	(41)				(41)
Common stock issued - compensation plans (in shares)		583,859
Dividends	(22)			(16)			(6)
Stock-based compensation expense	19			19
Exercise of stock options	11			11
Exercise of stock options (in shares)		946,923
Shares, ending balance at Dec. 31, 2016		182,600,533
Total stockholders' equity, ending balance at Dec. 31, 2016	$ 104	$ 2	$ 0	$ 789	$ (577)	$ 4	$ (114)

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Net income (loss)	$ 7	$ (90)	$ 401
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization	284	267	257
Amortization of deferred financing costs and issuance discount	20	8	0
Other operating charges and credits, net	52	7	18
(Gain) loss on sale of assets and businesses	(254)	9	(40)
Equity in earnings of affiliates, net of dividends received of $18, $23 and $19	(12)	0	1
Deferred tax benefits	(111)	(198)	(22)
Asset related charges	124	206	0
Decrease (increase) in operating assets:
Accounts and notes receivable - trade, net	5	(64)	4
Inventories and other operating assets	147	19	(29)
Increase (decrease) in operating liabilities:
Accounts payable and other operating liabilities	332	18	(85)
Cash provided by operating activities	594	182	505
Investing activities
Purchases of property, plant and equipment	(338)	(519)	(604)
Proceeds from sales of assets, net	708	12	32
Foreign exchange contract settlements	(12)	42	0
Investment in affiliates	(1)	(32)	(8)
Other investing activities	0	0	20
Cash provided by (used for) investing activities	357	(497)	(560)
Financing activities
Proceeds from issuance of debt, net	0	3,491	0
Debt repayments	(381)	(10)	0
Dividends paid	(22)	(105)	0
Debt issuance costs	(4)	(79)	0
Proceeds from exercised stock options	11	0	0
Cash provided at separation by DuPont	0	247	0
Net transfers (to) from DuPont	0	(2,857)	55
Cash (used for) provided by financing activities	(396)	687	55
Effect of exchange rate changes on cash	(19)	(6)	0
Increase in cash and cash equivalents	536	366	0
Cash and cash equivalents at beginning of year	366	0	0
Cash and cash equivalents at end of year	902	366	0
Cash paid during the year for:
Interest, net of amounts capitalized	208	103	0
Income taxes, net of refunds	50	53	0
Non-cash change in property, plant and equipment included in accounts payable	$ (12)	$ 45	$ (11)

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement Of Cash Flows [Abstract]
Dividends received	$ 18	$ 23	$ 19

Background and Description of the Business	12 Months Ended
Background and Description of the Business	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Background and Description of the Business	Note 1. Background and Description of the Business The Chemours Company (Chemours or the Company) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide and performance chemicals & intermediates. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours’ operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India and France. As of December 31, 2016, Chemours has 26 production facilities globally, five dedicated to Titanium Technologies, 18 dedicated to Fluoroproducts, two dedicated to Chemical Solutions and one that supports multiple Chemours segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. DuPont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont’s common stock received one share of Chemours’ common stock for every five shares of DuPont’s common stock held on the Record Date. The separation was completed pursuant to a separation agreement and other agreements with DuPont, including an employee matters agreement, a tax matters agreement, a transition services agreement and an intellectual property cross-license agreement. These agreements govern the relationship between Chemours and DuPont following the separation and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours that were substantially completed during 2016. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to “we”, “us”, “our”, “Chemours” and the “Company” refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution.

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Note 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). The notes that follow are an integral part of the consolidated financial statements. Chemours did not operate as a separate, stand-alone entity for all periods included within these consolidated financial statements. Prior to the separation on July 1, 2015, Chemours operations were included in DuPont’s financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the accompanying consolidated financial statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Prior to July 1, 2015, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholders’ Equity in the consolidated financial statements. The consolidated financial statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. All of the allocations and estimates in the consolidated financial statements prior to July 1, 2015 are based on assumptions that management believes are reasonable. Therefore, the results of operations and cash flows prior to July 1, 2015 included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont on the Consolidated Statements of Stockholders’ Equity include a non-cash contribution from DuPont of $109 for the year ended December 31, 2015. This non-cash contribution occurred during physical separation activities at shared production facilities in the U.S. prior to the separation and certain assets identified at separation. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours. Comprehensive income as of December 31, 2016 includes an out of period adjustment of $31 million relating to 2015 cumulative translation adjustments with corresponding adjustment to other current assets. This adjustment is not material to the Company’s consolidated financial statements taken as a whole.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies These consolidated financial statements have been prepared in accordance with GAAP. The significant accounting policies described below, together with the other notes that follow, are an integral part of the consolidated financial statements. Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses, including allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time and various other assumptions that we believe are reasonable. Actual results could differ from those estimates. Principles of Consolidation and Combination The consolidated financial statements include the accounts Chemours and its subsidiaries, and entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as noncontrolling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock or has the ability to exercise significant influence over operating and financial policies of the investee are accounting for using the equity method of accounting. As a result, Chemours’ share of the earnings or losses of such equity affiliates is included in the Consolidated Statements of Operations and Chemours’ share of such equity affiliates equity is included in the Consolidated Balance Sheets. The financial statements for the periods prior to the separation on July 1, 2015 include the combined assets, liabilities, revenues, and expenses of Chemours. We eliminated all intercompany accounts and transactions in the preparation of the accompanying consolidated financial statements. Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, when title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales and noncash sales incentives are recorded as a charge to cost of goods sold at the time the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the Consolidated Statements of Operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable and collectability is reasonably assured. Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits or highly liquid investments with original maturities of three months or less. Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ accounts receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines that they are uncollectible. Inventories Chemours’ inventories are valued at the lower of cost or market. Inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Inventories held outside the U.S. are determined by the average cost method. Elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at cost or market, whichever is lower; cost is generally determined by the average cost method. Approximately 48% and 54% of inventory is on a LIFO basis as of December 31, 2016 and 2015, respectively. The remainder is accounted for using the average cost method. Property, Plant and Equipment Property, plant and equipment is carried at cost and is depreciated using the straight-line method. Property, plant and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method or other substantially similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the balance sheet and included in determining gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on the extension to the useful life. Capitalized repair and maintenance costs are recorded on the Consolidated Balance Sheets in “Other assets”. Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired, including identified intangibles, in a business combination is recorded as goodwill. Goodwill is tested for impairment annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as one level below operating segment except for Titanium Technologies, which is both an operating segment and a reporting unit. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. The Company utilizes an income approach (or discounted cash flow method) and market approach to calculate the fair value of its reporting units. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. Impairment of Long-Lived Assets Chemours evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For purposes of recognition or measurement of an impairment loss, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of an asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of other than by sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value less cost to sell. Depreciation is discontinued for long-lived assets classified as held for sale. Research and Development Research and development costs are expensed as incurred. Research and development expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products and regulatory approval of new and existing products. Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the information is only sufficient to establish a range of probable liability and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based upon existing remediation laws and technologies. Inherent uncertainties exist in such evaluations primarily due to unknown environmental conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technology, regulatory and legal information become available. Environmental liabilities and expenditures included claims for matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation. Accrued liabilities are undiscounted and do not include claims against third parties. These liabilities are included in “Other accrued liabilities” and “Other liabilities” in the Consolidated Balance Sheet. Costs related to environmental remediation are charged to expense in the period incurred, in “Cost of goods sold” of the Consolidated Statement of Operations. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized. Asset Retirement Obligations Chemours records asset retirement obligations at fair value at the time the liability is incurred. Fair value is measured using expected future cash outflows discounted at Chemours’ credit-adjusted risk-free interest rate, which are considered level 3 inputs. Accretion expense is recognized as an operating expense classified within cost of goods sold on the Consolidated Income Statements using the credit-adjusted risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 25 years. Litigation Chemours accrues for litigation matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation liabilities and expenditures included in the consolidated financial statements represent litigation matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation. Legal costs such as outside counsel fees and expenses are charged to expense in the period services are received. Insurance Chemours insures certain risks where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the Company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the separation, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of insurance and self-insurance is used, reflecting comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans have historically been obligations of DuPont. As such, these obligations were not included in the Consolidated Balance Sheets, with the exception of self-insurance liabilities related to workers compensation, vehicle liability and employee related benefits. Defined Benefit Plans We have defined benefit plans covering certain of our employees outside the U.S., which are generally required by local regulations. The benefits, which primarily relate to pension, are accrued over the employees’ service periods. We use actuarial methods and assumptions in the valuation of defined benefit obligations and the determination of net periodic pension income or expense. Differences between actual and expected results or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur but rather systematically over subsequent periods. Stock-based Compensation Chemours’ stock-based compensation consists of stock options, restricted share units (RSUs) and performance share units (PSUs) to employees and non-employee directors. Stock options are measured at fair value on the grant date or date of modification, as applicable. We recognize compensation expense on a straight-line basis over the requisite service period. The number of awards ultimately expected to vest is determined by use of an estimated forfeiture rate. The estimated forfeiture rate is based on historical data for the employee group awarded options and expected employee turnover rates, which management reevaluates each period. Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more likely than not threshold and accrues interest related to unrecognized income tax positions, which is included in other income, net in our Consolidated Statements of Operations. Income tax related penalties are included in the provision for income taxes. Chemours does not provide for income taxes on undistributed earnings of all foreign subsidiaries that are intended to be indefinitely reinvested. Prior to separation, income taxes presented attributed current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by ASC 740, Income Taxes (ASC 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies ASC 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise. Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (1) extensions of the parent (U.S. dollar functional currency) and (2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the consolidated financial statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories; prepaid expenses; property, plant and equipment; goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the separation, certain of Chemours foreign entities set their local currency as the functional currency. Derivatives Chemours enters into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred. Please refer to Note 21 for additional information. Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities; (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability. Recent Accounting Pronouncements Accounting Guidance Issued Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)." The objective of this standard update is to remove inconsistent practices with regard to revenue recognition between US GAAP and IFRS. The standard intends to improve comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. The provisions of ASU No. 2014-09 will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company plans to adopt ASU 2014-09 as of January 1, 2018. Subsequent to the issuance of ASU No. 2014-09, the FASB has issued multiple updates in connection with Topic 606. These updates affect the guidance contained within ASU 2014-09 and will be assessed as part of the Company's revenue recognition project plan. The Company’s project plan includes a three-phase approach to implementing this standard update. Phase one, the assessment phase, is currently in process and is expected to be completed in the second quarter of 2017. In connection with this initial phase, the Company is currently performing the following activities: conducting internal surveys of its businesses to initially identify a set of applicable revenue recognition changes related to the new standard update, holding revenue recognition workshops with sales and business unit finance leadership highlighting the impacts of the new standard update, and reviewing a representative sample of revenue arrangements across all businesses to assess and validate the impact of the new guidance. Once completed, the Company will pursue the second phase of the project, where the objectives will be to establish and document key accounting policies, assess disclosure, business process and control impacts, and determine an initial quantitative impact resulting from the new standard update. Lastly, phase three’s objectives will comprise of effectively implementing the new standard update and embedding the new accounting treatment into the Company’s business processes and controls to support the financial reporting requirements. The Company is still evaluating the impact that the new standard update will have on the Company’s consolidated financial statements and will be unable to quantify its impact until the third phase of the project has been completed. The method of adoption has not yet been determined and is also not expected to be finalized until the third phase of the project plan has been completed. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to determine the fair value of individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company plans to adopt this guidance in 2017. In August 2016, the FASB issued various updates to the Accounting Standards Update (ASU) 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”, which clarifies and amends certain cash receipts and cash payments presentation and classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method (unless impractical to do so) to each period presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance but does not expect the adoption will have a significant impact on its cash flows. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements, and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and debt covenants. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718)”. The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal periods, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017 and the adoption did not have a significant impact on the Company’s financial position, results of operations and of cash flows. In April 2015, the FASB issued ASU No. 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement”, which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”. The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no impact on the Company’s financial position, results of operations and cash flows. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern”. The update requires management to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. Chemours adopted the guidance effective December 31, 2016. No disclosure was considered necessary as of December 31, 2016 as a result of management’s evaluation.

Relationship with DuPont and Related Entities	12 Months Ended
Relationship with DuPont and Related Entities	Dec. 31, 2016
Related Party Transactions [Abstract]
Relationship with DuPont and Related Entities	Note 4. Relationship with DuPont and Related Entities Prior to the separation, Chemours sold finished goods to DuPont and its non-Chemours businesses. Related party sales to DuPont recorded by Titanium Technologies, Fluoroproducts and Chemical Solutions for the year ended December 31, 2015 were $2, $34 and $21, respectively, and for the year ended December 31, 2014 were $0, $45 and $65, respectively. Subsequent to the separation, beginning on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Also prior to the separation, DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support. A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other. The allocated leveraged functional service expenses and general corporate expenses included in the Consolidated Statements of Operations were $238 and $492 for the years December 31, 2015 and 2014, respectively, and were recorded within cost of goods sold, selling, general and administrative expense and research and development expense for $23, $205 and $10, respectively, for the year ended December 31, 2015, and $32, $411 and $49, respectively, for the year ended December 31, 2014. Subsequent to the separation on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Accordingly, no costs from DuPont were allocated to Chemours after July 1, 2015. Cash Management and Financing The separation agreement sets forth a process to true-up cash and working capital transferred to us from DuPont at separation. In January 2016, Chemours and DuPont entered into an agreement, contingent upon the credit agreement amendment (described in Note 19), which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreement. As a result, Chemours is no longer required to make any payments to DuPont, nor will DuPont make any payments to Chemours. In addition, the agreement set forth an advance payment by DuPont of approximately $190, which Chemours received in February 2016, for certain specified goods and services that Chemours expects to provide to DuPont through mid-2017 under existing agreements with Chemours. The advance payment was recorded as deferred liability included in other accrued liabilities of the Consolidated Balance Sheets and approximately $58 remains outstanding as of December 31, 2016. Tax Matters Agreement The tax matters agreement that Chemours and DuPont entered into governs the parties’ respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state and local taxes (and any related interest, penalties or audit adjustments) reportable on a consolidated, combined or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the date of the separation and Chemours is responsible for any U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the date of the separation.

Research and Development Expense	12 Months Ended
Research and Development Expense	Dec. 31, 2016
Research And Development [Abstract]
Research and Development Expense	Note 5. Research and Development Expense Research and development expense directly incurred by Chemours was $80, $87 and $94 for the years ended December 31, 2016, 2015 and 2014, respectively. Research and development expense for the years ended December 31, 2015 and 2014 includes $10 and $49, respectively, which represents an assignment of costs associated primarily with DuPont’s Corporate Central Research and Development long-term research activities. This assignment was based on the cost of research projects for which Chemours was determined to be the sponsor or co-sponsor. All research services previously provided by DuPont’s Central Research and Development to Chemours were specifically requested by Chemours, covered by service-level agreements and billed based on usage. DuPont research and development services were no longer used after the separation on July 1, 2015.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

Restructuring and Asset Related Charges, Net

12 Months Ended

Dec. 31, 2016

Restructuring And Related Activities [Abstract]

Restructuring and Asset Related Charges, Net

Note 6. Restructuring and Asset Related Charges, Net

For the years ended December 31, 2016, 2015 and 2014, Chemours recorded charges for employee separation and asset related charges as follows:

	Year Ended December 31,
	2016		2015		2014
Restructuring Related Charges:
Employee Separation Charges	$	4	$	137	$	18
Decommissioning and other charges, net - Restructuring		47		18		—
Asset Related Charges - Restructuring		—		133		3
Total restructuring charges, net		51		288		21
Asset Related Charges - Impairment 1		119		45		—
Total restructuring and asset related charges, net	$	170	$	333	$	21

Impairment charges for the year ended December 31, 2016 include $48 of impairment charges related to the aniline facility in Pascagoula, Mississippi (see Note 13 for further information), $58 of impairment charges in connection with the sale of the Sulfur business (see Note 7 for further information), and $13 of impairment charges in connection with the sale of the Company’s corporate headquarters building (see Note 15 for further information). Impairment charges for the year ended December 31, 2015 represent asset impairment related to the reactive metals manufacturing facility (see Note 13 for further information).

The charges related to the restructuring programs impacted segment earnings for the years ended December 31, 2016, 2015 and 2014 are as follows:

	Year Ended December 31,
	2016		2015		2014
Plant and product line closures ¹
Titanium Technologies	$	30	$	140	$	—
Fluoroproducts		7		24		—
Chemical Solutions		8		12		—
Sub-total		45		176		—
Global restructuring ²
Titanium Technologies		2		33		3
Fluoroproducts		4		54		16
Chemical Solutions		—		25		—
Sub-total		6		112		19
Total	$	51	$	288	$	19

Includes charges related to employee separation, decommissioning and dismantling costs, and asset related charges in connection with the restructuring activities.

Includes approximately $24 related to corporate overhead functions that was allocated to the segments for the year ended December 31, 2015.

Plant and product line closures

Titanium Technologies Plant and Product Line Closures: In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing site located in the U.S. The Edge Moor plant produced TiO₂ product for use in the paper industry and other applications where demand had steadily declined, resulting in underused capacity at the plant. In addition, the Company permanently shut down one underused TiO₂ production line at its New Johnsonville, Tennessee plant. The Company stopped production at Edge Moor in September 2015 and immediately began decommissioning the plant. These actions resulted in the write-off of substantially all of the Edge Moor plant asset carrying value in 2015.

As a result, for the year ended December 31, 2015, the Company recorded charges of approximately $140, which consisted of employee separation costs of $11, property, plant and equipment and other asset impairment charges of $115, and decommission costs and other charges of $14. For the year ended December 31, 2016, the Company recorded additional charges of approximately $30, which relates to decommissioning, dismantling and removal activities. The Company substantially completed the dismantling and removal activities in January 2017.

Fluoroproducts Restructuring: Also, in August 2015, in an effort to improve the profitability of the Fluoroproducts segment, management approved the shutdown of certain production lines of the segment’s manufacturing facilities in the U.S. As a result, for the year ended December 31, 2015, the Company recorded restructuring charges of approximately $21, which consist of property, plant and equipment accelerated depreciation of $18, employee separation costs of $2, and decommissioning and other costs of $1. For the year ended December 31, 2016, the Company recorded additional charges of approximately $7, which relates to decommissioning, dismantling and removal activities. The Company expects to incur additional charges of approximately $3 for decommissioning, dismantling and removal costs in 2017, which will be expensed as incurred.

RMS Plant Closure: In the fourth quarter of 2015, the Company announced the completion of the strategic review of its RMS business and the decision to stop production at the Niagara Falls, New York site. The Niagara Falls plant has approximately 200 employees and contractors impacted by this action. The production stopped in September 2016 and the Company immediately began decommissioning the plant.

As a result, for the year ended December 31, 2015, the Company recorded approximately $12 of employee separation costs. For the year ended December 31, 2016, the Company recorded approximately $8, which consist of contract termination charges of $2 and decommissioning and other related charges of $6. Additional restructuring charges of approximately $9 for decommissioning and site redevelopment are expected to be incurred in 2017. Impairment of RMS related assets were recorded in the third quarter of 2015 (see Note 13 for further information).

2015 Global restructuring

In November 2015, Chemours announced an additional global workforce reduction of approximately 430 positions. This action is part of ongoing efforts to streamline and simplify the structure of the organization worldwide and to reduce costs. As a result of these actions, the Company recorded approximately $48 of employee separation costs during the fourth quarter of 2015. The associated headcount reductions were completed as of December 31, 2016, and all related payments are expected to be completed in 2017.

In June 2015, in light of continued weakness in the global titanium dioxide market cycle and continued foreign currency impacts due to the strengthening of the U.S. dollar, Chemours implemented a restructuring plan to reduce and simplify its cost structure. This plan resulted in a global workforce reduction of more than 430 positions. As a result, we recorded a pre-tax charge of $64 for employee separation costs in the year ended December 31, 2015. All actions associated with this charge were completed as of December 31, 2016.

In 2014, Chemours implemented a restructuring plan to increase productivity and recorded a pre-tax charge of $19 related to this initiative. The charge consisted of $16 related to employee separation costs and $3 for asset shut-down costs. All actions associated with this charge were completed as of December 31, 2015.

The following table shows the change in the employee separation related liability account associated with the restructuring programs:

	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			Total
Year ended December 31, 2014	$	—		$	—		$	—		$	—		$	—
Charges to income for the year ended December 31, 2015 ¹		11			2			12			112			137
Charges to liability accounts:
Payments		—			—			—			(39	)		(39	)
Net currency translation and other adjustment ²														—
Year ended December 31, 2015	$	11		$	2		$	12		$	73		$	98
Charges (credits) to income for the year ended December 31, 2016 ¹		—			—			(2	)		6			4
Charges to liability accounts:
Payments		(7	)		(1	)		(1	)		(59	)		(68	)
Net currency translation and other adjustment ²		—			—			(1	)		1			—
Balance as of December 31, 2016	$	4		$	1		$	8		$	21		$	34

¹	Due to unexpected resignations of certain employees at the Company’s Niagara site during 2016, approximately $2 of employee separation charges, related to the RMS plant closure, were reversed to income during the year ended December 31, 2016.

²	Amounts include net currency translation adjustment of less than $1 for the period presented and rounding differences.

There are no significant outstanding liabilities related to the decommissioning and other restructuring related charges.

Sales of Assets and Businesses

12 Months Ended

Dec. 31, 2016

Discontinued Operations And Disposal Groups [Abstract]

Sales of Assets and Businesses

Note 7. Sales of Assets and Businesses

On June 13, 2016, the Company entered into an asset purchase agreement with Veolia North America (“Veolia”), pursuant to which Veolia agreed to acquire the Sulfur business of Chemours’ Chemical Solutions segment for a purchase price of $325 in cash, subject to customary working capital and other adjustments, of which approximately $10 was received in May 2016. The Company completed the sale and received the remaining proceeds of approximately $311 on July 29, 2016, net of estimated working capital adjustments. Prior to the completion of the sale, in the second quarter of 2016, the Company recorded an impairment loss of approximately $58 in “Restructuring and asset related charges, net” of the Consolidated Statement of Operations. When the sale was completed, the Company also recorded an additional pre-tax loss on sale of approximately $4, net of a benefit from contract adjustments, in “Other income, net” in the Consolidated Statement of Operations. The net book value of the assets and liabilities disposed were $342 and $11, respectively.

On April 22, 2016, the Company entered into a stock and asset purchase agreement with LANXESS Corporation, (“Lanxess”), pursuant to which Lanxess agreed to acquire the C&D business of Chemours’ Chemical Solutions segment by acquiring certain Chemours’ subsidiaries and assets for a purchase price of $230 in cash, subject to customary working capital and other adjustments. The Company completed the sale and received proceeds of $223 on August 31, 2016, net of working capital adjustments and approximately $2 of cash transferred. As a result, for the year ended December 31, 2016, the Company recorded a pre-tax gain of approximately $169 in “Other income, net” in the Consolidated Statement of Operations. The net book values of the assets and liabilities disposed were $48 (including goodwill of $13) and $6, respectively, and the Company incurred approximately $9 of transaction and other related charges.

In November 2015, the Company signed a definitive agreement to sell its aniline facility in Beaumont, Texas to The Dow Chemical Company (“Dow”), and the net book value of the related asset group (including goodwill) was classified as assets held-for-sale at December 31, 2015 included in “Prepaid expenses and other” of the Consolidated Balance Sheet. The transaction closed on March 1, 2016 and Chemours received $140 in cash from Dow. The net book value of the assets disposed was $41 (including goodwill of $4), and the Company incurred approximately $11 of transaction and other related charges. As a result of this transaction, for the year ended December 31, 2016, Chemours recognized a pre-tax gain in the Chemical Solutions segment of approximately $88 recorded in “Other income, net” in the Consolidated Statement of Operations.

The aggregate amount and major components of assets and liabilities disposed during the year ended December 31, 2016 are as follows:

	December 31, 2016
Current assets:
Accounts receivables	$	22
Inventories		17
Total current assets		39
Property, plant and equipment, net		298
Goodwill		17
Other assets		136
Less: Impairment loss		(58	)
Total non-current assets, net		393
Total assets		432
Accounts payable and accrued liabilities		17
Total liabilities		17
Net assets disposed	$	415

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Other Income (Expense), Net

12 Months Ended

Dec. 31, 2016

Other Income And Expenses [Abstract]

Other Income (Expense), Net

Note 8. Other Income (Expense), Net

	Year Ended December 31,
	2016			2015			2014
Leasing, contract services and miscellaneous income ¹	$	35		$	25		$	17
Royalty income²		15			19			28
Gain (loss) on sale of assets and businesses ³		254			(9	)		40
Exchange (losses) gains, net ⁴		(57	)		19			(66	)
Total other income, net	$	247		$	54		$	19

Miscellaneous income includes accrued interest related to unrecognized tax benefits.

Royalty income is primarily for technology and trademark licensing.

The twelve months ended December 31, 2016 includes a gain on sale of C&D business and aniline factory; and a loss on sale of Sulfur business. See Note 7 for further details.

⁴

Exchange losses, net includes gains and losses on foreign currency forward contracts. See Note 21 for additional information.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Note 9. Income Taxes

	Year Ended December 31,
(Dollars in millions)	2016			2015				2014
Current tax expense:
U.S. federal	$	—		$	37		¹	$	85
U.S. state and local		—			1		¹		13
International		93			62				73
Total current tax expense		93			100				171
Deferred tax (benefit) expense:
U.S. federal		(101	)		(187	)			(20	)
U.S. state and local		(17	)		(14	)			(3	)
International		7			3				1
Total deferred tax benefit		(111	)		(198	)			(22	)
Total (benefit from) provision for income taxes	$	(18	)	$	(98	)		$	149

Recorded pursuant to the tax matters agreement.

The significant components of deferred tax assets and liabilities are as follows:

(Dollars in millions)	December 31, 2016			December 31, 2015
Deferred tax assets:
Environmental and other reserves	$	150		$	158
Litigation reserves		149			22
Stock compensation and accrued employee benefits		35			42
Other assets and other accrued liabilities		27			35
Tax loss carryforwards		95			124
Total deferred tax assets		456			381
Valuation allowance		(50	)		—
Total deferred tax assets, net		406			381
Deferred tax liabilities:
Pension and other liabilities		(16	)		(7	)
Property, plant and equipment		(441	)		(530	)
Inventories and other assets		(40	)		(31	)
Total deferred tax liabilities		(497	)		(568	)
Net deferred tax liability	$	(91	)	$	(187	)

An analysis of the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2016						2015							2014
(Dollars in millions)	$			%			$				%			$			%
Statutory U.S. federal income tax rate	$	(4	)		35.0	%	$	(66	)			35.0	%	$	192			35.0	%
State income taxes, net of federal benefit		(16	)		150.4	%		(10	)			5.1	%		6			1.0	%
Lower effective tax rate on international operations-net		(61	)		552.5	%		(23	)			12.0	%		(53	)		(9.6	)%
Depletion		(6	)		51.2	%		(6	)			3.4	%		(8	)		(1.5	)%
Goodwill		5			(47.9	)%		6				(3.2	)%		—			—	%
Exchange losses (gains)		4			(39.1	)%		(1	)			0.5	%		15			2.7	%
Provision to return and other adjustments		6			(57.9	)%		—				—	%		—			—	%
Permanent items		3			(27.3	)%		1				(0.5	)%		(5	)		(0.9	)%
Valuation allowance		50			(451.6	)%		—		¹		—	%		11			2.0	%
Section 199 domestic manufacturing deduction		—			(—	)%		—				—	%		(4	)		(0.7	)%
Other, net		1			(1.7	)%		1				(0.2	)%		(5	)		(0.9	)%
Total effective tax rate	$	(18	)		163.6	%	$	(98	)			52.1	%	$	149			27.1	%

Release of the valuation allowance during 2015 was related to tax loss carryforward incurred prior to July 1, 2015 that is attributable to DuPont’s tax periods pursuant to the tax matters agreement and did not impact the effective tax rate as the adjustment was recorded in the “DuPont Company Net Investment” of the Consolidated Statements of Stockholders’ Equity for the year ended December 31, 2015.

(Loss) income before income taxes for U.S. and international operations was:

	Year Ended December 31,
(Dollars in millions)	2016			2015			2014
U.S. (including exports)	$	(481	)	$	(492	)	$	244
International		470			304			306
Total (loss) income before income taxes	$	(11	)	$	(188	)	$	550

Chemours recorded a tax benefit of $18 for the year ended December 31, 2016, a tax benefit of $98 for the year ended December 31, 2015 and a tax provision of $149 for the year ended December 31, 2014. The $80 decrease in tax benefits and the corresponding change in the effective income tax rates were primarily due to a $50 valuation allowance recorded on U.S. foreign tax credits, the Company’s geographical mix of earnings as well as the gain on the sale of assets and business, which resulted in a tax expense and a corresponding change in the effective income tax rate for the year ended December 31, 2016 as compared to the same period in 2015; offset by the tax benefit on the $335 PFOA MDL Settlement accrual (see Note 20).

The decrease in state income tax provision and the corresponding decrease in the state effective tax rate, net of federal tax benefit, for the year ended December 31, 2016 when compared to 2015 and 2014 is due to the tax benefit recognized as a result of changes in state tax law which decreased apportionment in states where the Company has significant operations as well as the state benefit of the litigation accruals discussed above. The tax benefit from international operations is primarily driven by Chemours’ overall geographic mix of earnings as well as gains on foreign divestitures that were not subject to tax. In comparing the impact of foreign operations on our overall effective tax rate from 2015 to 2016, the significant driver of the change in the benefit is a reduction in the pre-tax loss within the US while income from foreign operations has increased over the prior period.

The Company recorded a valuation allowance of $50 as of December 31, 2016 on its U.S. foreign tax credits based on available positive and negative evidence. For the three years ended December 31, 2016, the Company has incurred pre-tax losses in the U.S., which limit the ability to consider other subjective evidence such as the Company’s projections for future growth. The amount of the foreign tax credits that are considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period increase or if objective negative evidence in the form of cumulative losses is no longer present. Exchange gains (losses) principally reflect the impact of non-taxable gains and losses resulting from remeasurement of foreign currency-denominated monetary assets and liabilities. Depletion represents the tax benefit from the percentage depletion deductions taken pursuant to Section 613 of the Code. Goodwill represents the tax effect of the non-deductible goodwill associated with asset sales that took place in 2016. In 2015, the goodwill adjustment was the tax impact of reallocations based on Chemours’ new business reporting units and impairment charges, as described in Note 14. In addition, Chemours is entitled to a domestic manufacturing deduction relating to income from certain qualifying domestic production activities pursuant to Section 199 of the Code in tax years 2014, as well as a one-time tax benefit recognized in 2014 relating to a tax accounting method change. Due to net operating losses in 2015 and 2016, the Company is not computing a benefit related to Section 199 in those years. Consistent with the discussion in Note 2, the pre-spin effective tax rate stated herein may not be indicative of the future effective tax rate of Chemours as a result of the separation from DuPont.

Under the tax laws of various jurisdictions in which the Company operates, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward or back, subject to statutory limitations, to reduce taxable income or taxes payable in the future or prior years. At December 31, 2016, the U.S federal and state tax losses are $42, which substantially expire in 2035. The Company also has U.S. foreign tax credit carryforwards of $50, of which $27 expire in 2025 and $23 expire in 2026, which are fully offset by a valuation allowance. Lastly, the Company has foreign net operating losses of $3, which substantially expire between 2025 and 2026.

At December 31, 2016, the Company deemed approximately $2,100 of unremitted earnings of subsidiaries outside the U.S. as indefinitely reinvested. No deferred tax liability has been recognized with regard to the remittance of such earnings. It is not practical to estimate the income tax liability that might be incurred if such earnings were remitted to the U.S.

Each year, Chemours and/or its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions. The following significant jurisdictions’ tax returns are subject to examination by their respective taxing authorities in the open years listed:


Jurisdiction	Open Years
China		2011 through 2016
Mexico		2011 through 2016
Netherlands		2012 through 2016
Taiwan		2014 through 2016
United States		2015 through 2016

Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the tax matters agreement. As a result, income tax uncertainties are recognized in the Company’s consolidated financial statements in accordance with accounting for income taxes, when applicable. Although it is difficult to predict the timing, we estimate that approximately $6 of unrecognized income tax benefits, excluding the impact relating to accrued interest and penalties, could be resolved within the next twelve months as a result of an accounting method change request filed with the Internal Revenue Service in the fourth quarter of 2016. We are not aware of any other matters that would result in significant changes to the amount of unrecognized income tax benefits reflected in the Consolidated Balance Sheet as of December 31, 2016.

As previously discussed in Note 3, prior to the separation, Chemours was included in DuPont’s consolidated income tax returns, and Chemours’ income taxes for those periods are computed and reported herein under the “separate return method”. Use of the separate return method may result in differences when the sum of the amounts allocated to stand-alone tax provisions are compared with amounts presented in the consolidated financial statements. In that event, the related deferred tax assets and liabilities could be significantly different from those presented herein for these periods. Certain tax attributes, e.g. net operating loss carryforwards, which were actually reflected in DuPont’s consolidated financial statements may or may not exist at the stand-alone Chemours level. Chemours’ consolidated financial statements do not reflect any amounts due to DuPont for income tax related matters prior to separation as it is assumed that all such amounts due to DuPont were settled on December 31 of each year.

The following table shows the change in our unrecognized tax benefit.

	Year Ended December 31,
(Dollars in millions)	2016			2015				2014
Total unrecognized tax benefits as of January 1	$	7		$	39			$	26
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		(1	)		—				(1	)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		—			—				15
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations		—			(32	)	¹		(1	)
Total unrecognized tax benefits as of December 31	$	6		$	7			$	39
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—		$	—			$	39
Total amount of interest and penalties recognized in the Consolidated Statements of Operations		—			1		¹		2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets		—			—				8

Reduction to the unrecognized tax benefits represents DuPont’s responsibilities for uncertain income tax positions recorded prior to July 1, 2015 pursuant to the tax matters agreement. The reduction was recorded in “DuPont Company Net Investment” of the Consolidated Statements of Stockholders’ Equity for the year ended December 31, 2015.

The following is a rollforward of the deferred tax asset valuation allowance for the years ended December 31, 2016, 2015 and 2014.

	Year Ended December 31,
(Dollars in millions)	2016		2015			2014
Balance at beginning of period	$	—	$	36		$	26
Net charges to income tax expense		50		—			10
Release of valuation allowance ¹		—		(36	)		—
Balance at end of period	$	50	$	—		$	36

Release of the valuation allowance during 2015 was related to tax loss carryforward incurred prior to July 1, 2015 that is attributable to DuPont’s tax periods pursuant to the tax matters agreement. The adjustment was recorded in the “DuPont Company Net Investment” of the Consolidated Statements of Stockholders’ Equity for the year ended December 31, 2015.

Earnings Per Share of Common Stock

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

Note 10. Earnings Per Share of Common Stock

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.

	Year Ended December 31,
	2016		2015			2014
Numerator:
Net income (loss) attributable to Chemours	$	7	$	(90	)	$	400
Denominator:
Weighted average number of common shares outstanding- Basic		181,621,422		180,993,623			180,966,833	¹
Dilutive effect of the Company’s employee compensation plans ²		1,795,078		—			—
Weighted average number of common shares outstanding - Diluted ²		183,416,500		180,993,623			180,966,833

For 2014, pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

Diluted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted weighted average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect. Chemours had no equity awards outstanding prior to the spin-off.

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:

	Year Ended December 31,
	2016		2015		2014
Average number of stock options		5,820,499		8,358,894		—

Accounts and Notes Receivable - Trade, Net

12 Months Ended

Dec. 31, 2016

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Note 11. Accounts and Notes Receivable – Trade, Net

	December 31,
	2016		2015
Accounts receivable—trade, net ¹	$	742	$	757
VAT, GST and other taxes ²		46		68
Leases receivable—current		—		13
Other receivables ³		19		21
Total	$	807	$	859

Accounts receivable – trade is net of allowances of $5 and $4 as of December 31, 2016 and 2015, respectively. Allowances are equal to the estimated uncollectible amounts.

Value Added Tax (VAT) and Goods and Services Tax (GST).

Other receivables consist of notes receivable, advances and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was $7, $1 and $1 for the years ended December 31, 2016, 2015 and 2014, respectively.

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2016

Inventory Net [Abstract]

Inventories

Note 12. Inventories

	December 31,
	2016			2015
Finished products	$	532		$	613
Semi-finished products		150			172
Raw materials, stores and supplies		285			433
Subtotal		967			1,218
Adjustment of inventories to LIFO basis		(200	)		(246	)
Total	$	767		$	972

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued using the LIFO method at substantially all of the U.S. locations, which comprised $465 and $657 or 48% and 54% of inventories before the LIFO adjustments at December 31, 2016 and December 31, 2015, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued using the average cost method.

Property, Plant, and Equipment

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Property, Plant and Equipment

Note 13. Property, Plant and Equipment

Chemours’ property, plant and equipment consisted of:

	December 31,
	2016			2015
Equipment	$	6,748		$	7,327
Buildings		814			737
Construction in progress		293			804
Land		106			111
Mineral rights		36			36
Total		7,997			9,015
Accumulated depreciation		(5,213	)		(5,838	)
Net property, plant and equipment	$	2,784		$	3,177

Depreciation expense amounted to $281, $264 and $254 for the years ended December 31, 2016, 2015 and 2014, respectively. Property, plant and equipment includes gross assets under capital leases of $5 and $7 at December 31, 2016 and 2015, respectively. Interest expense capitalized as part of property, plant and equipment was $18 and $21 for the years ended December 31, 2016 and 2015. Chemours did not incur interest in the year ended December 31, 2014.

During the third quarter of 2016, the Company evaluated the carrying value of its aniline manufacturing facility in Pascagoula, Mississippi for recoverability given current business plans. The evaluation performed indicated that the carrying amount of this asset group was not recoverable when compared to the expected undiscounted cash flows. Based on management’s assessment of the fair value of the asset group, the Company determined that the carrying value of the Pascagoula aniline asset group exceeded its fair value and as a result, a $48 pre-tax impairment charge was recorded in the Chemical Solutions segment, which represents an impairment of substantially all of the remaining net book value of the Pascagoula aniline asset group.

During the third quarter of 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, excluding cyanides, the Company determined that the carrying value of the RMS manufacturing facility of the Chemical Solutions segment may not be recoverable given the strategic decision to discontinue investment in the business. An impairment evaluation was performed which indicated that the carrying amount of this asset group in the U.S. was not recoverable when compared to the expected undiscounted cash flows. Based on management’s assessment of the fair value of the asset group, the Company determined that the carrying value of that asset group exceeded the fair value and as a result, a $45 pre-tax impairment charge was recorded in the Chemical Solutions segment, which represents an impairment of substantially all of the remaining net book value of the RMS asset group.

The fair value of the asset groups were determined using an income approach based on the present value of the estimated future cash flows. The key assumptions used included growth rates and cash flow projections, discount rate, tax rate and an estimated terminal value. The amount was recorded in “restructuring and asset related charges, net” in the Consolidated Statements of Operations. Refer to Note 6 for additional information.

Goodwill and Other Intangible Assets, Net

12 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

Note 14. Goodwill and Other Intangible Assets, Net

Goodwill: The following table summarizes changes in the carrying amount of goodwill by reportable segment:

	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2014	$	13	$	85	$	100		$	198
Impairment charge		—		—		(25	)		(25	)
Currency translation and other		—		—		(7	)		(7	)
Balance as of December 31, 2015	$	13	$	85	$	68		$	166
Sale of business ¹		—		—		(13	)		(13	)
Currency translation and other		—		—		—			—
Balance as of December 31, 2016	$	13	$	85	$	55		$	153

Represents goodwill disposed in connection with the sale of the C&D business (See Note 7).

Accumulated impairment losses as of December 31, 2016, 2015 and 2014 included in goodwill are $25, $25 and $0, respectively.

The Company has three operating segments: Titanium Technologies, Fluoroproducts and Chemical Solutions (see Note 24). The Company defines its reporting units as one level below the operating segments except for Titanium Technologies, which is an operating segment and a reporting unit. The Company tested the goodwill attributable for each of reporting units within the operating segments for impairment as of October 1, 2016 and concluded that the estimated fair value of each reporting unit, for which goodwill is recorded, substantially exceeded the reporting unit’s carrying value, indicating that none of the Company’s goodwill was impaired.

In October 2016, the Fluoroproducts segment leader announced a new organizational structure change to better manage the business and drive accountability. The change in the organizational structure also changed the reporting units of Fluoroproducts segment to Fluorochemicals and Fluoropolymers effective November 1, 2016. Prior to this change, the Fluoroproducts segment’s reporting units were Fluorochemicals, Industrial Resins and Diversified Technologies, which were tested for annual impairment as of October 1, 2016. The reporting unit change did not result in any impairment based on a separate impairment evaluation performed at the effective date of the change, as estimated fair value of the new reporting unit substantially exceeded its carrying value.

In 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio and the resulting changes to the reporting units in the third quarter of 2015, the Chemical Solutions segments recorded a $25 pre-tax impairment charge related to its Sulfur reporting unit. Sulfur reporting unit was disposed through the sale of its assets and business during 2016 (see Note 7).

The Company evaluates goodwill for impairment using a two-step process. The first step is utilizing a discounted cash flow methodology to calculate the fair value of its reporting units; and where market comparables are available, the Company considers EBITDA multiples as part of the reporting unit valuation analysis. Key assumptions used in the discounted cash flows include projected growth rates, discount rates, tax rates and terminal values. Factors considered in developing cash flows and EBITDA projections include: 1) macroeconomic conditions; 2) industry and market considerations; 3) costs of raw materials and labor or other costs; 4) overall financial performance; and 5) other relevant entity-specific events. The discount rate used represents the weighted average cost of capital for the reporting units considering the risks and uncertainty inherent in the cash flows of the reporting units and in the internally developed forecasts. The second step of the quantitative test is required if the first step of the quantitative test indicates a potential impairment. The second step is performed by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of its goodwill. If the carrying amount of goodwill is greater than its implied fair value, an impairment loss is recorded. The use of these unobservable inputs results in the fair value estimate being classified as a Level 3 asset measured at fair value on a nonrecurring basis subsequent to its original recognition.

The determination of whether or not goodwill is impaired involves a significant level of judgment in the assumptions underlying the approaches’ used to determine the estimated fair value of our reporting units. Chemours believes that assumptions and rates used in the impairment assessment are reasonable. However, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. The Company will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions or changes in management’s business strategy, indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management’s estimates.

Intangible Assets, Net: The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:

	December 31, 2016							December 31, 2015
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(7	)	$	2	$	10	$	(8	)	$	2
Patents		19		(18	)		1		19		(17	)		2
Purchased trademarks		5		(2	)		3		5		(2	)		3
Purchased and licensed technology		3		(2	)		1		8		(6	)		2
Other ¹		10		—			10		3		(2	)		1
Total	$	46	$	(29	)	$	17	$	45	$	(35	)	$	10

Represents non-cash favorable supply contracts acquired in connection with the sale of Sulfur business and recognized during the third quarter of 2016 based on the present value of the difference between their contractual cash flows and estimated cash flows had the contracts been executed at a determinable market price. These contract intangibles will be amortized to cost of goods sold over the remaining life of the supply contracts through 2021.

The aggregate pre-tax amortization expense for definite-lived intangible assets was $3, $3 and $3 for the years ended December 31, 2016, 2015 and 2014, respectively. The estimated aggregate pretax amortization expense for 2017, 2018, 2019, 2020 and 2021 is $4, $3, $3, $3 and $1, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from 5 to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. There are no indefinite-lived intangible assets.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Other Assets

12 Months Ended

Dec. 31, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Other Assets

Note 15. Other Assets

	December 31, 2016		December 31, 2015
Leases receivable - non-current ¹	$	—	$	125
Capitalized repair and maintenance costs		145		149
Pension assets ²		159		138
Advances and deposits		—		11
Deferred income taxes		41		47
Asset held for sale		29		—
Miscellaneous ³		43		38
Total	$	417	$	508

Relates to Sulfur business which was included in the assets disposed in 2016. See Direct Financing Leases below.

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $13 and $19 as of December 31, 2016 and 2015, respectively.

Asset Held for Sale

In December 2016, the Company’s corporate headquarters building located in Wilmington, Delaware, was classified as held for sale in connection with a sale agreement entered into in January 2017. The transaction is expected to be completed in the first quarter of 2017, and the Company expects to receive approximately $32 proceeds, subject to customary closing adjustments. As a result, the Company recorded approximately $13 pre-tax impairment charge for the year ended December 31, 2016. The Company intends to lease a portion of the building subject to the completion of the sale.

Direct Financing Leases

Prior to the sale of the Sulfur business, Chemours had constructed fixed assets on land that it leased from third parties at two of its facilities in the U.S. (Borderland and Morses Mill). Management has analyzed these arrangements and determined these assets represent direct financing leases, whereby Chemours was the lessor of this equipment. Lease receivables were recorded, which represent the balance of the minimum future lease payments. The current portion of lease receivables was previously included in accounts and notes receivable - trade, net, as shown in Note 11 and the long-term portion was previously included in other assets, as shown above. These lease receivables were included in the sale of the Sulfur business that was completed in August 2016 (see Note 7).

Accounts Payable

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Accounts Payable

Note 16. Accounts Payable

	December 31, 2016		December 31, 2015
Trade payables	$	858	$	945
VAT and other payables		26		28
Total	$	884	$	973

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Other Accrued Liabilities

Note 17. Other Accrued Liabilities

	December 31, 2016		December 31, 2015
Compensation and other employee-related costs	$	154	$	109
Employee separation costs ¹		31		76
Accrued litigation ²		342		11
Environmental remediation ²		71		68
Income taxes		39		32
Customer rebates		53		53
Deferred revenue ³		76		20
Accrued interest		21		21
Miscellaneous ⁴		85		64
Total	$	872	$	454

See Note 6 for further information.

Accrued litigation includes $335 litigation accrual related to the PFOA MDL Settlement. See Note 20 for further discussion of accrued litigation and environmental remediation.

Deferred revenue includes $58 prepayment by DuPont for specified goods and services, which Chemours expects to provide through mid-2017.

⁴

Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations (see Note 20) and other miscellaneous expenses.

Other Liabilities

12 Months Ended

Dec. 31, 2016

Other Liabilities Disclosure [Abstract]

Other Liabilities

Note 18. Other Liabilities

	December 31, 2016		December 31, 2015
Environmental remediation ¹	$	208	$	223
Employee-related costs ²		113		108
Employee separation costs ³		3		23
Accrued litigation ¹		53		58
Asset retirement obligations ¹		41		41
Deferred revenue		5		11
Miscellaneous ⁴		101		89
Total	$	524	$	553

See Note 20 for further details on environmental remediation, asset retirement obligations and accrued litigation.

See Note 22 for further details on long-term employee benefits.

See Note 6 for further information.

⁴

Miscellaneous primarily includes an accrued indemnification liability.

Debt

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Debt

Note 19. Debt

Long-term debt was comprised of the following at December 31, 2016 and 2015:

	December 31, 2016		December 31, 2015
Long-term debt:
Senior secured term loan	$	1,372	$	1,493
Senior unsecured notes:
6.625%, due May 2023		1,158		1,350
7.00%, due May 2025		750		750
6.125%, due May 2023 (€295 at December 31, 2016; €360 at December 31, 2015)		308		395
Other		3		26
Total		3,591		4,014
Less: Unamortized issue discount on senior secured term loan		5		7
Less: Unamortized debt issuance costs		42		53
Less: Short-term borrowings and current maturities		15		39
Long-term debt, net	$	3,529	$	3,915

Senior Secured Credit Facilities

On May 12, 2015, Chemours entered into a credit agreement that provides for a seven-year senior secured term loan (the Term Loan Facility) in a principal amount of $1,500 repayable in equal quarterly installments at a rate of one percent of the original principal amount per year, with the balance payable on the final maturity date. The Term Loan Facility was issued with a $7 original issue discount and bears interest at a rate of LIBOR plus 3.00%, with a 0.75% LIBOR floor. The proceeds from the Term Loan Facility were used to fund a portion of the distribution to DuPont, along with related fees and expenses.

The credit agreement also provided for a five-year senior secured revolving credit facility (the Revolving Credit Facility), which has been reduced to $750 as part of the amendment completed on February 19, 2016 (discussed below). The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. No borrowings were outstanding under our Revolving Credit Facility but had $132 and $129 in letters of credit issued and outstanding under this facility at December 31, 2016 and 2015, respectively. The Revolving Credit Facility bears variable interest of a range based on our total net leverage ratio between (a) 0.50% and 1.25% for base rate loans and (b) 1.50% and 2.25% for LIBOR loans. The applicable margins were 1.00% for base rate loans and 2.00% for LIBOR loans as of December 31, 2016 and 1.25% for base rate loans and 2.25% for LIBOR loans as of December 31, 2015. In addition, we are required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on our total net leverage ratio, between 0.20% and 0.35%. As of December 31, 2016 and 2015, commitment fees were assessed at a rate of 0.30% and 0.35%, respectively.

In September 2015, in connection with the Company’s transformation plan announced in August 2015, Chemours and its Revolving Credit Facility lenders entered into an amendment to the Revolving Credit Facility that modified the consolidated EBITDA definition in the covenant calculation to include pro forma benefits from future cost savings initiatives in the calculation of financial covenants that rely on consolidated EBITDA beginning from the quarter ended September 30, 2015. Since the revolver availability in any quarter is determined by the cushion remaining in the financial maintenance covenants at the end of the previous quarter, this amendment increased the Company’s access to the revolving credit facility.

In February 2016, Chemours and its Revolving Credit Facility lenders entered into a second amendment to the Revolving Credit Facility that (a) replaced the total net leverage ratio financial covenant with senior secured net leverage ratio; (b) reduced the minimum required levels of interest expense coverage ratio covenant; (c) increased the limits and extended the time horizon for inclusion of pro forma benefits of announced cost reduction initiatives into consolidated EBITDA definition for the purposes of calculating financial maintenance covenants; and (d) reduced the revolver availability from $1,000 to $750. As a result of this amendment, the Company recorded a charge of approximately $4 to write off a proportionate amount of unamortized debt issuance costs attributable to the reduction in revolver commitment, which was included in “Interest expense, net”.

In December 2016, Chemours entered into a third amendment to the credit agreement to change certain covenants and allow the Company to enter into a sale and leaseback transaction for the sale of its corporate headquarters building located in Wilmington, Delaware. The amendment requires the Company to use the proceeds from sale to repay portion of the term loans. These transactions are expected to be completed in the first quarter of 2017, and the Company expects to receive approximately $32 proceeds, subject to customary closing adjustments.

Fees and expenses incurred in connection with the amendments were approximately $3 and $1 for the years ended December 31, 2016 and 2015, respectively, which were primarily capitalized in “Other assets” of the Consolidated Balance Sheets and will be amortized to interest expense on a straight-line basis over the remaining term of the Revolving Credit Facility.

The credit agreement, as amended, contains financial covenants which, solely with respect to the Revolving Credit Facility, require Chemours not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries’ ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants as of December 31, 2016.

Chemours’ obligations under the senior secured credit facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the senior secured credit facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of Chemours and its material wholly-owned domestic subsidiaries’ assets, including 100% of the stock of domestic subsidiaries and 65% of the stock of certain foreign subsidiaries.

Senior Unsecured Notes

On May 12, 2015, Chemours issued senior unsecured notes (the “Notes”) with an aggregate principal of approximately $2,503 in a private placement, which comprise of $1,350 aggregate principal amount issued at an interest rate of 6.625% per annum and will mature on May 15, 2023 (the “2023 Notes”), $750 aggregate principal amount issued at an interest rate of 7.000% per annum and will mature on May 15, 2025 (the “2025 Notes”) and €360 aggregate principal amount issued at an interest rate of 6.125% and will mature on May 15, 2023 (the “Euro Notes”). The Notes require payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year.

The proceeds from the Notes were used to fund the cash and in-kind distributions to DuPont and to pay related fees and expenses. The in-kind distribution to DuPont of $507 aggregate principal amount of Chemours 2025 Notes were exchanged by DuPont with third parties for certain DuPont notes.

In connection with the issuance of the Notes, Chemours entered into a registration rights agreement, in which Chemours agreed to file with the SEC, a registration statement for the exchange of the Notes for new registered notes with identical terms. On March 18, 2016, Chemours filed a registration statement on Form S-4 with respect to the exchange offer. The registration statement was declared effective on April 12, 2016, and the exchange offer was completed on May 19, 2016. In addition, on May 5, 2016, the Euro Notes were listed for trading on the Global Exchange Market of the Irish Stock Exchange.

Each series of Notes is or will be fully and unconditionally guaranteed, jointly and severally, by Chemours’ existing and future domestic subsidiaries that guarantee (the Guarantors) the Senior Secured Credit Facilities or that guarantee other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $75 (the Guarantees). The Notes are unsecured and unsubordinated obligations of Chemours. The Guarantees are unsecured and unsubordinated obligations of the Guarantors. The Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the Notes. The Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt. Chemours’ is obligated to offer to purchase the Notes at a price of (a) 101 percent of their principal amount, together with accrued and unpaid interest, if any, to the date of purchase, upon the occurrence of certain change of control events and (b) 100 percent of their principal amount, together with accrued and unpaid interest, if any, to the date of purchase, with the proceeds from certain asset dispositions. These restrictions and prohibitions are subject to certain qualifications and exceptions set forth in the Indenture, including without limitation, reinvestment rights with respect to the proceeds of asset dispositions. Chemours is permitted to redeem some or all of the 2023 Notes and Euro Notes by paying a “make-whole” premium prior to May 15, 2018, and on or after May 15, 2018 and thereafter at specified redemption prices. Chemours may redeem some or all of the 2025 Notes on or after May 15, 2020 at specified redemption prices. Chemours may also redeem some or all of the 2023 Notes and Euro Notes by means other than a redemption, including tender offer and open market repurchases.

Term Loans and Notes Repayments

During the year ended December 31, 2016, the Company repurchased or repaid portions of its senior secured term loans (“Term Loans”), 2023 Notes and Euro Notes with aggregate principal and cash payment amounts as follows:

	Year Ended December 31, 2016
	Aggregate Principal		Cash Payment
Term Loans ¹	$	105	$	104
2023 Notes		192		182
Euro Notes		73		68
	$	370	$	354

¹ The Term Loans aggregate principal amounts exclude the required quarterly installment repayments equivalent to $15 per year.

For the year ended December 31, 2016, we recorded in “Interest expense, net” of the Consolidated Statements of Operations a net gain on extinguishment of debt of $10, net of approximately $5 charges related to the write-off of deferred financing costs associated with the extinguished debt.

Maturities

Chemours has required quarterly principal payments related to the Term Loan Facility equivalent to 1.00% per annum through March 2022, with the balance due at maturity. Term Loan principal maturities over the next five years are $15 in each year from 2017 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2022 and beyond will be $3,513.

In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, the Company is also required to make additional principal repayments, depending on leverage levels as defined in the credit agreement, equivalent to up to 50% of excess cash flow based on certain leverage targets with stepdowns to 25% and 0% as actual leverage decreases to below 3.00 to 1.00 leverage target.

Debt Fair Value

The fair values of the Term Loan Facility, the 2023 notes, the 2025 notes and the 2023 Euro notes at December 31, 2016 were approximately $1,370, $1,149, $739 and $305, respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

Note 20. Commitments and Contingent Liabilities

Guarantees

(a)

Obligations for Equity Affiliates and Others

Chemours has directly guaranteed various obligations of customers, suppliers and other third parties. At December 31, 2016 and December 31, 2015, Chemours had directly guaranteed less than $1 and $8 of such obligations, respectively. These represent the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties. No amounts were accrued at December 31, 2016 and 2015.

Chemours assesses the payment and performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

(b)

Operating Leases

Chemours uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the lease agreement. Future minimum lease payments (including residual value guarantee amounts) under non-cancelable operating leases are $62, $53, $46, $23 and $31 for the years ended December 31, 2017, 2018, 2019, 2020 and 2021, respectively, and $43 for the years thereafter. Net rental expense under operating leases was $68, $83 and $75 during the years ended December 31, 2016, 2015 and 2014, respectively.

Asset Retirement Obligations

Chemours has recorded asset retirement obligations primarily associated with closure, reclamation and removal costs for mining operations related to the production of TiO₂ in the Titanium Technologies segment. A summary of the changes in asset retirement obligations is as follows:

(Dollars in millions)	Year Ended December 31,
	2016			2015
Beginning balance	$	42		$	43
Accretion expense		2			1
Settlements/payments		(1	)		(2	)
Ending balance	$	43		$	42
Current portion	$	2		$	1
Non-current portion	$	41		$	41

Litigation

In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to or required under the separation-related agreements executed prior to the separation to indemnify DuPont against various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours’ consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, including PFOA multi-district litigation (“MDL”), management’s estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter relating to PFOA, these indemnification claims could materially adversely affect Chemours’ financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

(a)

Asbestos

At December 31, 2016 and 2015, there were approximately 1,900 lawsuits and 2,200 lawsuits, respectively, pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside the U.S. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At December 31, 2016 and 2015, Chemours had an accrual of $41 and $44 related to this matter, respectively. Chemours reviews this estimate and related assumptions quarterly. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter.

(b)

Benzene

In the separation, DuPont assigned its Benzene docket to Chemours. At December 31, 2016 and 2015, there are 27 and 29 cases pending against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products, such as paints, thinners and reducers.

Through DuPont, Chemours has received a claim by Phillips66 for indemnity and defense for three matters arising at a former DuPont / Conoco Texas site. Phillips66 seeks reimbursement for its settlement and fees in one matter and assumption of the defense in two matters.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood’s Acute Myelogenous Leukemia (AML) was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the Plaintiffs favor awarding $6.9 in compensatory damages and $1.5 in punitive damages. In March 2016, acting on the Company’s motion, the Court struck the punitive award. Through DuPont, Chemours has filed an appeal on the remaining award based upon substantial errors made at the trial court level. Plaintiffs have filed a cross appeal.

Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each Benzene matter is highly fact driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time.

(c)

PFOA

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) at its Fayetteville plant (Fayetteville, North Carolina) and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites including: Washington Works (Parkersburg, West Virginia), Chambers Works (Deepwater, New Jersey), Dordrecht Works (Netherlands), Changshu Works (China), and Shimizu (Japan). These sites are now owned and/or operated by Chemours.

Chemours recorded accruals of $349 and $20 related to the PFOA matters discussed below at December 31, 2016 and 2015, respectively. In the fourth quarter of 2016, the Company recorded an approximately $335 accrual related to the PFOA MDL settlement, which is further discussed below.

The accruals also include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection (NJDEP). These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Health Advisory. A provisional health advisory level was set in 2009 at 0.4 parts per billion (ppb) that includes PFOA in drinking water. In May 2016, the EPA announced a health advisory level of 0.07 ppb that includes PFOA in drinking water. As a result, we recorded an additional $4 in the second quarter of 2016 based on management’s best estimate of the impact of the new health advisory level on the company’s obligations to the EPA, which have expanded the testing and water supply commitments previously established. Based on prior testing, the Company has initiated additional testing and treatment in certain additional locations in and around Chambers Works and Washington Works plants. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

Drinking Water Actions

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of December 31, 2016, less than $1 has been disbursed from the escrow account related to medical monitoring.

In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At separation, this obligation was assigned to Chemours, which is included in the accrual amounts recorded as of December 31, 2016.

Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At December 31, 2016 and 2015, there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia, an increase of approximately 600 over year end 2014. These lawsuits are consolidated in an MDL in Ohio federal court. Based on the information currently available to the Company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 30 lawsuits alleging wrongful death.

Although the majority of the plaintiffs in the MDL allege multiple diseases, the table below approximates the number of plaintiffs in each of the six probable link disease categories.

Alleged Injury	Approximate Number of Plaintiffs
Kidney cancer		200
Testicular cancer		70
Ulcerative colitis		300
Preeclampsia		200
Thyroid disease		1,430
High cholesterol		1,340

In the third quarter of 2014, six plaintiffs from the MDL were selected for individual bellwether trials.

Settlement of MDL between DuPont and MDL Plaintiffs

On February 11, 2017, DuPont entered into an agreement in principle with plaintiffs’ counsel representing the MDL plaintiffs providing for a global settlement of all cases and claims in the MDL, including all filed and unfiled personal injury cases and claims that are part of the plaintiffs’ counsel’s claim inventory, as well as cases that have been tried to a jury verdict (the “MDL Settlement”). The total settlement amount is $670.7 million dollars in cash, half of which will be paid by Chemours and half paid by DuPont. DuPont’s payment would not be subject to indemnification or reimbursement by Chemours, and Chemours has accrued $335 million associated with this matter at December 31, 2016. In exchange for payment of the total settlement amount, DuPont and Chemours will receive a complete release of all claims by the settling plaintiffs. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. The MDL Settlement is not subject to court approval; however, the MDL Settlement may not proceed in certain conditions, including a walk-away right that enables DuPont to terminate the MDL Settlement if more than a specified number of plaintiffs determine not to participate. In connection with the MDL Settlement, DuPont and MDL plaintiffs’ counsel have sought a stay (the “Stay of MDL Litigation”) of all judicial proceedings related to this action in the federal district court and in the U.S. Court of Appeals for the Sixth Circuit. If the MDL Settlement is terminated or otherwise does not proceed, additional lawsuits may go to trial or appeal.

Litigation and Procedural Posture Prior to Stay of MDL Litigation

All six bellwether cases in the MDL have now been tried, resolved, appealed or otherwise addressed. Two bellwether cases have been tried. The first case (Bartlett v. DuPont / kidney cancer) was tried to a verdict in October 2015. The jury found in favor of the plaintiff, awarding $1.1 in damages for negligence and $0.5 for emotional distress. The jury found that DuPont’s conduct did not warrant punitive damages. A second case (Freeman v. DuPont / testicular cancer) was tried to verdict in July 2016. The jury found in favor of the plaintiff awarding $5.1 in compensatory damages and $0.5 in punitive damages and attorneys’ fees. Plaintiff’s counsel alleges that they are entitled to at least $6.9 in attorneys’ fees and costs for the Freeman trial. Absent the Stay of MDL Litigation, the Court would make a determination after post-trial submissions by the parties. The Court’s determination would be subject to appeal. Court rulings made before and during both trials resulted in several significant grounds for appeal and an appeal to the Sixth Circuit has been filed for the first case. Oral argument on the appeal of the first case was held in December 2016. The Company, through DuPont, is pursuing post-trial motions and appeals for the second case.

Three bellwether PFOA cases were settled in 2016 as trial approached. These cases (Wolf v. DuPont / ulcerative colitis, Dowdy v. DuPont / kidney cancer, Baker v. DuPont / kidney cancer) were settled for amounts well below the incremental cost of preparing for trials. To date, the settlements have been individually and in aggregate immaterial to the Company. The final case (Pugh v. DuPont / ulcerative colitis) was removed from the bellwethers when it was determined that the plaintiff did not suffer from the alleged disease.

The trial court announced that, starting in May 2017, 40 individual plaintiff trials will be scheduled for a 12-month period. Following the conclusion of the six bellwether cases, on July 19, 2016, the court moved two of the 40 matters (Vigneron v. DuPont / testicular cancer and Moody v. DuPont / testicular cancer) forward and set the cases for trial on November 14, 2016 and January 17, 2017, respectively. The trial court’s multi-year plan pertains only to the approximately 270 cases claiming cancer. Based on the current plan, the remaining cases, comprising approximately 93% of the docket, will remain inactive.

The November 2016 trial (Vigneron v. DuPont / testicular cancer) resulted in a verdict in favor of the Plaintiff for $2 in compensatory damages, $10.5 in punitive damages, and attorney’s fees and costs. Absent the Stay of MDL Litigation, the Company, through DuPont, will pursue post-trial motions and appeals. The January 2017 trial (Moody v. DuPont / testicular cancer) commenced in the first quarter of 2017 but was stayed pending the MDL Settlement and its implementation.

A confidential mediation process was established by the court early in this MDL.

Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. The MDL Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by DuPont or Chemours. No other claims in the MDL have been settled or resolved during the periods presented.

Settlement between DuPont and Chemours related to MDL

DuPont and Chemours have also agreed, subject to and following the completion of the MDL Settlement, to a limited sharing of potential future PFOA liabilities (i.e., “indemnifiable losses,” as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours would annually pay future PFOA liabilities up to $25 million and, if such amount is exceeded, DuPont would pay any excess amount up to the next $25 million (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess liabilities under the terms of the separation agreement. After the five-year period, this limited sharing agreement would expire, and Chemours’ indemnification obligations under the separation agreement would continue unchanged. Chemours has also agreed that, upon the MDL Settlement becoming effective, it will not contest its liability to DuPont under the separation agreement for PFOA liabilities on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties or attorneys’ fees, and waives any such defenses with respect to PFOA liabilities. Chemours has, however, retained defenses as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

PFOA Summary

While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

Chemours has accrued $335 million associated with the MDL Settlement at December 31, 2016.

If the MDL Settlement does not proceed, any cases stayed or additional lawsuits may go to trial or appeal. An adverse ruling at trial or on appeal could result in our incurring additional costs and liabilities, which are difficult to estimate beyond accrued amounts and involve significant uncertainty due to the uniqueness of the individual MDL plaintiff’s claims and the defenses to those claims, both as to potential liability and damages on an individual claim basis, and numerous unsettled legal issues, among other factors, such as general versus specific causation, lack of specific fact discovery allowed to date on vast majority of the cases, lack of validation of basic facts associated with plaintiffs and related claims, and the three cases tried to verdict to date did not inform of the many salient facts and legal issues needed for assessment of the other cases. The appellate courts will rule on matters that have been tried. The Company believes there are strong common and individual grounds for appealing these verdicts and, if any such verdict is overturned, any subsequent verdict relying on such overturned ruling would likely also be overturned. The trials and appeals of the MDL matters will occur over the course of many years. Significant unfavorable outcomes in a number of cases in the MDL could have a material adverse effect on Chemours’ consolidated financial position, results of operations or cash flows.

There could also be new lawsuits filed related to DuPont’s use of PFOA, its manufacture of PFOA, or its customers use of DuPont products that may not be within the scope of the MDL Settlement. Any such new litigation could also result in Chemours incurring additional costs and liabilities. Management believes it is reasonably possible that the Company could incur losses related to other PFOA matters in excess of amounts accrued but any such losses are not estimable at this time.

(d)

U.S. Smelter and Lead Refinery, Inc.

Five lawsuits, including two putative class actions, were filed against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Three of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, damages under the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA”) and damages under the Fair Housing Act (“FHA”). At separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. DuPont has requested that Chemours defend and indemnify it, and Chemours has agreed to do so under a reservation of rights. Management believes a loss is reasonably possible but not estimable at this time.

Environmental

Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

At December 31, 2016 and 2015, the Consolidated Balance Sheets included a liability relating to these matters of $278 and $297, respectively, which, in management’s opinion, is appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of on-going maintenance and monitoring (“OM&M”) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately $535 above the amount accrued at December 31, 2016.

For the years ended December 31, 2016, 2015, and 2014, Chemours incurred environmental remediation expenses of $44, $38, and $59, respectively.

Based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the Company’s financial position, results of operations or cash flows at any given year, as such obligation can be satisfied or settled over many years.

Financial Instruments

12 Months Ended

Dec. 31, 2016

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Financial Instruments

Note 21. Financial Instruments

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, Chemours enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management. This program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program has procedures consistent with Chemours’ financial risk management policies and guidelines.

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis in the Consolidated Balance Sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred.

At December 31, 2016, there were 45 forward exchange currency contracts outstanding with an aggregate gross notional value of $518. Chemours recognized a net loss of $15 for the year ended December 31, 2016 and a net gain of $42 for the year ended December 31, 2015, which is recorded in “other income, net” in the Consolidated Statements of Operations.

Net Investment Hedge - Foreign Currency Borrowings

Beginning on July 1, 2015, Chemours designated its €360 million Euro notes (see Note 19) as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours uses the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro notes due to remeasurement of the effective portion is reported in accumulated other comprehensive loss in the Consolidated Balance Sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the Consolidated Statements of Operations. Chemours evaluates the effectiveness of its net investment hedge quarterly at the beginning of each quarter. Chemours did not record any ineffectiveness for the year ended December 31, 2016. The Company recognized a gain of $14 and $8 for the years ended December 31, 2016 and 2015 on its net investment hedges within accumulated other comprehensive income.

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2
Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	2
Total liability derivatives		$	4	$	2

We classify our foreign currency forward contracts in Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=64837297&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64837297&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Long-Term Employee Benefits

12 Months Ended

Dec. 31, 2016

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Long-Term Employee Benefits

Note 22. Long-Term Employee Benefits

Plans Covering Employees in the U.S.

Chemours sponsors a variety of employee benefit plans which cover substantially all U.S. employees. Prior to July 1, 2015, U.S. employees generally participated in DuPont’s primary pension plan, the Retirement Savings Plan and certain other long-term employee benefit plans. In conjunction with the separation on July 1, 2015, Chemours employees stopped participating in DuPont plans and became participants in newly established Chemours plans. DuPont retained all liabilities related to its U.S. plans post-separation.

On July 1, 2015, Chemours established a defined contribution plan, similar in design to the DuPont Retirement Savings plan, which covered all eligible U.S. employees. The purpose of the Plan is to encourage employees to save for their future retirement needs. The plan is a tax qualified contributory profit sharing plan, with cash or deferred arrangement, and any eligible employee of Chemours may participate. Chemours matches 100% of the first 6% of the employee’s contribution election. Chemours may also provide an additional discretionary retirement savings contribution to eligible employees’ compensation. The amount of this contribution, if any, is at the sole discretion of the Company. The plan’s matching contributions vest immediately upon contribution. The discretionary contribution vests for employees with at least three years of service.

In lieu of a defined benefit plan like DuPont’s primary pension plan, Chemours provides an enhanced 401(k) contribution for employees who previously participated in DuPont’s pension plan. The enhanced benefits consist of an additional contribution of 1% to 7% of the employee’s eligible compensation depending on the employee’s length of service with DuPont at the time of separation. The plan will continue for a period up to 2019, subject to early termination.

Plans Covering Employees Outside the U.S.

Pension coverage for employees of Chemours non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans established after separation and comparable to the DuPont plans in those countries. Obligations under such plans are funded by depositing funds with trustees, covered by insurance contracts or are unfunded.

Participation in the Plans

Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. plans, except for the plans in the Netherlands and Taiwan, as though they were participants in a multi-employer plan with the other businesses of DuPont. The following table presents the multi-employer pension expense allocated by DuPont to Chemours for the plans in which Chemours participated prior to separation. The allocation of cost was based on active employee headcount and is included in the Consolidated Statement of Operations. These amounts do not represent cash payments to DuPont or DuPont’s plans.

	EIN / Pension	Year Ended December 31,
Plan Name	Number	2016		2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	48	$	51
All other U.S. and non-U.S. Plans			—		5		(1	)

Single and Multiple Employer Plans

Beginning in the first quarter of 2015, Chemours has accounted for the plans covering its employees in the Netherlands and Taiwan as a multiple employer plan and a single employer plan, respectively. In the third quarter of 2015, in connection with the separation, additional plans in Germany, Belgium, Japan, Korea, Mexico and Switzerland were established. As of December 31, 2015, these plans were all accounted for as single employer plans.

The net periodic benefit costs for the pension and amounts recognized in other comprehensive income for the years ended December 31, 2016, 2015 and 2014 were as follows:

	Year Ended December 31,
	2016			2015			2014
Net periodic pension cost (income):
Service cost	$	14		$	16		$	—
Interest cost		19			19			—
Expected return on plan assets		(63	)		(83	)		—
Amortization of actuarial loss		23			16			—
Amortization of prior service (credit) cost		(1	)		4			—
Curtailment gain		(2	)		—			—
Settlement loss		5			—			—
Net periodic pension income	$	(5	)	$	(28	)	$	—
Changes in plan assets and benefit obligations recognized in other comprehensive loss (income):
Net loss	$	17		$	11		$	—
Amortization of actuarial loss		(28	)		(16	)		—
Prior service credit		—			(24	)		—
Amortization of prior service credit (cost) and curtailment gain		3			(4	)		—
Effect of foreign exchange rates		(15	)		(33	)		—
Total benefit recognized in other comprehensive income	$	(23	)	$	(66	)	$	—
Total recognized in net periodic pension income and other comprehensive income	$	(28	)	$	(94	)	$	—

The pre-tax amounts recognized in accumulated other comprehensive loss are summarized below:

	Year Ended December 31,
	2016			2015			2014
Net loss	$	336		$	363		$	—
Prior service credit		(11	)		(16	)		—
Total amount recognized in accumulated other comprehensive loss	$	325		$	347		$	—

The estimated pre-tax net loss and prior service credit for the defined benefit pension plans that will be amortized from accumulated other comprehensive income (loss) into net periodic benefit cost during 2017 are $16 and $2, respectively.

Summarized information on the Company’s pension benefit plans is as follows:

	2016			2015
Change in benefit obligation
Benefit obligation at beginning of year	$	1,103		$	—
Assumption and establishment of pension plans		—			1,332
Service cost		14			16
Interest cost		19			19
Plan participants’ contributions		2			2
Actuarial loss (gain)		69			(76	)
Benefits paid		(36	)		(39	)
Plan Amendments		—			(24	)
Curtailments		(3	)		—
Settlements & transfers		(12	)		(6	)
Other events		(2	)		—
Currency translation		(49	)		(121	)
Benefit obligation at end of year		1,105			1,103
Change in plan assets
Fair value of plan assets at beginning of year		1,137			—
Assumption and establishment of pension plans		—			1,297
Actual return on plan assets		113			(7	)
Employer contributions		16			16
Plan participants’ contributions		2			2
Benefits paid		(36	)		(39	)
Settlements & transfers		(12	)		(6	)
Currency translation		(51	)		(126	)
Fair value of plan assets at end of year		1,169			1,137
Funded status at end of year	$	64		$	34

The net amounts recognized in the Consolidated Balance Sheet as of December 31, 2016 and 2015 consist of:

	2016			2015
Noncurrent assets	$	159		$	138
Current liabilities		(1	)		(2	)
Noncurrent liabilities		(94	)		(102	)
Net amount recognized	$	64		$	34

The accumulated benefit obligation for all pension plans was $1,042 and $1,030 as of December 31, 2016 and 2015, respectively.

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2016 and 2015:

Pension plans with projected benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	183	$	194
Accumulated benefit obligation		152		158
Fair value of plan assets		87		93

Pension plans with accumulated benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	179	$	190
Accumulated benefit obligation		151		157
Fair value of plan assets		84		90

Assumptions

The Company generally utilizes discount rates that are developed by matching the expected cash flows of each benefit plan to various yield curves constructed from a portfolio of high quality, fixed income instruments provided by the plan’s actuary as of the measurement date. The expected rate of return on assets reflects economic assumptions applicable to each country.

The following assumptions have been used to determine the benefit obligations and net benefit cost:

Weighted average assumptions used to determine benefit obligations

at December 31,

2016

2015

Discount rate

1.8

2.4

Rate of compensation increase¹

2.5

2.6

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Weighted average assumptions used to determine net benefit cost for the years ended December 31,	2016			2015
Discount rate		2.4	%		1.7	%
Rate of compensation increase		2.5	%		3.9	%
Expected return on plan assets		5.7	%		7.2	%

Plan Assets

Each pension plan’s assets are invested through a master trust fund. The strategic asset allocation for the trust fund is selected by management, reflecting the results of comprehensive asset and liability modeling. Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The weighted average target allocation for Chemours’ pension plan assets is summarized as follows:

	2016			2015
Cash and cash equivalents		2.5	%		2.7	%
U.S. and non-U.S. equity securities		41.6	%		42.3	%
Fixed income securities		55.9	%		55.0	%
Total		100.0	%		100.0	%

Fixed income securities include corporate issued, government issued and asset backed securities. Corporate debt investments encompass a range of credit risk and industry diversification.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The table below presents the fair values of Chemours’ pension assets by level within the fair value hierarchy, as described in Note 3, as of December 31, 2016 and 2015.

	Fair Value Measurements at December 31, 2016
	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	433		$	8	$	425
Debt - corporate issued		142			76		66
Debt - asset backed		42			25		17
U.S. and non U.S. equities		502			28		474
Derivatives - asset position		3			—		3
Derivatives - liability position		(32	)		—		(32	)
Cash and cash equivalents		77			77		—
Other		7			—		7
		1,174		$	214	$	960
Pension trust payables, net ¹		(5	)
Total	$	1,169

Payables are primarily for investment securities purchased.

	Fair Value Measurements at December 31, 2015
	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	465		$	7	$	458
Debt - corporate issued		148			60		88
Debt - asset backed		33			—		33
U.S. and non U.S. equities		460			37		423
Derivatives - asset position		4			—		4
Derivatives - liability position		(16	)		—		(16	)
Cash and cash equivalents		40			40		—
Other		6			4		2
		1,140		$	148	$	992
Pension trust payables, net ¹		(3	)
Total	$	1,137

Payables are primarily for investment securities purchased.

For pension plan assets classified as Level 1, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension benefit plan assets classified as Level 2, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates and implied volatilities obtained from various market sources.

Cash Flow

Defined Benefit Plan

DuPont contributed, on behalf of Chemours, $35 to its pension plans other than the principal U.S. pension plan in 2014. DuPont contributed, on behalf of Chemours, $66 to its other long-term employee benefit plans in 2014. DuPont contributed, on behalf of Chemours, $38 in the first half of 2015 to its pension and other long-term benefit plans and Chemours contributed $8 during 2015 to its pension plans. Chemours contributed $16 during 2016. Chemours expects to contribute $15 to its pension plans in 2017.

Estimated future benefit payments

The following benefit payments are expected to be paid over the next five years and the five years thereafter as of December 31, 2016:

2017	$	52
2018		40
2019		42
2020		43
2021		43
2022 - 2026		232

Defined Contribution Plan

DuPont’s contributions to the plan on behalf of Chemours were allocated in the amounts of $52 for the year ended December 31, 2014. In addition, DuPont contributed on behalf of Chemours about $26 to its defined contribution plans for the first half of 2015. From July 1 to December 31, 2015, Chemours contributed $28 to its defined contribution plan. For the year ended December 31, 2016, Chemours contributed $44 to its defined contribution plan.

Stock-based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Share-based Compensation

Note 23. Stock-based Compensation

Total stock-based compensation cost included in the Consolidated Statements of Operations was $20, $17 and $7 for the years ended December 31, 2016, 2015 and 2014, respectively. The income tax benefits related to stock-based compensation arrangements were $8, $7 and $3 for the years ended December 31, 2016, 2015 and 2014, respectively.

Stock-based compensation expense in prior years and until separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours employees participated. Adopted at separation, the Chemours Company Equity and Incentive Plan grants certain employees, independent contractors, or non-employee directors of the Company different forms of awards, including stock options, restricted share units (RSUs) and performance share units (PSUs). The equity and incentive plan has maximum shares reserve of 13,500,000 for the grant of equity awards plus the number of shares of converted awards (described below). As of December 31, 2016, 7,806,040 shares of equity and incentive plan reserve are still available for grants. Chemours Compensation Committee determines the long-term incentive mix, including stock options PSU and RSU, and may authorize new grants annually.

In accordance with the employee matters agreement between DuPont and Chemours, certain executives and employees were entitled to receive equity compensation awards of Chemours in replacement of previously outstanding awards granted under various DuPont stock incentive plans prior to the separation. In connection with the spin-off, these awards were converted into new Chemours equity awards using a formula designed to preserve the intrinsic value of the awards immediately prior to the July 1, 2015 spin-off. At the date of conversion, total intrinsic value of the converted options was $18. As a result of the conversion of these awards, we recorded an approximate $3 incremental charge in the third quarter of 2015. The terms and conditions of the DuPont awards were replicated and as necessary, adjusted to ensure that the vesting schedule and economic value of the awards was unchanged by the conversion. Subject to vesting condition of the award, a retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date.

Stock Options

Chemours granted non-qualified options to employees in July 2015 representing replacement of previously granted performance stock unit awards at DuPont. The July 2015 grant will cliff vest March 1, 2018 and expire 10 years from date of grant. Other than those options, Chemours’ expense related to stock options was entirely related to options granted to replace outstanding option awards from DuPont that were converted to Chemours options on July 1, 2015. During 2016, Chemours granted non-qualified options to certain of its employees, which will serially vest over a three-year period and expire 10 years from the date of grant.

The fair value related to stock options granted was determined using Black-Scholes option pricing model and the weighted average assumptions are shown in the table below:

	Year Ended December 31,
	2016			2015
Risk-free interest rate		1.46	%		1.50	%
Expected term (years)		6.00			5.40
Volatility		60.00	%		42.00	%
Dividend yield		2.14	%		6.90	%
Fair value per stock option	$	3.41		$	3.17

The Company determined the dividend yield by dividing the expected annual dividend on the Company’s stock by the option exercise price. A historical daily measurement of volatility is determined based on Chemours peer companies’ average volatility adjusted for the Company’s debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. The expected term is determined using a simplified approach, calculated as the midpoint between the vesting period and the contractual life of the award. After the separation, the simplified approach was used due to the Company’s lack of historical experience upon which to estimate the expected lives of the options.

The following table summarizes Chemours stock option activity for the year ended December 31, 2016.

	Number of Shares (in thousands)			Weighted Average Exercise Price (per share)		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015		8,284		$	14.66		4.82	$	—
Granted		1,435			5.73
Exercised		(947	)		12.17
Forfeited		(447	)		15.53
Expired		(356	)		5.82
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Exercisable, December 31, 2016		3,912		$	14.04		3.25	$	31,487

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company’s closing stock price on the last trading day of December 31, 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter end. The amount changes based on the fair market value of the Company’s stock. Total intrinsic value of options exercised for year ended December 31, 2015 was insignificant.

As of December 31, 2016, there was $3,762 of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted average period of 1.64 years.

Restricted Share Units

At the time of separation, in accordance with the employee matters agreement, the Company issued RSUs that serially vest over a three-year period and, upon vesting, convert one-for-one to Chemours common stock to replace similar DuPont awards. Under the existing awards, a retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date. Additional RSUs were also granted to key senior management employees with a performance condition. These RSUs vest on the third anniversary of the date of grant subject to the satisfaction of the performance condition. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs, both with and without performance feature, as of December 31, 2016 are shown below. The weighted average grant date fair value of RSUs granted and converted during 2016 was $6.20.

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015		2,349		$	14.87
Granted		1,003			6.20
Vested		(829	)		14.74
Forfeited		(207	)		15.09
Nonvested, December 31, 2016		2,316		$	11.23

As of December 31, 2016, there was $12,128 of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted average period of 1.54 years.

Performance Share Units

During 2016, Chemours issued PSUs to key senior management employees which, vest and convert one-for-one to Chemours’ common stock to the extent specified performance goals, including certain market-based conditions, are met over the three year performance period specified in the grant, subject to exceptions. Each grantee is granted a target award of PSUs, and may earn between 0% and 200% of the target amount depending on the Company’s performance against the performance goals. During the year ended December 31, 2016, the Company recorded stock-based compensation related to PSUs as a component of selling, general and administrative expense of approximately $2. There were no PSUs granted prior to 2016.

The following table provides compensation costs for stock-based compensation related to PSUs:

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015		—		$	—
Granted		825			6.10
Vested		—			—
Forfeited		(22	)		6.10
Nonvested, December 31, 2016		803		$	6.10

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based condition is satisfied. The per unit weighted average fair value at the date of grant for PSUs granted during the period ended December 31, 2016 was $6.10. The fair value of each PSU grant is amortized monthly into compensation expense on a straight-line basis over their respective vesting periods over 36 months. The accrual of compensation costs is based on our estimate of the final expected value of the award, and is adjusted as required for the portion based on the performance-based condition. The Company assumes that forfeitures will be minimal, and recognizes forfeitures as they occur, which results in a reduction in compensation expense. As the payout of PSUs includes dividend equivalents, no separate dividend yield assumption is required in calculating the fair value of the PSUs.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Geographic and Segment Information

12 Months Ended

Dec. 31, 2016

Segments Geographical Areas [Abstract]

Geographic and Segment Information

Note 24. Geographic and Segment Information

Geographic Information

	For and As of the Year Ended December 31,
	2016				2015				2014
	Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment
North America ²	$	2,288	$	1,861	$	2,570	$	2,184	$	2,759	$	2,273
Asia Pacific		1,315		129		1,393		136		1,548		140
EMEA ³		1,081		278		977		308		1,190		372
Latin America ⁴		716		516		777		549		935		523
Total	$	5,400	$	2,784	$	5,717	$	3,177	$	6,432	$	3,308

¹	Net sales are attributed to countries based on customer location.

²	Includes net sales in Canada of $125, $140 and $147 in 2016, 2015 and 2014, respectively. Includes net property, plant and equipment in Canada of $11, $13 and $14 in 2016, 2015 and 2014, respectively.

³	EMEA includes Europe, Middle East and Africa.

⁴	Latin America includes Mexico.

Segment Information

Chemours’ operations are classified into three segments namely: Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the segments and foreign exchange gains and losses are reflected in Corporate and Other.

The Titanium Technologies segment is the leading global producer of TiO2, a premium white pigment used to deliver opacity. The Fluoroproducts segment is a leading global provider of fluoroproducts, such as refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading North American provider of industrial and specialty chemicals, which includes cyanides, sulfur products and performance chemicals and intermediates, used in gold production, oil refining, agriculture, industrial polymers and other industries. Chemours operates globally in substantially all of its product lines.

Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and amortization of other intangible assets, excluding write-down of assets. Segment net assets includes net working capital, net property, plant and equipment, and other noncurrent operating assets and liabilities of the segment. This is the measure of segment assets reviewed by the Chief Operating Decision Maker (“CODM”).

Adjusted EBITDA is the primary measure of segment profitability used by the CODM and is defined as income (loss) before income taxes excluding the following:

•

interest expense, depreciation and amortization,

•

non-operating pension and other postretirement employee benefit costs, which represent the components of net periodic costs (income) excluding service cost component,

•

exchange losses (gains) included in “other income, net” of the statement of operations,

•

restructuring, asset-related charges and other charges, net,

•

asset impairments,

•

losses (gains) on sale of business or assets, and

•

other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

All periods presented reflect the current definition of Adjusted EBITDA.

Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	2,364	$	2,264	$	772	$	—		$	5,400
Adjusted EBITDA		466		445		39		(128	)		822
Depreciation and amortization		119		101		30		34			284
Equity in earnings of affiliates		—		26		—		3			29
Net assets		1,513		1,400		292		(3,101	)		104
Investments in affiliates		—		116		—		20			136
Purchases of plant, property and equipment		105		120		104		9			338
2015
Net sales to external customers	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA		326		300		29		(82	)		573
Depreciation and amortization		125		88		52		2			267
Equity in earnings of affiliates		—		21		—		1			22
Net assets		1,659		1,567		839		(3,935	)		130
Investments in affiliates		—		127		—		9			136
Purchases of plant, property and equipment		255		142		117		5			519
2014
Net sales to external customers	$	2,937	$	2,327	$	1,168	$	—		$	6,432
Adjusted EBITDA		723		282		17		(146	)		876
Depreciation and amortization		125		83		48		1			257
Equity in earnings of affiliates		—		20		—		—			20
Net assets		1,748		1,480		782		(337	)		3,673
Investments in affiliates		—		124		—		—			124
Purchases of plant, property and equipment		365		133		106		—			604

Total Adjusted EBITDA reconciles to total consolidated net (loss) income in the Consolidated Statements of Operations as follows:

	Year Ended December 31,
	2016			2015			2014
(Loss) income before income taxes	$	(11	)	$	(188	)	$	550
Interest expense, net		213			132			—
Depreciation and amortization		284			267			257
Non-operating pension and other postretirement employee benefit (income) costs		(20	)		(3	)		22
Exchange losses (gains)		57			(19	)		66
Restructuring charges		51			285			21
Asset related charges¹		124			73			—
(Gains) losses on sale of assets and businesses		(254	)		9			(40	)
Transaction costs²		19			9			—
Legal and other charges³		359			8			—
Adjusted EBITDA	$	822		$	573		$	876

The year ended December 31, 2016 includes $48 pre-tax asset impairment of our Pascagoula Aniline facility (see Note 13), $58 pre-tax asset impairment in connection with the sale of the Sulfur business (see Note 7), $13 pre-tax asset impairment in connection with the sale of the Company’s corporate headquarters building (see Note 15) and other asset write-offs. The year ended December 31, 2015 includes $25 of goodwill impairment (see Note 14) and $45 asset impairment of RMS facility (see Note 13). All charges, except for the corporate headquarters building impairment (which is included in Corporate and Other), are recorded in the Chemical Solutions segment.

Includes accounting, legal and bankers transaction fees incurred related to the Company’s strategic initiatives, which includes pre-sale transaction costs incurred in connection with the sales of the C&D and Sulfur businesses (see Note 7).

Includes litigation settlements, water treatment accruals and $335 litigation accrual related to the PFOA MDL Settlement (see Note 20), and lease termination charges.

Net sales to external customers by product group were as follows:

	Year Ended December 31,
	2016		2015		2014
Titanium dioxide	$	2,364	$	2,392	$	2,937
Fluoropolymers		1,171		1,246		1,326
Fluorochemicals		1,093		984		1,001
Performance chemicals and intermediates		383		551		621
Mining solutions ¹		262		301		314
Sulfur		127		243		233
Total net sales to external customers	$	5,400	$	5,717	$	6,432

¹	Previously known as Cyanides product group, which was renamed to Mining Solutions effective for the year ended December 31, 2016.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Accumulated Other Comprehensive Income (Loss)

Note 25. Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss), net of income taxes, consisted of:

	Currency Translation Adjustment			Net Investment Hedge		Employee Benefits			Total
Balance at December 31, 2013	$	19		$	—	$	—		$	19
Other comprehensive income		—			—		—			—
Balance at December 31, 2014		19			—		—			19
Assumption and establishment of pension plans, net		—			—		(311	)		(311	)
Other comprehensive (loss) income		(304	)		8		52			(244	)
Balance at December 31, 2015		(285	)		8		(259	)		(536	)
Other comprehensive (loss) income		(73	)		14		18			(41	)
Balance at December 31, 2016	$	(358	)	$	22	$	(241	)	$	(577	)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Note 26. Quarterly Financial Data (Unaudited)

The following is a summary of the quarterly results of operations for the years ended December 31, 2016 and 2015.

	For the three months ended
2016	March 31		June 30			September 30		December 31			Full Year
Net Sales	$	1,297	$	1,383		$	1,398	$	1,322		$	5,400
Cost of goods sold		1,095		1,116			1,056		1,024			4,290
Income (loss) before income taxes		70		(41	)		234		(273	)		(11	)
Net income (loss)		51		(18	)		204		(230	)		7
Net income (loss) attributable to Chemours		51		(18	)		204		(230	)		7
Basic earnings (loss) per share		0.28		(0.10	)		1.12		(1.26	)		0.04
Diluted earnings (loss) per share		0.28		(0.10	)		1.11		(1.26	)		0.04

	For the three months ended
2015	March 31		June 30			September 30			December 31			Full Year
Net Sales	$	1,363	$	1,508		$	1,486		$	1,360		$	5,717
Cost of goods sold		1,111		1,282			1,222			1,147			4,762
Income (loss) before income taxes		58		(18	)		(107	)		(121	)		(188	)
Net income (loss)		43		(18	)		(29	)		(86	)		(90	)
Net income (loss) attributable to Chemours		43		(18	)		(29	)		(86	)		(90	)
Basic earnings (loss) per share ¹		0.24		(0.10	)		(0.16	)		(0.48	)		(0.50	)
Diluted earnings (loss) per share ¹		0.24		(0.10	)		(0.16	)		(0.48	)		(0.50	)

On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours’ common stock to holders of its common stock. Basic and diluted earnings (loss) per common share for all periods prior to July 1, 2015 were calculated using the shares distributed on July 1, 2015. Refer to Note 10 for information regarding the calculation of basic and diluted earnings per share.

*	The summation of the quarterly data may not foot due to rounding.

Guarantor Condensed Consolidating Financial Information

12 Months Ended

Dec. 31, 2016

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Guarantor Condensed Consolidating Financial Information

Note 27. Guarantor Condensed Consolidating Financial Information

The following guarantor financial information is included in accordance with Rule 3-10 of Regulation S-X (Rule 3-10) in connection with the issuance of the Notes by The Chemours Company (the “Parent Issuer”). The Notes are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured unsubordinated basis, in each case, subject to certain exceptions, by the Parent Issuer and by certain subsidiaries (together, the “Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, the “Non-Guarantor Subsidiaries”). The Guarantor Subsidiaries, excluding the Parent Issuer, will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:

•

the Consolidating Statements of Comprehensive Income (Loss) for the years ended December 31, 2016, 2015 and 2014;

•

the Consolidating Balance Sheets as of December 31, 2016 and 2015;

•

the Consolidating Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014.

As discussed in Note 2, Chemours did not operate as a separate, stand-alone entity for the full period covered by consolidated financial statements. Prior to our spin-off on July 1, 2015, Chemours operations were included in DuPont’s financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the condensed consolidated financial information has been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont.

The condensed consolidating financial information is presented using the equity method of accounting for the Company’s investments in 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this footnote should be read in conjunction with the consolidated financial statements presented and other notes related thereto contained in this Annual Report.

As discussed in Note 7, the Company entered into a stock and asset purchase agreement with Lanxess, pursuant to which Lanxess acquired the Company’s C&D business comprise of certain assets and subsidiaries of the Company, including International Dioxide, Inc., which was a guarantor subsidiary.

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,615			(1,543	)		4,290
Gross profit		—			531			607			(28	)		1,110
Selling, general and administrative expenses		21			794			139			(20	)		934
Research and development expense		—			77			3			—			80
Restructuring and asset related charges, net		—			168			2			—			170
Total expenses		21			1,039			144			(20	)		1,184
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(211	)		(3	)		1			—			(213	)
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			54			(20	)		247
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to noncontrolling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	4,044		$	3,269		$	(1,596	)	$	5,717
Cost of goods sold		—			3,708			2,650			(1,596	)		4,762
Gross profit		—			336			619			—			955
Selling, general and administrative expenses		15			426			204			(13	)		632
Research and development expense		—			95			2			—			97
Restructuring and asset related charges, net		—			295			38			—			333
Goodwill impairment		—			25			—			—			25
Total expenses		15			841			244			(13	)		1,087
Equity in earnings of affiliates		—			1			21			—			22
Equity in (net loss) earnings of subsidiaries		(47	)		—			—			47			—
Interest expense, net		(131	)		(1	)		—			—			(132	)
Intercompany interest income (expense), net		44			—			(44	)		—			—
Other income (expense), net		13			92			(31	)		(20	)		54
(Loss) income before income taxes		(136	)		(413	)		321			40			(188	)
(Benefit from) provision for income taxes		(46	)		(89	)		40			(3	)		(98	)
Net (loss) income		(90	)		(324	)		281			43			(90	)
Less: Net income attributable to noncontrolling interests		—			—			—			—			—
Net (loss) income attributable to Chemours	$	(90	)	$	(324	)	$	281		$	43		$	(90	)
Comprehensive (loss) income attributable to Chemours	$	(334	)	$	(324	)	$	29		$	295		$	(334	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2014
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—	$	4,593	$	3,722		$	(1,883	)	$	6,432
Cost of goods sold		—		3,863		3,093			(1,884	)		5,072
Gross profit		—		730		629			1			1,360
Selling, general and administrative expenses		—		429		256			—			685
Research and development expense		—		127		16			—			143
Restructuring and asset related charges, net		—		11		10			—			21
Total expenses		—		567		282			—			849
Equity in earnings of affiliates		—		—		20			—			20
Equity in earnings of subsidiaries		400		—		—			(400	)		—
Other income (expense), net		—		80		(61	)		—			19
Income before income taxes		400		243		306			(399	)		550
Provision for income taxes		—		75		76			(2	)		149
Net income		400		168		230			(397	)		401
Less: Net income attributable to noncontrolling interests		—		—		1			—			1
Net income attributable to Chemours	$	400	$	168	$	229		$	(397	)	$	400
Comprehensive income attributable to Chemours	$	400	$	168	$	229		$	(397	)	$	400

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable - trade, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant and equipment		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Net property, plant and equipment		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Short-term borrowings and current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Noncontrolling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2015
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	95		$	271		$	—		$	366
Accounts and notes receivable - trade, net		—		344			515			—			859
Intercompany receivable		3		459			54			(516	)		—
Inventories		—		493			501			(22	)		972
Prepaid expenses and other		—		49			52			3			104
Total current assets		3		1,440			1,393			(535	)		2,301
Property, plant and equipment		—		7,070			1,945			—			9,015
Less: Accumulated depreciation		—		(4,899	)		(939	)		—			(5,838	)
Net property, plant and equipment		—		2,171			1,006			—			3,177
Goodwill and other intangible assets, net		—		151			25			—			176
Investments in affiliates		—		9			127			—			136
Investment in subsidiaries		3,105		—			—			(3,105	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		19		275			214			—			508
Total assets	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	637		$	336		$	—		$	973
Short-term borrowings and current maturities of long-term debt		15		24			—			—			39
Intercompany payable		202		54			260			(516	)		—
Other accrued liabilities		21		287			146			-			454
Total current liabilities		238		1,002			742			(516	)		1,466
Long-term debt, net		3,913		2			—			-			3,915
Intercompany notes payable		—		—			1,150			(1,150	)		-
Deferred income taxes		—		173			61			—			234
Other liabilities		—		456			97			—			553
Total liabilities		4,151		1,633			2,050			(1,666	)		6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		126		2,413			711			(3,124	)		126
Noncontrolling interests		—		—			4			—			4
Total equity		126		2,413			715			(3,124	)		130
Total liabilities and equity	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Investing activities
Purchases of property, plant and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Foreign exchange contract settlements		—			(12	)		—			—			(12	)
Investment in affiliates		—			—			(1	)		—			(1	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Financing activities
Intercompany short-term borrowings, net	$	560		$	—		$	—		$	(560	)	$	—
Debt repayments		(369	)		(12	)		—			—			(381	)
Dividends paid		(22	)		—			—			—			(22	)
Debt issuance costs		(4	)		—			—			—			(4	)
Proceeds from issuance of stock options		11			—			—			—			11
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at beginning of year		—			95			271			—			366
Cash and cash equivalents at end of year	$	—		$	224		$	678		$	—		$	902

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(119	)	$	171		$	121		$	9		$	182
Investing activities
Purchases of property, plant and equipment		—			(292	)		(227	)		—			(519	)
Proceeds from sales of assets, net		—			6			6			—			12
Intercompany investing activities		—			(202	)		—			202			—
Foreign exchange contract settlements		—			42			—			—			42
Investment in affiliates		—			—			(32	)		—			(32	)
Cash used for investing activities		—			(446	)		(253	)		202			(497	)
Financing activities
Proceeds from issuance of debt, net		3,489			2			—			—			3,491
Intercompany short-term borrowings, net		202			—			—			(202	)		-
Debt repayments		(8	)		(2	)		—			—			(10	)
Dividends paid		(105	)		—			—			—			(105	)
Debt issuance costs		(79	)		—			—			—			(79	)
Cash provided at separation by DuPont		—			87			160			—			247
Net transfers (to) from DuPont		(3,380	)		283			249			(9	)		(2,857	)
Cash provided by financing activities		119			370			409			(211	)		687
Effect of exchange rate changes on cash		—			—			(6	)		—			(6	)
Increase in cash and cash equivalents		—			95			271			—			366
Cash and cash equivalents at beginning of year		—			—			—			—			—
Cash and cash equivalents at end of year	$	—		$	95		$	271		$	—		$	366

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2014
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash provided by operating activities	$	—	$	302		$	208		$	(5	)	$	505
Investing activities
Purchases of property, plant and equipment		—		(287	)		(317	)		—			(604	)
Proceeds from sales of assets, net		—		30			2			—			32
Investment in affiliates		—		-			(8	)		—			(8	)
Other investing activities		—		20			—			—			20
Cash used for investing activities		—		(237	)		(323	)		—			(560	)
Financing activities
Net transfers (to) from DuPont		—		(65	)		115			5			55
Cash (used for) provided by financing activities		—		(65	)		115			5			55
Effect of exchange rate changes on cash		—		—			—			—			—
Increase in cash and cash equivalents		—		—			—			—			—
Cash and cash equivalents at beginning of year		—		—			—			—			—
Cash and cash equivalents at end of year	$	—	$	—		$	—		$	—		$	—

- Definition

The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.

+ References + Details

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2016
Accounting Policies [Abstract]
Preparation of Financial Statements	Preparation of Financial Statements The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses, including allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time and various other assumptions that we believe are reasonable. Actual results could differ from those estimates.
Principles of Consolidation and Combination	Principles of Consolidation and Combination The consolidated financial statements include the accounts Chemours and its subsidiaries, and entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company’s ownership is less than 100%, the outside shareholders’ interests are shown as noncontrolling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock or has the ability to exercise significant influence over operating and financial policies of the investee are accounting for using the equity method of accounting. As a result, Chemours’ share of the earnings or losses of such equity affiliates is included in the Consolidated Statements of Operations and Chemours’ share of such equity affiliates equity is included in the Consolidated Balance Sheets. The financial statements for the periods prior to the separation on July 1, 2015 include the combined assets, liabilities, revenues, and expenses of Chemours. We eliminated all intercompany accounts and transactions in the preparation of the accompanying consolidated financial statements.
Revenue Recognition	Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, when title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales and noncash sales incentives are recorded as a charge to cost of goods sold at the time the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the Consolidated Statements of Operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable and collectability is reasonably assured.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits or highly liquid investments with original maturities of three months or less.
Receivables and Allowance for Doubtful Accounts	Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ accounts receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines that they are uncollectible.
Inventories	Inventories Chemours’ inventories are valued at the lower of cost or market. Inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Inventories held outside the U.S. are determined by the average cost method. Elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at cost or market, whichever is lower; cost is generally determined by the average cost method. Approximately 48% and 54% of inventory is on a LIFO basis as of December 31, 2016 and 2015, respectively. The remainder is accounted for using the average cost method.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is carried at cost and is depreciated using the straight-line method. Property, plant and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method or other substantially similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the balance sheet and included in determining gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on the extension to the useful life. Capitalized repair and maintenance costs are recorded on the Consolidated Balance Sheets in “Other assets”.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired, including identified intangibles, in a business combination is recorded as goodwill. Goodwill is tested for impairment annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Goodwill is evaluated for impairment at the reporting unit level, which is defined as one level below operating segment except for Titanium Technologies, which is both an operating segment and a reporting unit. A reporting unit is the level at which discrete financial information is available and reviewed by business management on a regular basis. The Company utilizes an income approach (or discounted cash flow method) and market approach to calculate the fair value of its reporting units. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Chemours evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For purposes of recognition or measurement of an impairment loss, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of an asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of other than by sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value less cost to sell. Depreciation is discontinued for long-lived assets classified as held for sale.
Research and Development	Research and Development Research and development costs are expensed as incurred. Research and development expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products and regulatory approval of new and existing products.
Environmental Liabilities and Expenditures	Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the information is only sufficient to establish a range of probable liability and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based upon existing remediation laws and technologies. Inherent uncertainties exist in such evaluations primarily due to unknown environmental conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technology, regulatory and legal information become available. Environmental liabilities and expenditures included claims for matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation. Accrued liabilities are undiscounted and do not include claims against third parties. These liabilities are included in “Other accrued liabilities” and “Other liabilities” in the Consolidated Balance Sheet. Costs related to environmental remediation are charged to expense in the period incurred, in “Cost of goods sold” of the Consolidated Statement of Operations. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized.
Asset Retirement Obligations	Asset Retirement Obligations Chemours records asset retirement obligations at fair value at the time the liability is incurred. Fair value is measured using expected future cash outflows discounted at Chemours’ credit-adjusted risk-free interest rate, which are considered level 3 inputs. Accretion expense is recognized as an operating expense classified within cost of goods sold on the Consolidated Income Statements using the credit-adjusted risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 25 years.
Litigation	Litigation Chemours accrues for litigation matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation liabilities and expenditures included in the consolidated financial statements represent litigation matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the separation. Legal costs such as outside counsel fees and expenses are charged to expense in the period services are received.
Insurance	Insurance Chemours insures certain risks where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the Company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the separation, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of insurance and self-insurance is used, reflecting comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans have historically been obligations of DuPont. As such, these obligations were not included in the Consolidated Balance Sheets, with the exception of self-insurance liabilities related to workers compensation, vehicle liability and employee related benefits.
Defined Benefit Plans	Defined Benefit Plans We have defined benefit plans covering certain of our employees outside the U.S., which are generally required by local regulations. The benefits, which primarily relate to pension, are accrued over the employees’ service periods. We use actuarial methods and assumptions in the valuation of defined benefit obligations and the determination of net periodic pension income or expense. Differences between actual and expected results or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur but rather systematically over subsequent periods.
Stock-based Compensation	Stock-based Compensation Chemours’ stock-based compensation consists of stock options, restricted share units (RSUs) and performance share units (PSUs) to employees and non-employee directors. Stock options are measured at fair value on the grant date or date of modification, as applicable. We recognize compensation expense on a straight-line basis over the requisite service period. The number of awards ultimately expected to vest is determined by use of an estimated forfeiture rate. The estimated forfeiture rate is based on historical data for the employee group awarded options and expected employee turnover rates, which management reevaluates each period.
Income Taxes	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more likely than not threshold and accrues interest related to unrecognized income tax positions, which is included in other income, net in our Consolidated Statements of Operations. Income tax related penalties are included in the provision for income taxes. Chemours does not provide for income taxes on undistributed earnings of all foreign subsidiaries that are intended to be indefinitely reinvested. Prior to separation, income taxes presented attributed current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by ASC 740, Income Taxes (ASC 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies ASC 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise.
Foreign Currency Translation	Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (1) extensions of the parent (U.S. dollar functional currency) and (2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the consolidated financial statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories; prepaid expenses; property, plant and equipment; goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the separation, certain of Chemours foreign entities set their local currency as the functional currency.
Derivatives	Derivatives Chemours enters into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred. Please refer to Note 21 for additional information.
Fair Value Measurement	Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities; (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management’s estimates of assumptions that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Guidance Issued Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)." The objective of this standard update is to remove inconsistent practices with regard to revenue recognition between US GAAP and IFRS. The standard intends to improve comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets. The provisions of ASU No. 2014-09 will be effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company plans to adopt ASU 2014-09 as of January 1, 2018. Subsequent to the issuance of ASU No. 2014-09, the FASB has issued multiple updates in connection with Topic 606. These updates affect the guidance contained within ASU 2014-09 and will be assessed as part of the Company's revenue recognition project plan. The Company’s project plan includes a three-phase approach to implementing this standard update. Phase one, the assessment phase, is currently in process and is expected to be completed in the second quarter of 2017. In connection with this initial phase, the Company is currently performing the following activities: conducting internal surveys of its businesses to initially identify a set of applicable revenue recognition changes related to the new standard update, holding revenue recognition workshops with sales and business unit finance leadership highlighting the impacts of the new standard update, and reviewing a representative sample of revenue arrangements across all businesses to assess and validate the impact of the new guidance. Once completed, the Company will pursue the second phase of the project, where the objectives will be to establish and document key accounting policies, assess disclosure, business process and control impacts, and determine an initial quantitative impact resulting from the new standard update. Lastly, phase three’s objectives will comprise of effectively implementing the new standard update and embedding the new accounting treatment into the Company’s business processes and controls to support the financial reporting requirements. The Company is still evaluating the impact that the new standard update will have on the Company’s consolidated financial statements and will be unable to quantify its impact until the third phase of the project has been completed. The method of adoption has not yet been determined and is also not expected to be finalized until the third phase of the project plan has been completed. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”, which eliminates the requirement to determine the fair value of individual assets and liabilities of a reporting unit to measure goodwill impairment. Under the amendments, goodwill impairment testing will be performed by comparing the fair value of the reporting unit with its carrying amount and recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, but not to exceed the total amount of goodwill allocated to the reporting unit. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and should be applied on a prospective basis. Early adoption is permitted for annual or interim goodwill impairment testing performed after January 1, 2017. The Company plans to adopt this guidance in 2017. In August 2016, the FASB issued various updates to the Accounting Standards Update (ASU) 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”, which clarifies and amends certain cash receipts and cash payments presentation and classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The amendments should be applied using a retrospective transition method (unless impractical to do so) to each period presented and earlier application is permitted. Chemours is currently evaluating the impact of adopting this guidance but does not expect the adoption will have a significant impact on its cash flows. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes the leases requirements in Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases in accordance with FASB Concepts Statement No. 6, Elements of Financial Statements, and, therefore, recognition of those lease assets and lease liabilities represents an improvement over previous GAAP, which did not require lease assets and lease liabilities to be recognized for most leases. A qualitative disclosure along with specific quantitative disclosures is required to provide enough information to supplement the amounts recorded in the financial statements so that users can understand more about the nature of an entity’s leasing activities. Lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients that entities may elect to apply. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application of the amendments in this update is permitted for all entities. Chemours is currently evaluating the impact of adopting this guidance on its financial position, results of operations and debt covenants. Recently Adopted Accounting Guidance In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718)”. The update sets forth areas for simplification within several aspects of the accounting for shared-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this update are effective for fiscal periods, and interim periods within those fiscal years, beginning after December 15, 2016. Chemours adopted this guidance effective January 1, 2017 and the adoption did not have a significant impact on the Company’s financial position, results of operations and of cash flows. In April 2015, the FASB issued ASU No. 2015-05, “Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement”, which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016 prospectively to all arrangements entered into or materially modified after the effective date. The adoption did not have a significant impact on our financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis”. The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016 and the adoption did not change our consolidated entities, and therefore had no impact on the Company’s financial position, results of operations and cash flows. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern”. The update requires management to evaluate whether there is substantial doubt about a company’s ability to continue as a going concern and to provide related footnote disclosures. The update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. Chemours adopted the guidance effective December 31, 2016. No disclosure was considered necessary as of December 31, 2016 as a result of management’s evaluation.

Restructuring and Asset Related Charges, Net (Tables)

12 Months Ended

Dec. 31, 2016

Restructuring And Related Activities [Abstract]

Schedule of Restructuring Program

For the years ended December 31, 2016, 2015 and 2014, Chemours recorded charges for employee separation and asset related charges as follows:

	Year Ended December 31,
	2016		2015		2014
Restructuring Related Charges:
Employee Separation Charges	$	4	$	137	$	18
Decommissioning and other charges, net - Restructuring		47		18		—
Asset Related Charges - Restructuring		—		133		3
Total restructuring charges, net		51		288		21
Asset Related Charges - Impairment 1		119		45		—
Total restructuring and asset related charges, net	$	170	$	333	$	21

Schedule of Restructuring Charges

The charges related to the restructuring programs impacted segment earnings for the years ended December 31, 2016, 2015 and 2014 are as follows:

	Year Ended December 31,
	2016		2015		2014
Plant and product line closures ¹
Titanium Technologies	$	30	$	140	$	—
Fluoroproducts		7		24		—
Chemical Solutions		8		12		—
Sub-total		45		176		—
Global restructuring ²
Titanium Technologies		2		33		3
Fluoroproducts		4		54		16
Chemical Solutions		—		25		—
Sub-total		6		112		19
Total	$	51	$	288	$	19

Includes charges related to employee separation, decommissioning and dismantling costs, and asset related charges in connection with the restructuring activities.

Includes approximately $24 related to corporate overhead functions that was allocated to the segments for the year ended December 31, 2015.

The following table shows the change in the employee separation related liability account associated with the restructuring programs:

	Titanium Technologies Site Closures			Fluoroproducts Lines Shutdown			Chemical Solutions Site Closures			2015 Global Restructuring			Total
Year ended December 31, 2014	$	—		$	—		$	—		$	—		$	—
Charges to income for the year ended December 31, 2015 ¹		11			2			12			112			137
Charges to liability accounts:
Payments		—			—			—			(39	)		(39	)
Net currency translation and other adjustment ²														—
Year ended December 31, 2015	$	11		$	2		$	12		$	73		$	98
Charges (credits) to income for the year ended December 31, 2016 ¹		—			—			(2	)		6			4
Charges to liability accounts:
Payments		(7	)		(1	)		(1	)		(59	)		(68	)
Net currency translation and other adjustment ²		—			—			(1	)		1			—
Balance as of December 31, 2016	$	4		$	1		$	8		$	21		$	34

¹	Due to unexpected resignations of certain employees at the Company’s Niagara site during 2016, approximately $2 of employee separation charges, related to the RMS plant closure, were reversed to income during the year ended December 31, 2016.

²	Amounts include net currency translation adjustment of less than $1 for the period presented and rounding differences.

Sales of Assets and Businesses (Tables)

12 Months Ended

Dec. 31, 2016

Discontinued Operations And Disposal Groups [Abstract]

Major Components of Assets Held for Sale

The aggregate amount and major components of assets and liabilities disposed during the year ended December 31, 2016 are as follows:

	December 31, 2016
Current assets:
Accounts receivables	$	22
Inventories		17
Total current assets		39
Property, plant and equipment, net		298
Goodwill		17
Other assets		136
Less: Impairment loss		(58	)
Total non-current assets, net		393
Total assets		432
Accounts payable and accrued liabilities		17
Total liabilities		17
Net assets disposed	$	415

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Other Income (Expense), Net (Tables)

12 Months Ended

Dec. 31, 2016

Other Income And Expenses [Abstract]

Schedule of Other Income (Expense)

	Year Ended December 31,
	2016			2015			2014
Leasing, contract services and miscellaneous income ¹	$	35		$	25		$	17
Royalty income²		15			19			28
Gain (loss) on sale of assets and businesses ³		254			(9	)		40
Exchange (losses) gains, net ⁴		(57	)		19			(66	)
Total other income, net	$	247		$	54		$	19

Miscellaneous income includes accrued interest related to unrecognized tax benefits.

Royalty income is primarily for technology and trademark licensing.

The twelve months ended December 31, 2016 includes a gain on sale of C&D business and aniline factory; and a loss on sale of Sulfur business. See Note 7 for further details.

⁴

Exchange losses, net includes gains and losses on foreign currency forward contracts. See Note 21 for additional information.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Provision

	Year Ended December 31,
(Dollars in millions)	2016			2015				2014
Current tax expense:
U.S. federal	$	—		$	37		¹	$	85
U.S. state and local		—			1		¹		13
International		93			62				73
Total current tax expense		93			100				171
Deferred tax (benefit) expense:
U.S. federal		(101	)		(187	)			(20	)
U.S. state and local		(17	)		(14	)			(3	)
International		7			3				1
Total deferred tax benefit		(111	)		(198	)			(22	)
Total (benefit from) provision for income taxes	$	(18	)	$	(98	)		$	149

Recorded pursuant to the tax matters agreement.

Schedule of Deferred Tax Assets and Liabilities Components

The significant components of deferred tax assets and liabilities are as follows:

(Dollars in millions)	December 31, 2016			December 31, 2015
Deferred tax assets:
Environmental and other reserves	$	150		$	158
Litigation reserves		149			22
Stock compensation and accrued employee benefits		35			42
Other assets and other accrued liabilities		27			35
Tax loss carryforwards		95			124
Total deferred tax assets		456			381
Valuation allowance		(50	)		—
Total deferred tax assets, net		406			381
Deferred tax liabilities:
Pension and other liabilities		(16	)		(7	)
Property, plant and equipment		(441	)		(530	)
Inventories and other assets		(40	)		(31	)
Total deferred tax liabilities		(497	)		(568	)
Net deferred tax liability	$	(91	)	$	(187	)

Schedule of Effective Income Tax Rate

An analysis of the Company’s effective tax rate is as follows:

	Year Ended December 31,
	2016						2015							2014
(Dollars in millions)	$			%			$				%			$			%
Statutory U.S. federal income tax rate	$	(4	)		35.0	%	$	(66	)			35.0	%	$	192			35.0	%
State income taxes, net of federal benefit		(16	)		150.4	%		(10	)			5.1	%		6			1.0	%
Lower effective tax rate on international operations-net		(61	)		552.5	%		(23	)			12.0	%		(53	)		(9.6	)%
Depletion		(6	)		51.2	%		(6	)			3.4	%		(8	)		(1.5	)%
Goodwill		5			(47.9	)%		6				(3.2	)%		—			—	%
Exchange losses (gains)		4			(39.1	)%		(1	)			0.5	%		15			2.7	%
Provision to return and other adjustments		6			(57.9	)%		—				—	%		—			—	%
Permanent items		3			(27.3	)%		1				(0.5	)%		(5	)		(0.9	)%
Valuation allowance		50			(451.6	)%		—		¹		—	%		11			2.0	%
Section 199 domestic manufacturing deduction		—			(—	)%		—				—	%		(4	)		(0.7	)%
Other, net		1			(1.7	)%		1				(0.2	)%		(5	)		(0.9	)%
Total effective tax rate	$	(18	)		163.6	%	$	(98	)			52.1	%	$	149			27.1	%

Schedule of Income before Income Taxes

(Loss) income before income taxes for U.S. and international operations was:

	Year Ended December 31,
(Dollars in millions)	2016			2015			2014
U.S. (including exports)	$	(481	)	$	(492	)	$	244
International		470			304			306
Total (loss) income before income taxes	$	(11	)	$	(188	)	$	550

Schedule of open tax years by significant jurisdiction


Jurisdiction	Open Years
China		2011 through 2016
Mexico		2011 through 2016
Netherlands		2012 through 2016
Taiwan		2014 through 2016
United States		2015 through 2016

Schedule of Unrecognized Tax Benefits

The following table shows the change in our unrecognized tax benefit.

	Year Ended December 31,
(Dollars in millions)	2016			2015				2014
Total unrecognized tax benefits as of January 1	$	7		$	39			$	26
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period		(1	)		—				(1	)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period		—			—				15
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations		—			(32	)	¹		(1	)
Total unrecognized tax benefits as of December 31	$	6		$	7			$	39
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—		$	—			$	39
Total amount of interest and penalties recognized in the Consolidated Statements of Operations		—			1		¹		2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets		—			—				8

Summary of Deferred Tax Asset Valuation Allowance

The following is a rollforward of the deferred tax asset valuation allowance for the years ended December 31, 2016, 2015 and 2014.

	Year Ended December 31,
(Dollars in millions)	2016		2015			2014
Balance at beginning of period	$	—	$	36		$	26
Net charges to income tax expense		50		—			10
Release of valuation allowance ¹		—		(36	)		—
Balance at end of period	$	50	$	—		$	36

Release of the valuation allowance during 2015 was related to tax loss carryforward incurred prior to July 1, 2015 that is attributable to DuPont’s tax periods pursuant to the tax matters agreement. The adjustment was recorded in the “DuPont Company Net Investment” of the Consolidated Statements of Stockholders’ Equity for the year ended December 31, 2015.

Earnings Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.

	Year Ended December 31,
	2016		2015			2014
Numerator:
Net income (loss) attributable to Chemours	$	7	$	(90	)	$	400
Denominator:
Weighted average number of common shares outstanding- Basic		181,621,422		180,993,623			180,966,833	¹
Dilutive effect of the Company’s employee compensation plans ²		1,795,078		—			—
Weighted average number of common shares outstanding - Diluted ²		183,416,500		180,993,623			180,966,833

For 2014, pro forma earnings per share was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:

	Year Ended December 31,
	2016		2015		2014
Average number of stock options		5,820,499		8,358,894		—

Accounts and Notes Receivable - Trade, Net (Tables)

12 Months Ended

Dec. 31, 2016

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable

	December 31,
	2016		2015
Accounts receivable—trade, net ¹	$	742	$	757
VAT, GST and other taxes ²		46		68
Leases receivable—current		—		13
Other receivables ³		19		21
Total	$	807	$	859

Accounts receivable – trade is net of allowances of $5 and $4 as of December 31, 2016 and 2015, respectively. Allowances are equal to the estimated uncollectible amounts.

Value Added Tax (VAT) and Goods and Services Tax (GST).

Other receivables consist of notes receivable, advances and other deposits.

Inventories (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Net [Abstract]

Schedule of Inventories

	December 31,
	2016			2015
Finished products	$	532		$	613
Semi-finished products		150			172
Raw materials, stores and supplies		285			433
Subtotal		967			1,218
Adjustment of inventories to LIFO basis		(200	)		(246	)
Total	$	767		$	972

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2016

Property Plant And Equipment [Abstract]

Summary of Property, Plant and Equipment

Chemours’ property, plant and equipment consisted of:

	December 31,
	2016			2015
Equipment	$	6,748		$	7,327
Buildings		814			737
Construction in progress		293			804
Land		106			111
Mineral rights		36			36
Total		7,997			9,015
Accumulated depreciation		(5,213	)		(5,838	)
Net property, plant and equipment	$	2,784		$	3,177

Goodwill and Other Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table summarizes changes in the carrying amount of goodwill by reportable segment:

	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2014	$	13	$	85	$	100		$	198
Impairment charge		—		—		(25	)		(25	)
Currency translation and other		—		—		(7	)		(7	)
Balance as of December 31, 2015	$	13	$	85	$	68		$	166
Sale of business ¹		—		—		(13	)		(13	)
Currency translation and other		—		—		—			—
Balance as of December 31, 2016	$	13	$	85	$	55		$	153

Represents goodwill disposed in connection with the sale of the C&D business (See Note 7).

Schedule of Other Intangible Assets

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:

	December 31, 2016							December 31, 2015
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Customer lists	$	9	$	(7	)	$	2	$	10	$	(8	)	$	2
Patents		19		(18	)		1		19		(17	)		2
Purchased trademarks		5		(2	)		3		5		(2	)		3
Purchased and licensed technology		3		(2	)		1		8		(6	)		2
Other ¹		10		—			10		3		(2	)		1
Total	$	46	$	(29	)	$	17	$	45	$	(35	)	$	10

Other Assets (Tables)

12 Months Ended

Dec. 31, 2016

Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]

Schedule of Other Assets

	December 31, 2016		December 31, 2015
Leases receivable - non-current ¹	$	—	$	125
Capitalized repair and maintenance costs		145		149
Pension assets ²		159		138
Advances and deposits		—		11
Deferred income taxes		41		47
Asset held for sale		29		—
Miscellaneous ³		43		38
Total	$	417	$	508

Relates to Sulfur business which was included in the assets disposed in 2016. See Direct Financing Leases below.

Pension assets represent the funded status of certain of the Company’s long-term employee benefit plans.

Miscellaneous includes deferred financing fees related to the Revolving Credit Facility of $13 and $19 as of December 31, 2016 and 2015, respectively.

Accounts Payable (Tables)

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Schedule of Accounts Payable

	December 31, 2016		December 31, 2015
Trade payables	$	858	$	945
VAT and other payables		26		28
Total	$	884	$	973

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Payables And Accruals [Abstract]

Schedule of Other Accrued Liabilities

	December 31, 2016		December 31, 2015
Compensation and other employee-related costs	$	154	$	109
Employee separation costs ¹		31		76
Accrued litigation ²		342		11
Environmental remediation ²		71		68
Income taxes		39		32
Customer rebates		53		53
Deferred revenue ³		76		20
Accrued interest		21		21
Miscellaneous ⁴		85		64
Total	$	872	$	454

See Note 6 for further information.

Accrued litigation includes $335 litigation accrual related to the PFOA MDL Settlement. See Note 20 for further discussion of accrued litigation and environmental remediation.

Deferred revenue includes $58 prepayment by DuPont for specified goods and services, which Chemours expects to provide through mid-2017.

⁴

Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations (see Note 20) and other miscellaneous expenses.

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Other Liabilities Disclosure [Abstract]

Schedule of Other Liabilities

	December 31, 2016		December 31, 2015
Environmental remediation ¹	$	208	$	223
Employee-related costs ²		113		108
Employee separation costs ³		3		23
Accrued litigation ¹		53		58
Asset retirement obligations ¹		41		41
Deferred revenue		5		11
Miscellaneous ⁴		101		89
Total	$	524	$	553

See Note 20 for further details on environmental remediation, asset retirement obligations and accrued litigation.

See Note 22 for further details on long-term employee benefits.

See Note 6 for further information.

⁴

Miscellaneous primarily includes an accrued indemnification liability.

Debt (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt was comprised of the following at December 31, 2016 and 2015:

	December 31, 2016		December 31, 2015
Long-term debt:
Senior secured term loan	$	1,372	$	1,493
Senior unsecured notes:
6.625%, due May 2023		1,158		1,350
7.00%, due May 2025		750		750
6.125%, due May 2023 (€295 at December 31, 2016; €360 at December 31, 2015)		308		395
Other		3		26
Total		3,591		4,014
Less: Unamortized issue discount on senior secured term loan		5		7
Less: Unamortized debt issuance costs		42		53
Less: Short-term borrowings and current maturities		15		39
Long-term debt, net	$	3,529	$	3,915

Schedule of Repurchases of Debt

	Year Ended December 31, 2016
	Aggregate Principal		Cash Payment
Term Loans ¹	$	105	$	104
2023 Notes		192		182
Euro Notes		73		68
	$	370	$	354

¹ The Term Loans aggregate principal amounts exclude the required quarterly installment repayments equivalent to $15 per year.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Commitments And Contingencies Disclosure [Abstract]

Summary of the changes in asset retirement obligations

A summary of the changes in asset retirement obligations is as follows:

(Dollars in millions)	Year Ended December 31,
	2016			2015
Beginning balance	$	42		$	43
Accretion expense		2			1
Settlements/payments		(1	)		(2	)
Ending balance	$	43		$	42
Current portion	$	2		$	1
Non-current portion	$	41		$	41

Schedule of Loss Contingencies by Contingency

Although the majority of the plaintiffs in the MDL allege multiple diseases, the table below approximates the number of plaintiffs in each of the six probable link disease categories.

Alleged Injury	Approximate Number of Plaintiffs
Kidney cancer		200
Testicular cancer		70
Ulcerative colitis		300
Preeclampsia		200
Thyroid disease		1,430
High cholesterol		1,340

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2016

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2
Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	2
Total liability derivatives		$	4	$	2

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.

		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2016		December 31, 2015
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	2
Total asset derivatives		$	2	$	2
Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	4	$	2
Total liability derivatives		$	4	$	2

Long-Term Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2016

General Discussion Of Pension And Other Postretirement Benefits [Abstract]

Schedule of Multiemployer Plans

The following table presents the multi-employer pension expense allocated by DuPont to Chemours for the plans in which Chemours participated prior to separation. The allocation of cost was based on active employee headcount and is included in the Consolidated Statement of Operations. These amounts do not represent cash payments to DuPont or DuPont’s plans.

	EIN / Pension	Year Ended December 31,
Plan Name	Number	2016		2015		2014
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	—	$	48	$	51
All other U.S. and non-U.S. Plans			—		5		(1	)

Schedules of Net Periodic Benefit Cost

The net periodic benefit costs for the pension and amounts recognized in other comprehensive income for the years ended December 31, 2016, 2015 and 2014 were as follows:

	Year Ended December 31,
	2016			2015			2014
Net periodic pension cost (income):
Service cost	$	14		$	16		$	—
Interest cost		19			19			—
Expected return on plan assets		(63	)		(83	)		—
Amortization of actuarial loss		23			16			—
Amortization of prior service (credit) cost		(1	)		4			—
Curtailment gain		(2	)		—			—
Settlement loss		5			—			—
Net periodic pension income	$	(5	)	$	(28	)	$	—
Changes in plan assets and benefit obligations recognized in other comprehensive loss (income):
Net loss	$	17		$	11		$	—
Amortization of actuarial loss		(28	)		(16	)		—
Prior service credit		—			(24	)		—
Amortization of prior service credit (cost) and curtailment gain		3			(4	)		—
Effect of foreign exchange rates		(15	)		(33	)		—
Total benefit recognized in other comprehensive income	$	(23	)	$	(66	)	$	—
Total recognized in net periodic pension income and other comprehensive income	$	(28	)	$	(94	)	$	—

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The pre-tax amounts recognized in accumulated other comprehensive loss are summarized below:

	Year Ended December 31,
	2016			2015			2014
Net loss	$	336		$	363		$	—
Prior service credit		(11	)		(16	)		—
Total amount recognized in accumulated other comprehensive loss	$	325		$	347		$	—

Summary of Benefit Obligations and Fair Value of Plan Assets and Funded Status of Plan

Summarized information on the Company’s pension benefit plans is as follows:

	2016			2015
Change in benefit obligation
Benefit obligation at beginning of year	$	1,103		$	—
Assumption and establishment of pension plans		—			1,332
Service cost		14			16
Interest cost		19			19
Plan participants’ contributions		2			2
Actuarial loss (gain)		69			(76	)
Benefits paid		(36	)		(39	)
Plan Amendments		—			(24	)
Curtailments		(3	)		—
Settlements & transfers		(12	)		(6	)
Other events		(2	)		—
Currency translation		(49	)		(121	)
Benefit obligation at end of year		1,105			1,103
Change in plan assets
Fair value of plan assets at beginning of year		1,137			—
Assumption and establishment of pension plans		—			1,297
Actual return on plan assets		113			(7	)
Employer contributions		16			16
Plan participants’ contributions		2			2
Benefits paid		(36	)		(39	)
Settlements & transfers		(12	)		(6	)
Currency translation		(51	)		(126	)
Fair value of plan assets at end of year		1,169			1,137
Funded status at end of year	$	64		$	34

Schedule of Amounts Recognized in the Consolidated Balance Sheet

The net amounts recognized in the Consolidated Balance Sheet as of December 31, 2016 and 2015 consist of:

	2016			2015
Noncurrent assets	$	159		$	138
Current liabilities		(1	)		(2	)
Noncurrent liabilities		(94	)		(102	)
Net amount recognized	$	64		$	34

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2016 and 2015:

Pension plans with projected benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	183	$	194
Accumulated benefit obligation		152		158
Fair value of plan assets		87		93

Pension plans with accumulated benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	179	$	190
Accumulated benefit obligation		151		157
Fair value of plan assets		84		90

Schedule of Projected Benefit Obligations in Excess of Fair Value of Plan Assets

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2016 and 2015:

Pension plans with projected benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	183	$	194
Accumulated benefit obligation		152		158
Fair value of plan assets		87		93

Pension plans with accumulated benefit obligation in excess of plan assets at December 31,	2016		2015
Projected benefit obligation	$	179	$	190
Accumulated benefit obligation		151		157
Fair value of plan assets		84		90

Schedule of Assumptions Used

The following assumptions have been used to determine the benefit obligations and net benefit cost:

Weighted average assumptions used to determine benefit obligations

at December 31,

2016

2015

Discount rate

1.8

2.4

Rate of compensation increase¹

2.5

2.6

The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant’s entire career at Chemours.

Weighted average assumptions used to determine net benefit cost for the years ended December 31,	2016			2015
Discount rate		2.4	%		1.7	%
Rate of compensation increase		2.5	%		3.9	%
Expected return on plan assets		5.7	%		7.2	%

Schedule of Allocation of Plan Assets

The weighted average target allocation for Chemours’ pension plan assets is summarized as follows:

	2016			2015
Cash and cash equivalents		2.5	%		2.7	%
U.S. and non-U.S. equity securities		41.6	%		42.3	%
Fixed income securities		55.9	%		55.0	%
Total		100.0	%		100.0	%

The table below presents the fair values of Chemours’ pension assets by level within the fair value hierarchy, as described in Note 3, as of December 31, 2016 and 2015.

	Fair Value Measurements at December 31, 2016
	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	433		$	8	$	425
Debt - corporate issued		142			76		66
Debt - asset backed		42			25		17
U.S. and non U.S. equities		502			28		474
Derivatives - asset position		3			—		3
Derivatives - liability position		(32	)		—		(32	)
Cash and cash equivalents		77			77		—
Other		7			—		7
		1,174		$	214	$	960
Pension trust payables, net ¹		(5	)
Total	$	1,169

Payables are primarily for investment securities purchased.

	Fair Value Measurements at December 31, 2015
	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	465		$	7	$	458
Debt - corporate issued		148			60		88
Debt - asset backed		33			—		33
U.S. and non U.S. equities		460			37		423
Derivatives - asset position		4			—		4
Derivatives - liability position		(16	)		—		(16	)
Cash and cash equivalents		40			40		—
Other		6			4		2
		1,140		$	148	$	992
Pension trust payables, net ¹		(3	)
Total	$	1,137

Payables are primarily for investment securities purchased.

Schedule of Expected Benefit Payments

The following benefit payments are expected to be paid over the next five years and the five years thereafter as of December 31, 2016:

2017	$	52
2018		40
2019		42
2020		43
2021		43
2022 - 2026		232

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Options Weighted Average Assumptions

The fair value related to stock options granted was determined using Black-Scholes option pricing model and the weighted average assumptions are shown in the table below:

	Year Ended December 31,
	2016			2015
Risk-free interest rate		1.46	%		1.50	%
Expected term (years)		6.00			5.40
Volatility		60.00	%		42.00	%
Dividend yield		2.14	%		6.90	%
Fair value per stock option	$	3.41		$	3.17

Schedule of Stock Options Activity

The following table summarizes Chemours stock option activity for the year ended December 31, 2016.

	Number of Shares (in thousands)			Weighted Average Exercise Price (per share)		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2015		8,284		$	14.66		4.82	$	—
Granted		1,435			5.73
Exercised		(947	)		12.17
Forfeited		(447	)		15.53
Expired		(356	)		5.82
Outstanding, December 31, 2016		7,969		$	13.72		5.08	$	66,668
Exercisable, December 31, 2016		3,912		$	14.04		3.25	$	31,487

Schedule of Restricted Stock Units Activity

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015		2,349		$	14.87
Granted		1,003			6.20
Vested		(829	)		14.74
Forfeited		(207	)		15.09
Nonvested, December 31, 2016		2,316		$	11.23

Schedule of Performance Share Units Activity

The following table provides compensation costs for stock-based compensation related to PSUs:

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2015		—		$	—
Granted		825			6.10
Vested		—			—
Forfeited		(22	)		6.10
Nonvested, December 31, 2016		803		$	6.10

Geographic and Segment Information (Tables)

12 Months Ended

Dec. 31, 2016

Segments Geographical Areas [Abstract]

Schedule of Net Sales and Net Property, Plant and Equipment by Geographical Area

	For and As of the Year Ended December 31,
	2016				2015				2014
	Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment
North America ²	$	2,288	$	1,861	$	2,570	$	2,184	$	2,759	$	2,273
Asia Pacific		1,315		129		1,393		136		1,548		140
EMEA ³		1,081		278		977		308		1,190		372
Latin America ⁴		716		516		777		549		935		523
Total	$	5,400	$	2,784	$	5,717	$	3,177	$	6,432	$	3,308

¹	Net sales are attributed to countries based on customer location.

²	Includes net sales in Canada of $125, $140 and $147 in 2016, 2015 and 2014, respectively. Includes net property, plant and equipment in Canada of $11, $13 and $14 in 2016, 2015 and 2014, respectively.

³	EMEA includes Europe, Middle East and Africa.

⁴	Latin America includes Mexico.

Schedule of Segment Information

All periods presented reflect the current definition of Adjusted EBITDA.

Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2016
Net sales to external customers	$	2,364	$	2,264	$	772	$	—		$	5,400
Adjusted EBITDA		466		445		39		(128	)		822
Depreciation and amortization		119		101		30		34			284
Equity in earnings of affiliates		—		26		—		3			29
Net assets		1,513		1,400		292		(3,101	)		104
Investments in affiliates		—		116		—		20			136
Purchases of plant, property and equipment		105		120		104		9			338
2015
Net sales to external customers	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA		326		300		29		(82	)		573
Depreciation and amortization		125		88		52		2			267
Equity in earnings of affiliates		—		21		—		1			22
Net assets		1,659		1,567		839		(3,935	)		130
Investments in affiliates		—		127		—		9			136
Purchases of plant, property and equipment		255		142		117		5			519
2014
Net sales to external customers	$	2,937	$	2,327	$	1,168	$	—		$	6,432
Adjusted EBITDA		723		282		17		(146	)		876
Depreciation and amortization		125		83		48		1			257
Equity in earnings of affiliates		—		20		—		—			20
Net assets		1,748		1,480		782		(337	)		3,673
Investments in affiliates		—		124		—		—			124
Purchases of plant, property and equipment		365		133		106		—			604

Reconciliation of EBITDA from Segments to Consolidated

Total Adjusted EBITDA reconciles to total consolidated net (loss) income in the Consolidated Statements of Operations as follows:

	Year Ended December 31,
	2016			2015			2014
(Loss) income before income taxes	$	(11	)	$	(188	)	$	550
Interest expense, net		213			132			—
Depreciation and amortization		284			267			257
Non-operating pension and other postretirement employee benefit (income) costs		(20	)		(3	)		22
Exchange losses (gains)		57			(19	)		66
Restructuring charges		51			285			21
Asset related charges¹		124			73			—
(Gains) losses on sale of assets and businesses		(254	)		9			(40	)
Transaction costs²		19			9			—
Legal and other charges³		359			8			—
Adjusted EBITDA	$	822		$	573		$	876

Includes litigation settlements, water treatment accruals and $335 litigation accrual related to the PFOA MDL Settlement (see Note 20), and lease termination charges.

Schedule of Net Sales to External Customers by Product Group

Net sales to external customers by product group were as follows:

	Year Ended December 31,
	2016		2015		2014
Titanium dioxide	$	2,364	$	2,392	$	2,937
Fluoropolymers		1,171		1,246		1,326
Fluorochemicals		1,093		984		1,001
Performance chemicals and intermediates		383		551		621
Mining solutions ¹		262		301		314
Sulfur		127		243		233
Total net sales to external customers	$	5,400	$	5,717	$	6,432

¹	Previously known as Cyanides product group, which was renamed to Mining Solutions effective for the year ended December 31, 2016.

Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss), net of income taxes, consisted of:

	Currency Translation Adjustment			Net Investment Hedge		Employee Benefits			Total
Balance at December 31, 2013	$	19		$	—	$	—		$	19
Other comprehensive income		—			—		—			—
Balance at December 31, 2014		19			—		—			19
Assumption and establishment of pension plans, net		—			—		(311	)		(311	)
Other comprehensive (loss) income		(304	)		8		52			(244	)
Balance at December 31, 2015		(285	)		8		(259	)		(536	)
Other comprehensive (loss) income		(73	)		14		18			(41	)
Balance at December 31, 2016	$	(358	)	$	22	$	(241	)	$	(577	)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Data

The following is a summary of the quarterly results of operations for the years ended December 31, 2016 and 2015.

	For the three months ended
2016	March 31		June 30			September 30		December 31			Full Year
Net Sales	$	1,297	$	1,383		$	1,398	$	1,322		$	5,400
Cost of goods sold		1,095		1,116			1,056		1,024			4,290
Income (loss) before income taxes		70		(41	)		234		(273	)		(11	)
Net income (loss)		51		(18	)		204		(230	)		7
Net income (loss) attributable to Chemours		51		(18	)		204		(230	)		7
Basic earnings (loss) per share		0.28		(0.10	)		1.12		(1.26	)		0.04
Diluted earnings (loss) per share		0.28		(0.10	)		1.11		(1.26	)		0.04

	For the three months ended
2015	March 31		June 30			September 30			December 31			Full Year
Net Sales	$	1,363	$	1,508		$	1,486		$	1,360		$	5,717
Cost of goods sold		1,111		1,282			1,222			1,147			4,762
Income (loss) before income taxes		58		(18	)		(107	)		(121	)		(188	)
Net income (loss)		43		(18	)		(29	)		(86	)		(90	)
Net income (loss) attributable to Chemours		43		(18	)		(29	)		(86	)		(90	)
Basic earnings (loss) per share ¹		0.24		(0.10	)		(0.16	)		(0.48	)		(0.50	)
Diluted earnings (loss) per share ¹		0.24		(0.10	)		(0.16	)		(0.48	)		(0.50	)

On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours’ common stock to holders of its common stock. Basic and diluted earnings (loss) per common share for all periods prior to July 1, 2015 were calculated using the shares distributed on July 1, 2015. Refer to Note 10 for information regarding the calculation of basic and diluted earnings per share.

Guarantor Condensed Consolidating Financial Information (Tables)

12 Months Ended

Dec. 31, 2016

Condensed Financial Information Of Parent Company Only Disclosure [Abstract]

Condensed Consolidated Statements of Comprehensive Income (Loss)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	3,749		$	3,222		$	(1,571	)	$	5,400
Cost of goods sold		—			3,218			2,615			(1,543	)		4,290
Gross profit		—			531			607			(28	)		1,110
Selling, general and administrative expenses		21			794			139			(20	)		934
Research and development expense		—			77			3			—			80
Restructuring and asset related charges, net		—			168			2			—			170
Total expenses		21			1,039			144			(20	)		1,184
Equity in earnings of affiliates		—			4			25			—			29
Equity in earnings of subsidiaries		100			—			—			(100	)		—
Interest (expense) income, net		(211	)		(3	)		1			—			(213	)
Intercompany interest income (expense), net		60			4			(64	)		—			—
Other income, net		20			193			54			(20	)		247
(Loss) income before income taxes		(52	)		(310	)		479			(128	)		(11	)
(Benefit from) provision for income taxes		(59	)		(52	)		100			(7	)		(18	)
Net income (loss)		7			(258	)		379			(121	)		7
Less: Net income attributable to noncontrolling interests		—			—			—			—			—
Net income (loss) attributable to Chemours	$	7		$	(258	)	$	379		$	(121	)	$	7
Comprehensive (loss) income attributable to Chemours	$	(34	)	$	(255	)	$	321		$	(66	)	$	(34	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—		$	4,044		$	3,269		$	(1,596	)	$	5,717
Cost of goods sold		—			3,708			2,650			(1,596	)		4,762
Gross profit		—			336			619			—			955
Selling, general and administrative expenses		15			426			204			(13	)		632
Research and development expense		—			95			2			—			97
Restructuring and asset related charges, net		—			295			38			—			333
Goodwill impairment		—			25			—			—			25
Total expenses		15			841			244			(13	)		1,087
Equity in earnings of affiliates		—			1			21			—			22
Equity in (net loss) earnings of subsidiaries		(47	)		—			—			47			—
Interest expense, net		(131	)		(1	)		—			—			(132	)
Intercompany interest income (expense), net		44			—			(44	)		—			—
Other income (expense), net		13			92			(31	)		(20	)		54
(Loss) income before income taxes		(136	)		(413	)		321			40			(188	)
(Benefit from) provision for income taxes		(46	)		(89	)		40			(3	)		(98	)
Net (loss) income		(90	)		(324	)		281			43			(90	)
Less: Net income attributable to noncontrolling interests		—			—			—			—			—
Net (loss) income attributable to Chemours	$	(90	)	$	(324	)	$	281		$	43		$	(90	)
Comprehensive (loss) income attributable to Chemours	$	(334	)	$	(324	)	$	29		$	295		$	(334	)

Condensed Consolidating Statements of Comprehensive Income (Loss)

	Year Ended December 31, 2014
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Net sales	$	—	$	4,593	$	3,722		$	(1,883	)	$	6,432
Cost of goods sold		—		3,863		3,093			(1,884	)		5,072
Gross profit		—		730		629			1			1,360
Selling, general and administrative expenses		—		429		256			—			685
Research and development expense		—		127		16			—			143
Restructuring and asset related charges, net		—		11		10			—			21
Total expenses		—		567		282			—			849
Equity in earnings of affiliates		—		—		20			—			20
Equity in earnings of subsidiaries		400		—		—			(400	)		—
Other income (expense), net		—		80		(61	)		—			19
Income before income taxes		400		243		306			(399	)		550
Provision for income taxes		—		75		76			(2	)		149
Net income		400		168		230			(397	)		401
Less: Net income attributable to noncontrolling interests		—		—		1			—			1
Net income attributable to Chemours	$	400	$	168	$	229		$	(397	)	$	400
Comprehensive income attributable to Chemours	$	400	$	168	$	229		$	(397	)	$	400

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2016
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	224		$	678		$	—		$	902
Accounts and notes receivable - trade, net		—		299			508			—			807
Intercompany receivable		3		1,050			46			(1,099	)		—
Inventories		—		341			476			(50	)		767
Prepaid expenses and other		—		38			32			7			77
Total current assets		3		1,952			1,740			(1,142	)		2,553
Property, plant and equipment		—		6,136			1,861			—			7,997
Less: Accumulated depreciation		—		(4,285	)		(928	)		—			(5,213	)
Net property, plant and equipment		—		1,851			933			—			2,784
Goodwill and other intangible assets, net		—		156			14			—			170
Investments in affiliates		—		—			136			—			136
Investment in subsidiaries		3,258		—			—			(3,258	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		13		178			226			—			417
Total assets	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	573		$	311		$	—		$	884
Short-term borrowings and current maturities of long-term debt		15		—			—			—			15
Intercompany payable		762		46			291			(1,099	)		—
Other accrued liabilities		21		718			133			—			872
Total current liabilities		798		1,337			735			(1,099	)		1,771
Long-term debt, net		3,526		3			—			—			3,529
Intercompany notes payable		—		—			1,150			(1,150	)		—
Deferred income taxes		—		59			73			—			132
Other liabilities		—		428			96			—			524
Total liabilities		4,324		1,827			2,054			(2,249	)		5,956
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		100		2,310			991			(3,301	)		100
Noncontrolling interests		—		—			4			—			4
Total equity		100		2,310			995			(3,301	)		104
Total liabilities and equity	$	4,424	$	4,137		$	3,049		$	(5,550	)	$	6,060

Condensed Consolidating Balance Sheets

	Year Ended December 31, 2015
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Assets
Current assets:
Cash and cash equivalents	$	—	$	95		$	271		$	—		$	366
Accounts and notes receivable - trade, net		—		344			515			—			859
Intercompany receivable		3		459			54			(516	)		—
Inventories		—		493			501			(22	)		972
Prepaid expenses and other		—		49			52			3			104
Total current assets		3		1,440			1,393			(535	)		2,301
Property, plant and equipment		—		7,070			1,945			—			9,015
Less: Accumulated depreciation		—		(4,899	)		(939	)		—			(5,838	)
Net property, plant and equipment		—		2,171			1,006			—			3,177
Goodwill and other intangible assets, net		—		151			25			—			176
Investments in affiliates		—		9			127			—			136
Investment in subsidiaries		3,105		—			—			(3,105	)		—
Intercompany notes receivable		1,150		—			—			(1,150	)		—
Other assets		19		275			214			—			508
Total assets	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298
Liabilities and equity
Current liabilities:
Accounts payable	$	—	$	637		$	336		$	—		$	973
Short-term borrowings and current maturities of long-term debt		15		24			—			—			39
Intercompany payable		202		54			260			(516	)		—
Other accrued liabilities		21		287			146			-			454
Total current liabilities		238		1,002			742			(516	)		1,466
Long-term debt, net		3,913		2			—			-			3,915
Intercompany notes payable		—		—			1,150			(1,150	)		-
Deferred income taxes		—		173			61			—			234
Other liabilities		—		456			97			—			553
Total liabilities		4,151		1,633			2,050			(1,666	)		6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity		126		2,413			711			(3,124	)		126
Noncontrolling interests		—		—			4			—			4
Total equity		126		2,413			715			(3,124	)		130
Total liabilities and equity	$	4,277	$	4,046		$	2,765		$	(4,790	)	$	6,298

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2016
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(176	)	$	355		$	415		$	—		$	594
Investing activities
Purchases of property, plant and equipment		—			(233	)		(105	)		—			(338	)
Proceeds from sales of assets, net		—			591			117			—			708
Intercompany investing activities		—			(560	)		—			560			—
Foreign exchange contract settlements		—			(12	)		—			—			(12	)
Investment in affiliates		—			—			(1	)		—			(1	)
Cash (used for) provided by investing activities		—			(214	)		11			560			357
Financing activities
Intercompany short-term borrowings, net	$	560		$	—		$	—		$	(560	)	$	—
Debt repayments		(369	)		(12	)		—			—			(381	)
Dividends paid		(22	)		—			—			—			(22	)
Debt issuance costs		(4	)		—			—			—			(4	)
Proceeds from issuance of stock options		11			—			—			—			11
Cash provided by (used for) financing activities		176			(12	)		—			(560	)		(396	)
Effect of exchange rate changes on cash		—			—			(19	)		—			(19	)
Increase in cash and cash equivalents		—			129			407			—			536
Cash and cash equivalents at beginning of year		—			95			271			—			366
Cash and cash equivalents at end of year	$	—		$	224		$	678		$	—		$	902

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2015
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash (used for) provided by operating activities	$	(119	)	$	171		$	121		$	9		$	182
Investing activities
Purchases of property, plant and equipment		—			(292	)		(227	)		—			(519	)
Proceeds from sales of assets, net		—			6			6			—			12
Intercompany investing activities		—			(202	)		—			202			—
Foreign exchange contract settlements		—			42			—			—			42
Investment in affiliates		—			—			(32	)		—			(32	)
Cash used for investing activities		—			(446	)		(253	)		202			(497	)
Financing activities
Proceeds from issuance of debt, net		3,489			2			—			—			3,491
Intercompany short-term borrowings, net		202			—			—			(202	)		-
Debt repayments		(8	)		(2	)		—			—			(10	)
Dividends paid		(105	)		—			—			—			(105	)
Debt issuance costs		(79	)		—			—			—			(79	)
Cash provided at separation by DuPont		—			87			160			—			247
Net transfers (to) from DuPont		(3,380	)		283			249			(9	)		(2,857	)
Cash provided by financing activities		119			370			409			(211	)		687
Effect of exchange rate changes on cash		—			—			(6	)		—			(6	)
Increase in cash and cash equivalents		—			95			271			—			366
Cash and cash equivalents at beginning of year		—			—			—			—			—
Cash and cash equivalents at end of year	$	—		$	95		$	271		$	—		$	366

Condensed Consolidating Statements of Cash Flows

	Year Ended December 31, 2014
	Parent Issuer		Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations and Adjustments			Consolidated
Operating activities
Cash provided by operating activities	$	—	$	302		$	208		$	(5	)	$	505
Investing activities
Purchases of property, plant and equipment		—		(287	)		(317	)		—			(604	)
Proceeds from sales of assets, net		—		30			2			—			32
Investment in affiliates		—		-			(8	)		—			(8	)
Other investing activities		—		20			—			—			20
Cash used for investing activities		—		(237	)		(323	)		—			(560	)
Financing activities
Net transfers (to) from DuPont		—		(65	)		115			5			55
Cash (used for) provided by financing activities		—		(65	)		115			5			55
Effect of exchange rate changes on cash		—		—			—			—			—
Increase in cash and cash equivalents		—		—			—			—			—
Cash and cash equivalents at beginning of year		—		—			—			—			—
Cash and cash equivalents at end of year	$	—	$	—		$	—		$	—		$	—

Background and Description of the Business (Narrative) (Details)		12 Months Ended
	Jul. 02, 2015	Dec. 31, 2016 segment facility $ / shares	Dec. 31, 2015 $ / shares	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		26
Common stock , par value (USD per share) \| $ / shares		$ 0.01	$ 0.01	$ 0.01
Spin off transaction distribution ratio	20.00%
Parent Issuer [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) \| $ / shares				$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		1
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		18
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		2

Basis of Presentation (Details) - USD ($) $ in Millions	12 Months Ended
Basis of Presentation (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Noncash contribution		$ 109
Cumulative translation adjustment	$ 31

Summary of Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Percentage of LIFO inventory	48.00%	54.00%
Consolidated Subsidiaries [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Non controlling interests, ownership percentage by parent	100.00%
Voting stock ownership percentage	50.00%
Consolidated Subsidiaries [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Voting stock ownership percentage	20.00%

Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2016
Equipment and Buildings [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Equipment and Buildings [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	25 years
Software Development [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Software Development [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets and Asset Retirement Obligations (Details)	12 Months Ended
	Dec. 31, 2016
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Useful life of asset retirement obligation	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Useful life of asset retirement obligation	25 years

Relationship with DuPont and Related Entities (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended		18 Months Ended
	Feb. 29, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		$ 238,000,000	$ 492,000,000	$ 0
Affiliated Entity [Member] \| Arrangement to Purchase Services and Materials [Member]
Related Party Transaction [Line Items]
Amount of agreement with related party	$ 190,000,000
Affiliated Entity [Member] \| Other Accrued Liabilities [Member] \| Arrangement to Purchase Services and Materials [Member]
Related Party Transaction [Line Items]
Deferred liability				$ 58,000,000
Affiliated Entity [Member] \| Cost of Goods Sold [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		23,000,000	32,000,000
Affiliated Entity [Member] \| Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		205,000,000	411,000,000
Affiliated Entity [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		10,000,000	49,000,000
Operating Segments [Member] \| Titanium Technologies [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties		2,000,000	0
Operating Segments [Member] \| Fluoroproducts [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties		34,000,000	45,000,000
Operating Segments [Member] \| Chemical Solutions [Member] \| Subsidiary of Common Parent [Member]
Related Party Transaction [Line Items]
Revenue from related parties		$ 21,000,000	$ 65,000,000

Research and Development Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Research and Development [Line Items]
Research and development expense	$ 80	$ 97	$ 143
Projects Incurred by Chemours [Member]
Research and Development [Line Items]
Research and development expense	$ 80	87	94
Corporate Central Research and Development [Member]
Research and Development [Line Items]
Research and development expense		$ 10	$ 49

Restructuring and Asset Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Employee Separation Charges				$ 4	$ 137	$ 18
Decommissioning and other charges, net - Restructuring				47	18
Asset Related Charges - Restructuring					133	3
Total restructuring charges, net				51	288	21
Asset Related Charges - Impairment	$ 48		$ 45	119	45
Total restructuring and asset related charges, net				170	$ 333	$ 21
Pascagoula, Mississippi [Member] \| Aniline Facility [Member]
Restructuring Cost and Reserve [Line Items]
Asset Related Charges - Impairment				48
Disposed by Sale [Member] \| Sulfur Business [Member]
Restructuring Cost and Reserve [Line Items]
Asset Related Charges - Impairment		$ 58		58
Chemical Solutions [Member] \| Pascagoula, Mississippi [Member] \| Aniline Facility [Member]
Restructuring Cost and Reserve [Line Items]
Asset Related Charges - Impairment				48
Chemical Solutions [Member] \| Disposed by Sale [Member] \| Sulfur Business [Member]
Restructuring Cost and Reserve [Line Items]
Asset Related Charges - Impairment				58
Chemical Solutions [Member] \| Corporate Headquarter Building [Member]
Restructuring Cost and Reserve [Line Items]
Asset Related Charges - Impairment				$ 13

Restructuring and Asset Related Charges, Net (Segment Earnings) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	$ 51	$ 288	$ 19
2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	6	112	19
Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	45	176	0
Operating Segments [Member] \| Titanium Technologies [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	2	33	3
Operating Segments [Member] \| Titanium Technologies [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	30	140	0
Operating Segments [Member] \| Fluoroproducts [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	4	54	16
Operating Segments [Member] \| Fluoroproducts [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	7	24	0
Operating Segments [Member] \| Chemical Solutions [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	0	25	0
Operating Segments [Member] \| Chemical Solutions [Member] \| Plant and Product Line Closures [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net	$ 8	12	$ 0
Corporate, Non-Segment [Member] \| 2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and asset related charges, net		$ 24

Restructuring and Asset Related Charges, Net (Restructuring Program Schedule) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	$ 98,000,000	$ 0
Charges (credits) to income	4,000,000	137,000,000
Payments	(68,000,000)	(39,000,000)
Net currency translation and other adjustment	0	0
Restructuring reserve, ending	34,000,000	98,000,000	$ 0
Employee separation charges	4,000,000	137,000,000	18,000,000
Maximum [Member]
Restructuring Reserve [Roll Forward]
Net currency translation and other adjustment	1,000,000
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	11,000,000	0
Charges (credits) to income	0	11,000,000
Payments	(7,000,000)	0
Net currency translation and other adjustment	0	0
Restructuring reserve, ending	4,000,000	11,000,000	0
Fluoroproducts Lines Shutdown [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	2,000,000	0
Charges (credits) to income	0	2,000,000
Payments	(1,000,000)	0
Net currency translation and other adjustment	0	0
Restructuring reserve, ending	1,000,000	2,000,000	0
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	12,000,000	0
Charges (credits) to income	(2,000,000)	12,000,000
Payments	(1,000,000)	0
Net currency translation and other adjustment	(1,000,000)	0
Restructuring reserve, ending	8,000,000	12,000,000	0
2015 Global Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	73,000,000	0
Charges (credits) to income	6,000,000	112,000,000
Payments	(59,000,000)	(39,000,000)
Net currency translation and other adjustment	1,000,000	0
Restructuring reserve, ending	21,000,000	$ 73,000,000	$ 0
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Employee separation [Member]
Restructuring Reserve [Roll Forward]
Employee separation charges	$ 2,000,000

Sales of Assets and Businesses (Narrative) (Details) - USD ($) $ in Millions				1 Months Ended	3 Months Ended			12 Months Ended
	Aug. 31, 2016	Jul. 29, 2016	Mar. 01, 2016	May 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 13, 2016	Apr. 22, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset related charges					$ 48		$ 45	$ 119	$ 45
Other Income, Net [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets								88
Disposed by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net assets disposed								432
Liabilities of assets held-for-sale								17
Goodwill								17
Sulfur Business [Member] \| Assets Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility				$ 10
Loss on sale		$ 4
Sulfur Business [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price										$ 325
Proceeds from sale		311
Net assets disposed		342
Liabilities of assets held-for-sale		$ 11
Sulfur Business [Member] \| Disposed by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset related charges						$ 58		58
Clean and Disinfect Product Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets								169
Clean and Disinfect Product Line [Member] \| Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price											$ 230
Net assets disposed								48
Liabilities of assets held-for-sale								6
Proceeds from sale	$ 223
Cash transferred in sale	$ 2
Goodwill								13
Transaction and other related charges								$ 9
Aniline Facility, Beaumont, Texas [Member] \| Disposed by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds from sale of facility			$ 140
Net assets disposed			41
Goodwill			4
Transaction costs			$ 11

Sales of Assets and Businesses (Major Components of Assets Held-for-sale) (Details) - Disposed by Sale [Member] $ in Millions	Dec. 31, 2016 USD ($)
Current assets:
Accounts receivables	$ 22
Inventories	17
Total current assets	39
Property, plant and equipment, net	298
Goodwill	17
Other assets	136
Less: Impairment loss	(58)
Total non-current assets, net	393
Total assets	432
Accounts payable and accrued liabilities	17
Total liabilities	17
Net assets disposed	$ 415

Other Income (Expense), Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Component of Other Income [Line Items]
Exchange (losses) gains, net	$ (57)	$ 19	$ (66)
Total other income, net	247	54	19
Other Income [Member]
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	35	25	17
Royalty income	15	19	28
Gain (loss) on sale of assets and businesses	254	(9)	40
Exchange (losses) gains, net	(57)	19	(66)
Total other income, net	$ 247	$ 54	$ 19

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current tax expense:
U.S. federal	$ 0	$ 37	$ 85
U.S. state and local	0	1	13
International	93	62	73
Total current tax expense	93	100	171
Deferred tax (benefit) expense:
U.S. federal	(101)	(187)	(20)
U.S. state and local	(17)	(14)	(3)
International	7	3	1
Total deferred tax benefit	(111)	(198)	(22)
Total (benefit from) provision for income taxes	$ (18)	$ (98)	$ 149

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Environmental and other reserves	$ 150	$ 158
Litigation reserves	149	22
Stock compensation and accrued employee benefits	35	42
Other assets and other accrued liabilities	27	35
Tax loss carryforwards	95	124
Total deferred tax assets	456	381
Valuation allowance	(50)	0
Total deferred tax assets, net	406	381
Deferred tax liabilities:
Pension and other liabilities	(16)	(7)
Property, plant and equipment	(441)	(530)
Inventories and other assets	(40)	(31)
Total deferred tax liabilities	(497)	(568)
Net deferred tax liability	$ (91)	$ (187)

Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	150.40%	5.10%	1.00%
Lower effective tax rate on international operations-net	552.50%	12.00%	(9.60%)
Depletion	51.20%	3.40%	(1.50%)
Goodwill	(47.90%)	(3.20%)	(0.00%)
Exchange losses (gains)	(39.10%)	0.50%	2.70%
Provision to return and other adjustments	(57.90%)	0.00%	0.00%
Permanent items	(27.30%)	(0.50%)	(0.90%)
Valuation allowance	(451.60%)	0.00%	2.00%
Section 199 domestic manufacturing deduction	(0.00%)	(0.00%)	(0.70%)
Other, net	(1.70%)	(0.20%)	(0.90%)
Total effective tax rate	163.60%	52.10%	27.10%

Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory U.S. federal income tax rate	$ (4)	$ (66)	$ 192
State income taxes, net of federal benefit	(16)	(10)	6
Lower effective tax rate on international operations-net	(61)	(23)	(53)
Depletion	(6)	(6)	(8)
Goodwill	5	6
Exchange losses (gains)	4	(1)	15
Provision to return and other adjustments	6
Permanent items	3	1	(5)
Valuation allowance	50		11
Section 199 domestic manufacturing deduction			(4)
Other, net	1	1	(5)
Total (benefit from) provision for income taxes	$ (18)	$ (98)	$ 149

Income Taxes - Summary of Income Before Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
U.S. (including exports)									$ (481)	$ (492)	$ 244
International									470	304	306
(Loss) income before income taxes	$ (273)	$ 234	$ (41)	$ 70	$ (121)	$ (107)	$ (18)	$ 58	$ (11)	$ (188)	$ 550

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Tax Credit Carryforward [Line Items]
Provision (benefit) for income taxes	$ (18,000,000)	$ (98,000,000)	$ 149,000,000
Valuation allowance	50,000,000	0
Decrease in tax benefits	80,000,000
Unremitted earnings of foreign subsidiaries	2,100,000,000
Deferred tax liability not recognized	0
Unrecognized income tax benefits	6,000,000	7,000,000	$ 39,000,000	$ 26,000,000
PFOA MDL Settlement [Member]
Tax Credit Carryforward [Line Items]
Decrease in tax benefits		$ 335,000,000
U.S Federal [Member]
Tax Credit Carryforward [Line Items]
Valuation allowance	50,000,000
Tax credit carryforwards	50,000,000
U.S Federal [Member] \| Expiration Year 2025 [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	27,000,000
U.S Federal [Member] \| Expiration Year 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforwards	23,000,000
U.S Federal and State [Member] \| Expiration Year 2035 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards	42,000,000
Foreign [Member] \| Expiration Between Years 2025 to 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax loss carryforwards	$ 3,000,000

Income Taxes - Summary of open tax years by significant jurisdiction (Details)	12 Months Ended
	Dec. 31, 2016
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2011
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2011
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2012
Non-U.S Jurisdiction [Member] \| Earliest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2014
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| China [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2016
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Mexico [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2016
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Netherlands [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2016
Non-U.S Jurisdiction [Member] \| Latest Tax Year [Member] \| Taiwan [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2016
U.S. Federal Jurisdiction [Member] \| Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2015
U.S. Federal Jurisdiction [Member] \| Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax years open to examination	2016

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Total unrecognized tax benefits as of January 1	$ 7	$ 39	$ 26
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	(1)	0	(1)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	0	0	15
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	0	(32)	(1)
Total unrecognized tax benefits as of December 31	6	7	39
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	0	0	39
Total amount of interest and penalties recognized in the Consolidated Statements of Operations	0	1	2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets	$ 0	$ 0	$ 8

Income Taxes - Summary of Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 0	$ 36	$ 26
Net charges to income tax expense	50	0	10
Release of valuation allowance	0	(36)	0
Balance at end of period	$ 50	$ 0	$ 36

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
	Jul. 02, 2015	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net income (loss) attributable to Chemours		$ (230)	$ 204	$ (18)	$ 51	$ (86)	$ (29)	$ (18)	$ 43	$ 7	$ (90)	$ 400
Denominator:
Weighted average number of common shares outstanding- Basic										181,621,422	180,993,623	180,966,833
Dilutive effect of the Company's employee compensation plans										1,795,078
Weighted average number of common shares outstanding - Diluted										183,416,500	180,993,623	180,966,833
Issuance of common stock at separation (in shares)	180,966,833

Earnings Per Share of Common Stock (Antidilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share [Abstract]
Average number of stock options	5,820,499	8,358,894

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Accounts receivable—trade, net	$ 742	$ 757
VAT, GST and other taxes	46	68
Leases receivable—current		13
Other receivables	19	21
Total	$ 807	$ 859

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 5	$ 4

Accounts and Notes Receivable - Trade, Net (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Bad debt expense	$ 7	$ 1	$ 1

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Inventory Net [Abstract]
Finished products	$ 532	$ 613
Semi-finished products	150	172
Raw materials, stores and supplies	285	433
Subtotal	967	1,218
Adjustment of inventories to LIFO basis	(200)	(246)
Total	767	972
LIFO inventory amount	$ 465	$ 657
Percentage of LIFO inventory	48.00%	54.00%

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 7,997	$ 9,015
Accumulated depreciation	(5,213)	(5,838)
Net property, plant and equipment	2,784	3,177	$ 3,308
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,748	7,327
Building [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	814	737
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	293	804
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	106	111
Mineral rights [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 36	$ 36

Property, Plant, and Equipment (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Depreciation expense			$ 281,000,000	$ 264,000,000	$ 254,000,000
Capital leased assets			5,000,000	7,000,000
Interest capitalized			18,000,000	21,000,000	$ 0
Asset related charges	$ 48,000,000	$ 45,000,000	$ 119,000,000	$ 45,000,000

Goodwill and Other Intangible Assets, Net (Schedule of Goodwill) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Goodwill [Roll Forward]

Goodwill, beginning balance

$ 166

$ 198

Impairment charge

(25)

$ 0

Sale of business

^[1]

(13)

Currency translation and other

(7)

Goodwill, ending balance

153

166

198

Chemical Solutions [Member]

Goodwill [Roll Forward]

Impairment charge

(25)

Operating Segments [Member] | Titanium Technologies [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

Impairment charge

Sale of business

^[1]

Currency translation and other

Goodwill, ending balance

Operating Segments [Member] | Fluoroproducts [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

Impairment charge

Sale of business

^[1]

Currency translation and other

Goodwill, ending balance

Operating Segments [Member] | Chemical Solutions [Member]

Goodwill [Roll Forward]

Goodwill, beginning balance

100

Impairment charge

(25)

Sale of business

^[1]

(13)

Currency translation and other

(7)

Goodwill, ending balance

$ 55

$ 68

$ 100

[1]	Represents goodwill disposed in connection with the sale of the C&D business (See Note 7).

Goodwill and Other Intangible Assets, Net (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($) segment	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Goodwill and Other Intangible Assets
Accumulated impairment losses included in goodwill	$ 25	$ 25	$ 0
Number of operating segments \| segment	3
Impairment charge	$ 0	25	0
Amortization expense, 2017	4
Amortization expense, 2018	3
Amortization expense, 2019	3
Amortization expense, 2020	3
Amortization expense, 2021	$ 1
Minimum [Member]
Goodwill and Other Intangible Assets
Useful life	5 years
Maximum [Member]
Goodwill and Other Intangible Assets
Useful life	20 years
Continuing Operations [Member]
Goodwill and Other Intangible Assets
Aggregate pre-tax amortization expense	$ 3	3	$ 3
Chemical Solutions [Member]
Goodwill and Other Intangible Assets
Impairment charge		$ 25

Goodwill and Other Intangible Assets, Net (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	$ 46	$ 45
Accumulated Amortization	(29)	(35)
Net	17	10
Customer Lists [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	9	10
Accumulated Amortization	(7)	(8)
Net	2	2
Patents [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	19	19
Accumulated Amortization	(18)	(17)
Net	1	2
Purchased Trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	5	5
Accumulated Amortization	(2)	(2)
Net	3	3
Purchased and Licensed Technology [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	3	8
Accumulated Amortization	(2)	(6)
Net	1	2
Other [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	10	3
Accumulated Amortization	0	(2)
Net	$ 10	$ 1

Other Assets (Details) $ in Millions	3 Months Ended	12 Months Ended
Other Assets (Details) $ in Millions	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) facility	Dec. 31, 2015 USD ($)
Other Assets [Line Items]
Leases receivable - non-current		$ 0	$ 125
Capitalized repair and maintenance costs		145	149
Pension assets		159	138
Advances and deposits			11
Deferred income taxes		41	47
Asset held for sale		29
Miscellaneous		43	38
Total		417	508
Other assets, impairment charges		$ 13
Number of facilities with fixed assets constructed on land \| facility		2
Scenario Forecast [Member]
Other Assets [Line Items]
Expected proceeds from sale and leaseback transaction	$ 32
Revolving Credit Facility [Member]
Other Assets [Line Items]
Deferred financing fee		$ 13	$ 19

Accounts Payable (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Trade payables	$ 858	$ 945
VAT and other payables	26	28
Total	$ 884	$ 973

Other Accrued Liabilities (Details) - USD ($)
$ in Millions

Dec. 31, 2016

Dec. 31, 2015

Accrued Liabilities, Current [Abstract]

Compensation and other employee-related costs

$ 154

$ 109

Employee separation costs

^[1]

Accrued litigation

^[2]

342

Environmental remediation

^[3]

872

$ 454

Parent Issuer [Member]

Accrued Liabilities, Current [Abstract]

Prepayment for specified goods and services

PFOA MDL Settlement [Member]

Accrued Liabilities, Current [Abstract]

Accrued litigation

$ 335

[1]	See Note 6 for further information.
[2]	See Note 20 for further discussion of accrued litigation and environmental remediation.
[3]	Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, asset retirement obligations (see Note 20) and other miscellaneous expenses.

Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Noncurrent [Abstract]
Environmental remediation	$ 208	$ 223
Employee-related costs	113	108
Employee separation costs	3	23
Accrued litigation	53	58
Asset retirement obligations	41	41
Deferred revenue	5	11
Miscellaneous	101	89
Total	$ 524	$ 553

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Debt (Components of Long-Term Debt) (Details) € in Millions, $ in Millions	Dec. 31, 2016 USD ($)	Dec. 31, 2016 EUR (€)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 EUR (€)	Jul. 01, 2015 EUR (€)	May 12, 2015 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 3,591		$ 4,014
Less: Unamortized issue discount on senior secured term loan	5		7
Less: Unamortized debt issuance costs	42		53
Less: Short-term borrowings and current maturities	15		39
Long-term debt, net	3,529		3,915
Other [Member]
Debt Instrument [Line Items]
Long-term debt	3		26
Senior unsecured notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross						$ 2,503
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,158		$ 1,350
Debt instrument interest rate	6.625%	6.625%	6.625%	6.625%
Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 750		$ 750
Debt instrument interest rate	7.00%	7.00%	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 308		$ 395
Debt instrument interest rate	6.125%	6.125%	6.125%	6.125%
Long-term debt, gross \| €		€ 295		€ 360	€ 360
Senior secured term loan [Member]
Debt Instrument [Line Items]
Long-term debt	$ 1,372		$ 1,493
Less: Unamortized issue discount on senior secured term loan						$ 7
Debt instrument interest rate	1.00%	1.00%

Debt (Senior Secured Credit Facilities) (Details) - USD ($)			3 Months Ended	6 Months Ended	12 Months Ended		17 Months Ended
	Feb. 19, 2016	May 12, 2015	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 01, 2019
Line of Credit Facility [Line Items]
Unamortized discount					$ 5,000,000	$ 7,000,000
Long-term debt					3,591,000,000	4,014,000,000
Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock		100.00%
Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock		65.00%
Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Expected proceeds from sale and leaseback transactions			$ 32,000,000
The Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term		7 years
Line of credit facility, maximum borrowing capacity		$ 1,500,000,000
Periodic payment, percentage of face amount		1.00%
Unamortized discount		$ 7,000,000
Long-term debt					1,372,000,000	1,493,000,000
The Term Loan Facility [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		3.00%
The Term Loan Facility [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		0.75%
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term		5 years
Line of credit facility, maximum borrowing capacity	$ 750,000,000	$ 1,000,000,000
Long-term debt					0	0
Letters of credit outstanding					$ 132,000,000	$ 129,000,000
Commitment fee percentage					0.30%	0.35%
Write off of financing costs	$ 4,000,000
Maximum net leverage ratio					3.50%
Revolving Credit Facility [Member] \| Other Assets [Member]
Line of Credit Facility [Line Items]
Debt issuance costs					$ 3,000,000	$ 1,000,000
Revolving Credit Facility [Member] \| Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Maximum net leverage ratio				3.00%			2.00%
Minimum interest coverage ratio				1.75%			3.00%
Maximum net leverage ratio decrease, semi-annually							0.25%
Minimum coverage ratio increase, semi-annually							0.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate					2.00%	2.25%
Revolving Credit Facility [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate					1.00%	1.25%
Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage		0.35%
Revolving Credit Facility [Member] \| Maximum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		2.25%
Revolving Credit Facility [Member] \| Maximum [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate		1.25%
Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage		0.20%
Revolving Credit Facility [Member] \| Minimum [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		1.50%
Revolving Credit Facility [Member] \| Minimum [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate		0.50%

Debt (Senior Unsecured Notes) (Details) - Senior unsecured notes [Member]		12 Months Ended
	May 12, 2015 USD ($)	Dec. 31, 2016	Dec. 31, 2015	May 12, 2015 EUR (€)
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,503,000,000
Senior unsecured notes, payment terms		Payment of principal at maturity and interest semi-annually in cash and in arrears on May 15 and November 15 of each year.
Obligation threshold for debt to become guaranteed	$ 75,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of control	101.00%			101.00%
Repurchase price obligation, percentage of principal amount redeemed in event of change of asset dispositions	100.00%			100.00%
2023 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount	$ 1,350,000,000
Debt instrument interest rate	6.625%			6.625%
Debt instrument maturity date	May 15, 2023
2025 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount	$ 750,000,000
Debt instrument interest rate	7.00%			7.00%
Debt instrument maturity date	May 15, 2025
Euro Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount \| €				€ 360,000,000
Debt instrument interest rate	6.125%			6.125%
Debt instrument maturity date	May 15, 2023
7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt Instrument, face amount	$ 507,000,000
Debt instrument interest rate		7.00%	7.00%

Debt Debt (Repayment Amounts) (Details) $ in Millions	12 Months Ended
Debt Debt (Repayment Amounts) (Details) $ in Millions	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Aggregate Principal	$ 370
Cash Payment	354
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Aggregate Principal	105
Cash Payment	104
2023 Notes [Member]
Debt Instrument [Line Items]
Aggregate Principal	192
Cash Payment	182
Euro Notes [Member]
Debt Instrument [Line Items]
Aggregate Principal	73
Cash Payment	$ 68

Debt Debt (Repayment Amounts) (Parenthetical) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Debt Disclosure [Abstract]
Term loan repayments equivalent	$ 15

Debt Debt (Term Loans and Note Repayments) (Details) - Interest Expense [Member] $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)
Debt Instrument [Line Items]
Gain on extinguishment of debt	$ 10
Write off of financing costs	$ 5

Debt (Maturities and Fair Value) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%	6.625%
Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%	7.00%
Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%	6.125%
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 1,149
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	739
Fair Value, Inputs, Level 2 [Member] \| Senior unsecured notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 305
Senior secured term loan [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2017	$ 15
2018	15
2019	15
2020	15
2021	15
2022 and beyond	$ 3,513
Additional principal repayment, percentage of excess cash flow	50.00%
Additional principal repayment, percentage of excess cash flow, stepdown level one	25.00%
Additional principal repayment, percentage of excess cash flow, stepdown level two	0.00%
Target leverage ratio	3.00%
Senior secured term loan [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,370

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Loss Contingencies [Line Items]
Accrual amount	$ 0	$ 0
Maximum [Member]
Loss Contingencies [Line Items]
Guarantee obligations	$ 1,000,000	$ 8,000,000

Commitments and Contingent Liabilities (Operating Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments, 2017	$ 62
Future minimum lease payments, 2018	53
Future minimum lease payments, 2019	46
Future minimum lease payments, 2020	23
Future minimum lease payments, 2021	31
Future minimum lease payments, thereafter	43
Net expense under operating leases	$ 68	$ 83	$ 75

Commitments and Contingent Liabilities (Asset Retirement Obligations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Beginning balance	$ 42	$ 43
Accretion expense	2	1
Settlements/payments	(1)	(2)
Ending balance	43	42
Current portion	2	1
Non-current portion	$ 41	$ 41

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details)		1 Months Ended		3 Months Ended		12 Months Ended
	Oct. 20, 2015 USD ($)	Nov. 30, 2016 USD ($)	May 31, 2013 doctor water_district	Dec. 31, 2016 USD ($) lawsuit Claim	Jun. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) lawsuit plantiff Claim	Dec. 31, 2014 lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Dec. 31, 2015 USD ($) lawsuit	Sep. 30, 2014 plantiff	Jan. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Loss contingency, settlement agreement, terms						DuPont and Chemours have also agreed, subject to and following the completion of the MDL Settlement, to a limited sharing of potential future PFOA liabilities (i.e., “indemnifiable losses,” as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours would annually pay future PFOA liabilities up to $25 million and, if such amount is exceeded, DuPont would pay any excess amount up to the next $25 million (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess liabilities under the terms of the separation agreement.
Maximum [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 535,000,000		$ 535,000,000
Bellwether Case [Member]
Loss Contingencies [Line Items]
Compensatory damages						5,100,000
Punitive damages						500,000
Attorney's fees						6,900,000
PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Additional estimated charges						335,000,000
Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Escrow deposit disbursements						1,000,000
MDL Settlement [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 335,000,000		$ 335,000,000
Date of Agreement						Feb. 11, 2017
Total settlement amount						$ 670,700,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				1,900		1,900				2,200
Accrual balance				$ 41,000,000		$ 41,000,000				$ 44,000,000
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				27		27				29
Years of exposure to benzene	24 years
Compensatory damages awarded	$ 6,900,000
Punitive damages awarded	$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 349,000,000		$ 349,000,000				$ 20,000,000
Additional estimated charges					$ 4,000,000
Period of payments						5 years
PFOA Matters [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments						$ 25,000,000
PFOA Matters [Member] \| PFOA MDL Settlement [Member]
Loss Contingencies [Line Items]
Additional estimated charges				335,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident									80,000
Number of doctors to release initial screening recommendations \| doctor			3
Number of water districts Company must provide treatment \| water_district			6
Compensatory damages		$ 2,000,000
Punitive damages		$ 10,500,000
Number of scheduled trials \| plantiff						40
Number of trials moved forward \| plantiff						2
Percentage of cases to remain inactive						93.00%
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments								$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments								$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 235,000,000		$ 235,000,000
Escrow deposit												$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				3,500		3,500				3,500
New claims filed \| lawsuit							600
Lawsuits alleging wrongful death \| lawsuit				30		30
PFOA MDL Plaintiffs selected for individual trial \| plantiff											6
PFOA Matters: Additional Actions [Member] \| Bellwether Case [Member]
Loss Contingencies [Line Items]
Damages awarded due to negligence						$ 1,100,000
Damages awarded due to emotional distress						$ 500,000
PFOA Matters: Drinking Water Actions - Cancer Cases [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| Claim				270		270
DuPont [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Settlement payments						$ 25,000,000

Commitments and Contingent Liabilities (Summary of Alleged Injuries in Lawsuit) (Details)	12 Months Ended
	Dec. 31, 2016 plantiff
PFOA Matters - Kidney Cancer [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	200
PFOA Matters - Testicular Cancer [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	70
PFOA Matters - Ulcerative Colitis [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	300
PFOA Matters - Preeclampsia [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	200
PFOA Matters - Thyroid Disease [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	1,430
PFOA Matters - High Cholesterol [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	1,340

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Environmental Remediation [Line Items]
Accrual for environmental remediation activities	$ 278	$ 297
Environmental remediation expense	$ 44	$ 38	$ 59
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	15 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	20 years
Loss contingency, potential additional loss	$ 535

Financial Instruments (Narrative) (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($) contract	Dec. 31, 2015 USD ($)	Dec. 31, 2016 EUR (€) contract	Dec. 31, 2015 EUR (€)	Jul. 01, 2015 EUR (€)	May 12, 2015 USD ($)
Senior unsecured notes [Member]
Derivative [Line Items]
Long-term debt, gross						$ 2,503
Senior Notes 6.125% Due May 2023 [Member] \| Senior unsecured notes [Member]
Derivative [Line Items]
Long-term debt, gross \| €			€ 295	€ 360	€ 360
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Recognized gain on derivative net investment hedge	$ 14	$ 8
Foreign currency forward contracts [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	45		45
Derivative notional value	$ 518
Foreign currency forward contracts [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income [Member]
Derivative [Line Items]
Derivative gain (loss)	$ (15)	$ 42

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Fair Value, Measurements, Recurring [Member] - Fair Value, Inputs, Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 2	$ 2
Liability derivatives	4	2
Foreign currency forward contracts [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	2	2
Foreign currency forward contracts [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 4	$ 2

Long-Term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Employer contributions during period	$ 28		$ 44
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	1.00%
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	7.00%
Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer matching contribution percent of match	100.00%
Employer matching contribution percent of employees' gross pay	6.00%
Employer contribution vesting period	3 years
Employer contributions during period		$ 26		$ 52

Long-Term Employee Benefits (Multiemployer Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
DuPont Pension and Retirement Plan (U.S.) [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 48	$ 51
Other U.S. and non-U.S. Plans [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 5	$ (1)

Long-Term Employee Benefits (Schedule of Net Periodic Benefit Cost and Amounts Recognized in Other Comprehensive Income) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Changes in plan assets and benefit obligations recognized in other comprehensive loss (income):

Net loss

$ 17

$ 11

$ 0

Amortization of actuarial loss

^[1]

(23)

(16)

Prior service credit

(24)

Amortization of prior service credit (cost) and curtailment gain

^[1]

(4)

Effect of foreign exchange rates

(15)

(33)

Total benefit recognized in other comprehensive income

(23)

(66)

$ 0

Foreign Pension Plan [Member]

Net periodic pension cost (income):

Service cost

Interest cost

Expected return on plan assets

(63)

(83)

Amortization of actuarial loss

Amortization of prior service (credit) cost

(1)

Curtailment gain

(2)

Settlement loss

Net periodic benefit cost

(5)

(28)

Changes in plan assets and benefit obligations recognized in other comprehensive loss (income):

Net loss

Amortization of actuarial loss

(28)

(16)

Prior service credit

(24)

Amortization of prior service credit (cost) and curtailment gain

(4)

Effect of foreign exchange rates

(15)

(33)

Total benefit recognized in other comprehensive income

(23)

(66)

Total recognized in net periodic pension income and other comprehensive income

$ (28)

$ (94)

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs. Refer to Note 22 for further information.

Long-Term Employee Benefits (Amounts Recognized in Accumulated Other Comprehensive Loss) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	$ 336	$ 363
Prior service credit	(11)	(16)
Total amount recognized in accumulated other comprehensive loss	325	$ 347
Estimated net loss to be amortized into net periodic benefit cost in the next fiscal year	16
Prior service credit to be amortized into net periodic benefit cost in the next fiscal year	$ 2

Long-Term Employee Benefits (Change in Benefit Obligation and Plan Assets) (Details) - Foreign Pension Plan [Member] $ in Millions	12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	$ 1,103	$ 0
Assumption and establishment of pension plans		1,332
Service cost	14	16
Interest cost	19	19
Plan participants’ contributions	2	2
Actuarial loss (gain)	69	(76)
Benefits paid	(36)	(39)
Plan Amendments		(24)
Curtailments	(3)
Settlements & transfers	(12)	(6)
Other events	(2)
Currency translation	(49)	(121)
Benefit obligation at end of year	1,105	1,103
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	1,137	0
Assumption and establishment of pension plans		1,297
Actual return on plan assets	113	(7)
Employer contributions	16	16
Plan participants’ contributions	2	2
Benefits paid	(36)	(39)
Settlements & transfers	(12)	(6)
Currency translation	(51)	(126)
Fair value of plan assets at end of year	1,169	1,137
Funded status at end of year	$ 64	$ 34

Long-Term Employee Benefits (Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	$ 159	$ 138
The accumulated benefit obligation for all pension plans	1,042	1,030
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	159	138
Current liabilities	(1)	(2)
Noncurrent liabilities	(94)	(102)
Net amount recognized	$ 64	$ 34

Long-Term Employee Benefits (Summary of Projected Benefit Obligations and Accumulated Benefit Obligations in Excess of Plan Assets) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Pension plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$ 183	$ 194
Accumulated benefit obligation	152	158
Fair value of plan assets	87	93
Pension plans with accumulated benefit obligation in excess of plan assets
Projected benefit obligation	179	190
Accumulated benefit obligation	151	157
Fair value of plan assets	$ 84	$ 90

Long-Term Employee Benefits (Assumptions) (Details)	12 Months Ended
Long-Term Employee Benefits (Assumptions) (Details)	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	1.80%	2.40%
Rate of compensation increase	2.50%	2.60%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	2.40%	1.70%
Rate of compensation increase	2.50%	3.90%
Expected return on plan assets	5.70%	7.20%

Long-Term Employee Benefits (Plan Assets) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	100.00%	100.00%
Fair value of plan assets, gross	$ 1,174	$ 1,140
Fair value of plan liabilities	(5)	(3)
Fair value of plan assets	1,169	1,137	$ 0
Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	214	148
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 960	$ 992
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	2.50%	2.70%
Fair value of plan assets	$ 77	$ 40
Cash and Cash Equivalents [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	77	40
Cash and Cash Equivalents [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 0	$ 0
Equity securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	41.60%	42.30%
Fair value of plan assets	$ 502	$ 460
Equity securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	28	37
Equity securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 474	$ 423
Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	55.90%	55.00%
Fixed Income Securities [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 433	$ 465
Fixed Income Securities [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	142	148
Fixed Income Securities [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	42	33
Fixed Income Securities [Member] \| Level 1 [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	8	7
Fixed Income Securities [Member] \| Level 1 [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	76	60
Fixed Income Securities [Member] \| Level 1 [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	25	0
Fixed Income Securities [Member] \| Level 2 [Member] \| Government Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	425	458
Fixed Income Securities [Member] \| Level 2 [Member] \| Corporate Issued [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	66	88
Fixed Income Securities [Member] \| Level 2 [Member] \| Asset backed [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	17	33
Derivatives - Asset Position[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	4
Derivatives - Asset Position[Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Derivatives - Asset Position[Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	3	4
Derivative Liability Position [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(32)	(16)
Derivative Liability Position [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	0
Derivative Liability Position [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	(32)	(16)
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7	6
Other [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0	4
Other [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 7	$ 2

Long-Term Employee Benefits (Cash Flow) (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
2017			$ 52
2018			40
2019			42
2020			43
2021			43
2022 - 2026			232
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions			16	$ 16
Estimated future employer contributions in next fiscal year			$ 15
Foreign Pension Plan [Member] \| Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 8	$ 38			$ 35
Other Long-Term Employee Benefit Plans [Member] \| Parent Issuer [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions					$ 66

Stock-based Compensation (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 02, 2015	Jul. 31, 2015	Sep. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jul. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost				$ 20	$ 17	$ 7
Income tax benefit				$ 8	$ 7	$ 3
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value							$ 18
Conversion of stock incremental cost			$ 3
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period		10 years		10 years
Stock-based compensation award vesting period				3 years
Unrecognized compensation cost related to stock options				$ 3,762
Unrecognized compensation cost period for recognition				1 year 7 months 21 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award vesting period				3 years
Unrecognized compensation cost period for recognition				1 year 6 months 15 days
Shares issued upon conversion of equity award				1
Restricted stock units granted and converted, weighted average grant date fair value (in dollars per share)				$ 6.20
Unrecognized compensation cost related to equity awards other than options				$ 12,128
Weighted-average fair value at grant date (in dollars per share)				$ 6.20
Performance Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost				$ 2
Shares issued upon conversion of equity award				1
Weighted-average fair value at grant date (in dollars per share)				$ 6.10
Performance Share Units [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				0.00%
Performance Share Units [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target award available for grant				200.00%
Chemours Company Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants (in shares)				7,806,040			13,500,000
Requisite service period	6 months

Stock-based Compensation (Stock Option Weighted Average Assumptions) (Details) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.46%	1.50%
Expected term (years)	6 years	5 years 4 months 24 days
Volatility	60.00%	42.00%
Dividend yield	2.14%	6.90%
Fair value per stock option (in dollars per share)	$ 3.41	$ 3.17

Stock-based Compensation (Stock Option Activity) (Details) - Stock Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning balance, shares	8,284
Granted, shares	1,435
Exercised, shares	(947)
Forfeited, shares	(447)
Expired, shares	(356)
Outstanding, ending balance, shares	7,969	8,284
Exercisable, shares	3,912
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding, weighted average exercise price, beginning balance (in dollars per share)	$ 14.66
Granted, weighted average exercise price (in dollars per share)	5.73
Exercised, weighted average exercise price (in dollars per share)	12.17
Forfeited, weighted average exercise price (in dollars per share)	15.53
Expired, weighted average exercise price (in dollars per share)	5.82
Outstanding, weighted average exercise price, ending balance (in dollars per share)	13.72	$ 14.66
Exercisable, weighted average exercise price (in dollars per share)	$ 14.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	5 years 29 days	4 years 9 months 26 days
Options exercisable, weighted average remaining contractual term	3 years 3 months
Options outstanding, aggregate intrinsic value	$ 66,668
Options exercisable, aggregate intrinsic value	$ 31,487

Stock-based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares \| shares	2,349
Granted, shares \| shares	1,003
Vested, shares \| shares	(829)
Forfeited, shares \| shares	(207)
Nonvested, ending balance, shares \| shares	2,316
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 14.87
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	6.20
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	14.74
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	15.09
Nonvested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 11.23

Stock-based Compensation (Performance Share Units Activity) (Details) - Performance Share Units [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Nonvested, beginning balance, shares \| shares	0
Granted, shares \| shares	825
Vested, shares \| shares	0
Forfeited, shares \| shares	(22)
Nonvested, ending balance, shares \| shares	803
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Nonvested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 0
Granted, weighted average grant date fair value (in dollars per share) \| $ / shares	6.10
Vested, weighted average grant date fair value (in dollars per share) \| $ / shares	0
Forfeited, weighted average grant date fair value (in dollars per share) \| $ / shares	6.10
Nonvested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 6.10

Geographic and Segment Information - Geographic Information (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2016 USD ($) segment	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales	$ 1,322	$ 1,398	$ 1,383	$ 1,297	$ 1,360	$ 1,486	$ 1,508	$ 1,363	$ 5,400	$ 5,717	$ 6,432
Net Property, Plant and Equipment	2,784				3,177				$ 2,784	3,177	3,308
Number of reportable segments \| segment									3
North America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									$ 2,288	2,570	2,759
Net Property, Plant and Equipment	1,861				2,184				1,861	2,184	2,273
Asia Pacific [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,315	1,393	1,548
Net Property, Plant and Equipment	129				136				129	136	140
EMEA [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									1,081	977	1,190
Net Property, Plant and Equipment	278				308				278	308	372
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									716	777	935
Net Property, Plant and Equipment	516				549				516	549	523
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Net Sales									125	140	147
Net Property, Plant and Equipment	$ 11				$ 13				$ 11	$ 13	$ 14

Geographic and Segment Information - (Schedule of Segment Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Net sales to external customers	$ 5,400	$ 5,717	$ 6,432
Adjusted EBITDA	822	573	876
Depreciation and amortization	284	267	257
Equity in earnings of affiliates	29	22	20
Net assets	104	130	3,673
Investments in affiliates	136	136	124
Purchases of plant, property and equipment	338	519	604
Operating Segments [Member] \| Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	2,364	2,392	2,937
Adjusted EBITDA	466	326	723
Depreciation and amortization	119	125	125
Net assets	1,513	1,659	1,748
Purchases of plant, property and equipment	105	255	365
Operating Segments [Member] \| Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	2,264	2,230	2,327
Adjusted EBITDA	445	300	282
Depreciation and amortization	101	88	83
Equity in earnings of affiliates	26	21	20
Net assets	1,400	1,567	1,480
Investments in affiliates	116	127	124
Purchases of plant, property and equipment	120	142	133
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Net sales to external customers	772	1,095	1,168
Adjusted EBITDA	39	29	17
Depreciation and amortization	30	52	48
Net assets	292	839	782
Purchases of plant, property and equipment	104	117	106
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Adjusted EBITDA	(128)	(82)	(146)
Depreciation and amortization	34	2	1
Equity in earnings of affiliates	3	1
Net assets	(3,101)	(3,935)	$ (337)
Investments in affiliates	20	9
Purchases of plant, property and equipment	$ 9	$ 5

Geographic and Segment Information - (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
(Loss) income before income taxes	$ (273)	$ 234	$ (41)	$ 70	$ (121)	$ (107)	$ (18)	$ 58	$ (11)	$ (188)	$ 550
Interest expense, net									213	132	0
Depreciation and amortization									284	267	257
Non-operating pension and other postretirement employee benefit (income) costs									(20)	(3)	22
Exchange losses (gains)									57	(19)	66
Restructuring charges									51	285	21
Asset related charges									124	73
(Gain) loss on sale of assets and businesses									(254)	9	(40)
Transaction costs									19	9
Legal and other charges									359	8
Adjusted EBITDA									822	573	876
Asset Related Charges - Impairment		$ 48				$ 45			119	45
Other assets, impairment charges									13
Goodwill impairment									0	25	0
PFOA MDL Settlement [Member]
Segment Reporting Information [Line Items]
Litigation accruals									335
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Goodwill impairment										25
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization									30	52	48
Adjusted EBITDA									39	29	$ 17
Asset Related Charges - Impairment										45
Goodwill impairment										$ 25
Disposed by Sale [Member] \| Sulfur Business [Member]
Segment Reporting Information [Line Items]
Asset Related Charges - Impairment			$ 58						58
Disposed by Sale [Member] \| Sulfur Business [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Asset Related Charges - Impairment									58
Headquarters Building Located in Wilmington, Delaware [Member] \| Disposed by Sale [Member]
Segment Reporting Information [Line Items]
Other assets, impairment charges									13
Aniline Facility [Member] \| Pascagoula, Mississippi [Member]
Segment Reporting Information [Line Items]
Asset Related Charges - Impairment									48
Aniline Facility [Member] \| Pascagoula, Mississippi [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Asset Related Charges - Impairment									$ 48

Geographic and Segment Information - (Schedule of Net Sales to External Customers by Product Group) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 5,400	$ 5,717	$ 6,432
Titanium Dioxide [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	2,364	2,392	2,937
Fluoropolymers [member]
Segment Reporting Information [Line Items]
Total net sales to external customers	1,171	1,246	1,326
Fluorochemicals [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	1,093	984	1,001
Performance Chemicals and Intermediates [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	383	551	621
Mining Solution [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	262	301	314
Sulfur [Member]
Segment Reporting Information [Line Items]
Total net sales to external customers	$ 127	$ 243	$ 233

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 126
Assumption and establishment of pension plans, net	18	$ 52	$ 0
Ending Balance	100	126
Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(285)	19	19
Assumption and establishment of pension plans, net		0
Other comprehensive (loss) income	(73)	(304)	0
Ending Balance	(358)	(285)	19
Derivative Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	8	0	0
Assumption and establishment of pension plans, net		0
Other comprehensive (loss) income	14	8	0
Ending Balance	22	8	0
Employee Benefits [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(259)	0	0
Assumption and establishment of pension plans, net		(311)
Other comprehensive (loss) income	18	52	0
Ending Balance	(241)	(259)	0
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(536)	19	19
Assumption and establishment of pension plans, net		(311)
Other comprehensive (loss) income	(41)	(244)	0
Ending Balance	$ (577)	$ (536)	$ 19

Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Jul. 02, 2015

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Net Sales

$ 1,322

$ 1,398

$ 1,383

$ 1,297

$ 1,360

$ 1,486

$ 1,508

$ 1,363

$ 5,400

$ 5,717

$ 6,432

Cost of goods sold

1,024

1,056

1,116

1,095

1,147

1,222

1,282

1,111

4,290

4,762

5,072

Income (loss) before income taxes

(273)

234

(41)

(121)

(107)

(18)

(11)

(188)

550

Net income (loss)

(230)

204

(18)

(86)

(29)

(18)

(90)

401

Net income (loss) attributable to Chemours

$ (230)

$ 204

$ (18)

$ 51

$ (86)

$ (29)

$ (18)

$ 43

$ 7

$ (90)

$ 400

Basic earnings (loss) per share (in dollars per share)

$ (1.26)

$ 1.12

$ (0.10)

$ 0.28

$ (0.48)

$ (0.16)

$ (0.10)

$ 0.24

$ 0.04

$ (0.50)

$ 2.21

^[1]

Diluted earnings (loss) per share (in dollars per share)

$ (1.26)

$ 1.11

$ (0.10)

$ 0.28

$ (0.48)

$ (0.16)

$ (0.10)

$ 0.24

$ 0.04

$ (0.50)

$ 2.21

^[1]

Stock issued, common stock

180,966,833

[1]

Guarantor Condensed Consolidating Financial Information (Condensed Consolidated Statements of Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Condensed Income Statements, Captions [Line Items]
Net sales	$ 1,322	$ 1,398	$ 1,383	$ 1,297	$ 1,360	$ 1,486	$ 1,508	$ 1,363	$ 5,400	$ 5,717	$ 6,432
Cost of goods sold	1,024	1,056	1,116	1,095	1,147	1,222	1,282	1,111	4,290	4,762	5,072
Gross profit									1,110	955	1,360
Selling, general and administrative expense									934	632	685
Research and development expense									80	97	143
Restructuring and asset related charges, net									170	333	21
Goodwill impairment									0	25	0
Total expenses									1,184	1,087	849
Equity in earnings of affiliates									29	22	20
Equity in (net loss) earnings of subsidiaries										0	0
Interest (expense) income, net									(213)	(132)
Intercompany interest income (expense), net										0
Other income (expense), net									247	54	19
(Loss) income before income taxes	(273)	234	(41)	70	(121)	(107)	(18)	58	(11)	(188)	550
(Benefit from) provision for income taxes									(18)	(98)	149
Net income (loss)	(230)	204	(18)	51	(86)	(29)	(18)	43	7	(90)	401
Less: Net income attributable to noncontrolling interests									0	0	1
Net income (loss) attributable to Chemours	$ (230)	$ 204	$ (18)	$ 51	$ (86)	$ (29)	$ (18)	$ 43	7	(90)	400
Comprehensive (loss) income attributable to Chemours									(34)	(334)	400
Eliminations and Adjustments [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									(1,571)	(1,596)	(1,883)
Cost of goods sold									(1,543)	(1,596)	(1,884)
Gross profit									(28)	0	1
Selling, general and administrative expense									(20)	(13)	0
Research and development expense										0	0
Restructuring and asset related charges, net										0	0
Goodwill impairment										0
Total expenses									(20)	(13)	0
Equity in earnings of affiliates										0	0
Equity in (net loss) earnings of subsidiaries									(100)	47	(400)
Interest (expense) income, net										0
Intercompany interest income (expense), net										0
Other income (expense), net									(20)	(20)	0
(Loss) income before income taxes									(128)	40	(399)
(Benefit from) provision for income taxes									(7)	(3)	(2)
Net income (loss)									(121)	43	(397)
Less: Net income attributable to noncontrolling interests										0	0
Net income (loss) attributable to Chemours									(121)	43	(397)
Comprehensive (loss) income attributable to Chemours									(66)	295	(397)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales										0	0
Cost of goods sold										0	0
Gross profit										0	0
Selling, general and administrative expense									21	15	0
Research and development expense										0	0
Restructuring and asset related charges, net										0	0
Goodwill impairment										0
Total expenses									21	15	0
Equity in earnings of affiliates										0	0
Equity in (net loss) earnings of subsidiaries									100	(47)	400
Interest (expense) income, net									(211)	(131)
Intercompany interest income (expense), net									60	44
Other income (expense), net									20	13	0
(Loss) income before income taxes									(52)	(136)	400
(Benefit from) provision for income taxes									(59)	(46)	0
Net income (loss)									7	(90)	400
Less: Net income attributable to noncontrolling interests										0	0
Net income (loss) attributable to Chemours									7	(90)	400
Comprehensive (loss) income attributable to Chemours									(34)	(334)	400
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									3,749	4,044	4,593
Cost of goods sold									3,218	3,708	3,863
Gross profit									531	336	730
Selling, general and administrative expense									794	426	429
Research and development expense									77	95	127
Restructuring and asset related charges, net									168	295	11
Goodwill impairment										25
Total expenses									1,039	841	567
Equity in earnings of affiliates									4	1	0
Equity in (net loss) earnings of subsidiaries										0	0
Interest (expense) income, net									(3)	(1)
Intercompany interest income (expense), net									4	0
Other income (expense), net									193	92	80
(Loss) income before income taxes									(310)	(413)	243
(Benefit from) provision for income taxes									(52)	(89)	75
Net income (loss)									(258)	(324)	168
Less: Net income attributable to noncontrolling interests										0	0
Net income (loss) attributable to Chemours									(258)	(324)	168
Comprehensive (loss) income attributable to Chemours									(255)	(324)	168
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Condensed Income Statements, Captions [Line Items]
Net sales									3,222	3,269	3,722
Cost of goods sold									2,615	2,650	3,093
Gross profit									607	619	629
Selling, general and administrative expense									139	204	256
Research and development expense									3	2	16
Restructuring and asset related charges, net									2	38	10
Goodwill impairment										0
Total expenses									144	244	282
Equity in earnings of affiliates									25	21	20
Equity in (net loss) earnings of subsidiaries										0	0
Interest (expense) income, net									1	0
Intercompany interest income (expense), net									(64)	(44)
Other income (expense), net									54	(31)	(61)
(Loss) income before income taxes									479	321	306
(Benefit from) provision for income taxes									100	40	76
Net income (loss)									379	281	230
Less: Net income attributable to noncontrolling interests										0	1
Net income (loss) attributable to Chemours									379	281	229
Comprehensive (loss) income attributable to Chemours									$ 321	$ 29	$ 229

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 902	$ 366	$ 0	$ 0
Accounts and notes receivable - trade, net	807	859
Intercompany receivable		0
Inventories	767	972
Prepaid expenses and other	77	104
Total current assets	2,553	2,301
Property, plant and equipment	7,997	9,015
Less: Accumulated depreciation	(5,213)	(5,838)
Net property, plant and equipment	2,784	3,177	3,308
Goodwill and other intangible assets, net	170	176
Investments in affiliates	136	136	124
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	417	508
Total assets	6,060	6,298
Current liabilities:
Accounts payable	884	973
Short-term borrowings and current maturities of long-term debt	15	39
Intercompany payable		0
Other accrued liabilities	872	454
Total current liabilities	1,771	1,466
Long-term debt, net	3,529	3,915
Intercompany notes payable		0
Deferred income taxes	132	234
Other liabilities	524	553
Total liabilities	5,956	6,168
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	100	126
Noncontrolling interests	4	4
Total equity	104	130	3,673	3,217
Total liabilities and equity	6,060	6,298
Eliminations and Adjustments [Member]
Current assets:
Cash and cash equivalents		0	0	0
Accounts and notes receivable - trade, net		0
Intercompany receivable	(1,099)	(516)
Inventories	(50)	(22)
Prepaid expenses and other	7	3
Total current assets	(1,142)	(535)
Property, plant and equipment		0
Less: Accumulated depreciation		0
Net property, plant and equipment		0
Goodwill and other intangible assets, net		0
Investments in affiliates		0
Investment in subsidiaries	(3,258)	(3,105)
Intercompany notes receivable	(1,150)	(1,150)
Other assets		0
Total assets	(5,550)	(4,790)
Current liabilities:
Accounts payable		0
Short-term borrowings and current maturities of long-term debt		0
Intercompany payable	(1,099)	(516)
Other accrued liabilities		0
Total current liabilities	(1,099)	(516)
Long-term debt, net		0
Intercompany notes payable	(1,150)	(1,150)
Deferred income taxes		0
Other liabilities		0
Total liabilities	(2,249)	(1,666)
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	(3,301)	(3,124)
Noncontrolling interests		0
Total equity	(3,301)	(3,124)
Total liabilities and equity	(5,550)	(4,790)
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents		0	0	0
Accounts and notes receivable - trade, net		0
Intercompany receivable	3	3
Inventories		0
Prepaid expenses and other		0
Total current assets	3	3
Property, plant and equipment		0
Less: Accumulated depreciation		0
Net property, plant and equipment		0
Goodwill and other intangible assets, net		0
Investments in affiliates		0
Investment in subsidiaries	3,258	3,105
Intercompany notes receivable	1,150	1,150
Other assets	13	19
Total assets	4,424	4,277
Current liabilities:
Accounts payable		0
Short-term borrowings and current maturities of long-term debt	15	15
Intercompany payable	762	202
Other accrued liabilities	21	21
Total current liabilities	798	238
Long-term debt, net	3,526	3,913
Intercompany notes payable		0
Deferred income taxes		0
Other liabilities		0
Total liabilities	4,324	4,151
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	100	126
Noncontrolling interests		0
Total equity	100	126
Total liabilities and equity	4,424	4,277
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	224	95	0	0
Accounts and notes receivable - trade, net	299	344
Intercompany receivable	1,050	459
Inventories	341	493
Prepaid expenses and other	38	49
Total current assets	1,952	1,440
Property, plant and equipment	6,136	7,070
Less: Accumulated depreciation	(4,285)	(4,899)
Net property, plant and equipment	1,851	2,171
Goodwill and other intangible assets, net	156	151
Investments in affiliates		9
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	178	275
Total assets	4,137	4,046
Current liabilities:
Accounts payable	573	637
Short-term borrowings and current maturities of long-term debt		24
Intercompany payable	46	54
Other accrued liabilities	718	287
Total current liabilities	1,337	1,002
Long-term debt, net	3	2
Intercompany notes payable		0
Deferred income taxes	59	173
Other liabilities	428	456
Total liabilities	1,827	1,633
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	2,310	2,413
Noncontrolling interests		0
Total equity	2,310	2,413
Total liabilities and equity	4,137	4,046
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Current assets:
Cash and cash equivalents	678	271	$ 0	$ 0
Accounts and notes receivable - trade, net	508	515
Intercompany receivable	46	54
Inventories	476	501
Prepaid expenses and other	32	52
Total current assets	1,740	1,393
Property, plant and equipment	1,861	1,945
Less: Accumulated depreciation	(928)	(939)
Net property, plant and equipment	933	1,006
Goodwill and other intangible assets, net	14	25
Investments in affiliates	136	127
Investment in subsidiaries		0
Intercompany notes receivable		0
Other assets	226	214
Total assets	3,049	2,765
Current liabilities:
Accounts payable	311	336
Short-term borrowings and current maturities of long-term debt		0
Intercompany payable	291	260
Other accrued liabilities	133	146
Total current liabilities	735	742
Long-term debt, net		0
Intercompany notes payable	1,150	1,150
Deferred income taxes	73	61
Other liabilities	96	97
Total liabilities	2,054	2,050
Commitments and contingent liabilities
Equity
Total Chemours stockholders’ equity	991	711
Noncontrolling interests	4	4
Total equity	995	715
Total liabilities and equity	$ 3,049	$ 2,765

Guarantor Condensed Consolidating Financial Information (Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Cash (used for) provided by operating activities	$ 594	$ 182	$ 505
Investing activities
Purchases of property, plant and equipment	(338)	(519)	(604)
Proceeds from sales of assets, net	708	12	32
Intercompany investing activities		0
Foreign exchange contract settlements	(12)	42	0
Investment in affiliates	(1)	(32)	(8)
Other investing activites	0	0	20
Cash provided by (used for) investing activities	357	(497)	(560)
Financing activities
Proceeds from issuance of debt, net	0	3,491	0
Intercompany short-term borrowings, net		0
Debt repayments	(381)	(10)	0
Dividends paid	(22)	(105)	0
Debt issuance costs	(4)	(79)	0
Proceeds from issuance of stock options	11	0	0
Cash provided at separation by DuPont	0	247	0
Net transfers (to) from DuPont	0	(2,857)	55
Cash (used for) provided by financing activities	(396)	687	55
Effect of exchange rate changes on cash	(19)	(6)	0
Increase in cash and cash equivalents	536	366	0
Cash and cash equivalents at beginning of year	366	0	0
Cash and cash equivalents at end of year	902	366	0
Eliminations and Adjustments [Member]
Operating activities
Cash (used for) provided by operating activities		9	(5)
Investing activities
Purchases of property, plant and equipment		0	0
Proceeds from sales of assets, net		0	0
Intercompany investing activities	560	202
Foreign exchange contract settlements		0
Investment in affiliates		0	0
Other investing activites			0
Cash provided by (used for) investing activities	560	202	0
Financing activities
Proceeds from issuance of debt, net		0
Intercompany short-term borrowings, net	(560)	(202)
Debt repayments		0
Dividends paid		0
Debt issuance costs		0
Cash provided at separation by DuPont		0
Net transfers (to) from DuPont		(9)	5
Cash (used for) provided by financing activities	(560)	(211)	5
Effect of exchange rate changes on cash		0	0
Increase in cash and cash equivalents		0	0
Cash and cash equivalents at beginning of year	0	0	0
Cash and cash equivalents at end of year		0	0
Parent Issuer [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	(176)	(119)	0
Investing activities
Purchases of property, plant and equipment		0	0
Proceeds from sales of assets, net		0	0
Intercompany investing activities		0
Foreign exchange contract settlements		0
Investment in affiliates		0	0
Other investing activites			0
Cash provided by (used for) investing activities		0	0
Financing activities
Proceeds from issuance of debt, net		3,489
Intercompany short-term borrowings, net	560	202
Debt repayments	(369)	(8)
Dividends paid	(22)	(105)
Debt issuance costs	(4)	(79)
Proceeds from issuance of stock options	11
Cash provided at separation by DuPont		0
Net transfers (to) from DuPont		(3,380)	0
Cash (used for) provided by financing activities	176	119	0
Effect of exchange rate changes on cash		0	0
Increase in cash and cash equivalents		0	0
Cash and cash equivalents at beginning of year	0	0	0
Cash and cash equivalents at end of year		0	0
Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	355	171	302
Investing activities
Purchases of property, plant and equipment	(233)	(292)	(287)
Proceeds from sales of assets, net	591	6	30
Intercompany investing activities	(560)	(202)
Foreign exchange contract settlements	(12)	42
Investment in affiliates		0	0
Other investing activites			20
Cash provided by (used for) investing activities	(214)	(446)	(237)
Financing activities
Proceeds from issuance of debt, net		2
Intercompany short-term borrowings, net		0
Debt repayments	(12)	(2)
Dividends paid		0
Debt issuance costs		0
Cash provided at separation by DuPont		87
Net transfers (to) from DuPont		283	(65)
Cash (used for) provided by financing activities	(12)	370	(65)
Effect of exchange rate changes on cash		0	0
Increase in cash and cash equivalents	129	95	0
Cash and cash equivalents at beginning of year	95	0	0
Cash and cash equivalents at end of year	224	95	0
Non-Guarantor Subsidiaries [Member] \| Reportable Legal Entities [Member]
Operating activities
Cash (used for) provided by operating activities	415	121	208
Investing activities
Purchases of property, plant and equipment	(105)	(227)	(317)
Proceeds from sales of assets, net	117	6	2
Intercompany investing activities		0
Foreign exchange contract settlements		0
Investment in affiliates	(1)	(32)	(8)
Other investing activites			0
Cash provided by (used for) investing activities	11	(253)	(323)
Financing activities
Proceeds from issuance of debt, net		0
Intercompany short-term borrowings, net		0
Debt repayments		0
Dividends paid		0
Debt issuance costs		0
Cash provided at separation by DuPont		160
Net transfers (to) from DuPont		249	115
Cash (used for) provided by financing activities		409	115
Effect of exchange rate changes on cash	(19)	(6)	0
Increase in cash and cash equivalents	407	271	0
Cash and cash equivalents at beginning of year	271	0	0
Cash and cash equivalents at end of year	$ 678	$ 271	$ 0

Restructuring and Asset Related Charges, Net (Narrative) (Details) $ in Millions	1 Months Ended			3 Months Ended	12 Months Ended
	Nov. 30, 2015 position	Aug. 31, 2015 production_line	Jun. 30, 2015 position	Dec. 31, 2015 USD ($) position	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					$ 51	$ 288	$ 19
Titanium Technologies Site Closure [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						140
Titanium Technologies Site Closure [Member] \| Operating Segments [Member] \| Employee separation [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						11
Titanium Technologies Site Closure [Member] \| Operating Segments [Member] \| Property, Plant and Equipment Related Charges [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						115
Titanium Technologies Site Closure [Member] \| Operating Segments [Member] \| Decommissioning Costs [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						14
Titanium Technologies Site Closure [Member] \| Operating Segments [Member] \| Additional Restructuring Charges [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					30
Fluoroproducts Restructuring [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					7	21
Fluoroproducts Restructuring [Member] \| Operating Segments [Member] \| Employee separation [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						2
Fluoroproducts Restructuring [Member] \| Operating Segments [Member] \| Property, Plant and Equipment Related Charges [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						18
Fluoroproducts Restructuring [Member] \| Operating Segments [Member] \| Decommissioning Costs [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						1
Fluoroproducts Restructuring [Member] \| Operating Segments [Member] \| Additional Restructuring Charges [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					3
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					8
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Employee separation [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges						12
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Decommissioning Costs [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					6
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Additional Restructuring Charges [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					9
Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Contract Termination [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					2
2015 Global Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					6	112	19
Expected number of positions to be eliminated \| position	430
Number of positions eliminated (more than) \| position			430
2015 Global Restructuring [Member] \| Employee separation [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges				$ 48		64
2015 Global Restructuring [Member] \| Operating Segments [Member] \| Titanium Technologies [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					2	33	3
2015 Global Restructuring [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					4	54	16
2015 Global Restructuring [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges					$ 0	$ 25	0
2014 Restructuring Program [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							19
2014 Restructuring Program [Member] \| Employee separation [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							16
2014 Restructuring Program [Member] \| Asset Shut Down Charges [Member]
Restructuring Cost and Reserve [Line Items]
Employee separation and asset related charges							$ 3
New Johnsonville, Tennessee [Member] \| Titanium Technologies Site Closure [Member]
Restructuring Cost and Reserve [Line Items]
Number of production lines shut down during period \| production_line		1
Niagara Falls, NY [Member] \| Reactive Metals Solutions Plant (RMS) Closure [Member] \| Operating Segments [Member] \| Chemical Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Expected number of positions to be eliminated \| position				200